(Mark One)

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 10-Q**

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

## For the quarterly period ended September 25, 2020 OR

* **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

## For the transition period from to

**Commission File Number 001-02217**



(Exact name of Registrant as specified in its charter)

## Delaware 58-0628465

(State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)

## One Coca-Cola Plaza

## Atlanta Georgia 30313

(Address of principal executive offices) (Zip Code)

## Registrant's telephone number, including area code: (404) 676-2121 Securities registered pursuant to Section 12(b) of the Act:

|  |  |  |
| --- | --- | --- |
| **Title of each class Common Stock, $0.25 Par Value**  **Floating Rate Notes Due 2021** | **Trading Symbol(s) KO**  **KO21C** | **Name of each exchange on which registered New York Stock Exchange**  **New York Stock Exchange** |
| **0.75% Notes Due 2023** | **KO23B** | **New York Stock Exchange** |
| **0.500% Notes Due 2024** | **KO24** | **New York Stock Exchange** |
| **1.875% Notes Due 2026** | **KO26** | **New York Stock Exchange** |
| **0.750% Notes Due 2026** | **KO26C** | **New York Stock Exchange** |
| **1.125% Notes Due 2027** | **KO27** | **New York Stock Exchange** |
| **0.125% Notes Due 2029** | **KO29A** | **New York Stock Exchange** |
| **1.250% Notes Due 2031** | **KO31** | **New York Stock Exchange** |
| **0.375% Notes Due 2033** | **KO33** | **New York Stock Exchange** |
| **1.625% Notes Due 2035** | **KO35** | **New York Stock Exchange** |
| **1.100% Notes Due 2036** | **KO36** | **New York Stock Exchange** |
| **0.800% Notes Due 2040** | **KO40B** | **New York Stock Exchange** |

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒ No ☐

Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

|  |  |  |  |
| --- | --- | --- | --- |
| Large accelerated filer | ☒ | Accelerated filer | ☐ |
| Non-accelerated filer | ☐ | Smaller reporting company | ☐ |
| Emerging growth company | ☐ |  |  |

If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or

revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark if the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐ No ☒ Indicate the number of shares outstanding of each of the issuer's classes of common stock as of the latest practicable date.

Class of Common Stock Shares Outstanding as of October 19, 2020

$0.25 Par Value 4,297,434,612

## THE COCA-COLA COMPANY AND SUBSIDIARIES

**Table of Contents**

**Page**

Forward-Looking Statements 1

**Part I. Financial Information**

|  |  |  |
| --- | --- | --- |
| Item 1. | Financial Statements (Unaudited) | 2 |
|  | Condensed Consolidated Statements of Income  Three and Nine Months Ended September 25, 2020 and September 27, 2019 | 2 |
|  | Condensed Consolidated Statements of Comprehensive Income  Three and Nine Months Ended September 25, 2020 and September 27, 2019 | 3 |
|  | Condensed Consolidated Balance Sheets  September 25, 2020 and December 31, 2019 | 4 |
|  | Condensed Consolidated Statements of Cash Flows  Nine Months Ended September 25, 2020 and September 27, 2019 | 5 |
|  | Notes to Condensed Consolidated Financial Statements | 6 |
| Item 2. | Management's Discussion and Analysis of Financial Condition and Results of Operations | 36 |
| Item 3. | Quantitative and Qualitative Disclosures About Market Risk | 54 |
| Item 4. | Controls and Procedures | 54 |
|  | **Part II. Other Information** |  |
| Item 1. | Legal Proceedings | 54 |
| Item 1A. | Risk Factors | 54 |
| Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 57 |
| Item 6. | Exhibits | 57 |
|  | Signatures | 61 |

**FORWARD-LOOKING STATEMENTS**

*This report contains information that may constitute "forward-looking statements." Generally, the words "believe," "expect," "intend," "estimate," "anticipate," "project," "will" and similar expressions identify forward-looking statements, which generally are not historical in nature. However, the absence of these words or similar expressions does not mean that a statement is not forward-looking. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future — including statements relating to volume growth, share of sales and earnings per share growth, and statements expressing general views about future operating results — are forward-looking statements. Management believes that these forward-looking statements are reasonable as and when made. However, caution should be taken not to place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in Part II, "Item 1A. Risk Factors" and elsewhere in this report and in our Annual Report on Form 10-K for the year ended December 31, 2019, and those described from time to time in our future reports filed with the Securities and Exchange Commission.*

1

## Part I. Financial Information

### Item 1. Financial Statements (Unaudited)

**THE COCA-COLA COMPANY AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF INCOME** (UNAUDITED)

(In millions except per share data)

Three Months Ended Nine Months Ended

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **September 25,**  **2020** | September 27,  2019 |  | **September 25,**  **2020** | September 27,  2019 |
| **Net Operating Revenues** | **$ 8,652** | $ 9,507 |  | **$ 24,403** | $ 28,198 |
| Cost of goods sold | **3,471** | 3,767 |  | **9,855** | 11,053 |
| **Gross Profit** | **5,181** | 5,740 |  | **14,548** | 17,145 |
| Selling, general and administrative expenses | **2,511** | 3,116 |  | **7,142** | 8,879 |
| Other operating charges | **372** | 125 |  | **747** | 344 |
| **Operating Income** | **2,298** | 2,499 |  | **6,659** | 7,922 |
| Interest income | **82** | 153 |  | **294** | 428 |
| Interest expense | **660** | 230 |  | **1,127** | 711 |
| Equity income (loss) — net | **431** | 346 |  | **774** | 808 |
| Other income (loss) — net | **30** | 324 |  | **788** | (81) |
| **Income Before Income Taxes** | **2,181** | 3,092 |  | **7,388** | 8,366 |
| Income taxes | **441** | 503 |  | **1,094** | 1,446 |
| **Consolidated Net Income** | **1,740** | 2,589 |  | **6,294** | 6,920 |
| Less: Net income (loss) attributable to noncontrolling interests | **3** | (4) |  | **3** | 42 |
| **Net Income Attributable to Shareowners of The Coca-Cola Company** | **$ 1,737** | $ 2,593 |  | **$ 6,291** | $ 6,878 |
| **Basic Net Income Per Share1** | **$ 0.40** | $ 0.61 |  | **$ 1.47** | $ 1.61 |
| **Diluted Net Income Per Share1** | **$ 0.40** | $ 0.60 |  | **$ 1.46** | $ 1.60 |
| **Average Shares Outstanding** | **4,296** | 4,280 |  | **4,293** | 4,273 |
| Effect of dilutive securities | **25** | 41 |  | **28** | 38 |
| **Average Shares Outstanding Assuming Dilution** | **4,321** | 4,321 |  | **4,321** | 4,311 |
| 1 Calculated based on net income attributable to shareowners of The Coca-Cola Company. |  |  |  |  |  |
| Refer to Notes to Condensed Consolidated Financial Statements. |  |  |  |  |  |

2

## THE COCA-COLA COMPANY AND SUBSIDIARIES

**CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME**

(UNAUDITED)

(In millions)

Three Months Ended Nine Months Ended

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **September 25,**  **2020** | | | September 27,  2019 |  | **September 25,**  **2020** | | September 27,  2019 |  |
| **Consolidated Net Income** | **$** | **1,740** $ | 2,589 | **$** | | **6,294** $ | 6,920 | |
| **Other Comprehensive Income:** |  | |  |  | | |  | |
| Net foreign currency translation adjustments | **1,052** | | (960) | **(2,283)** | | | (679) | |
| Net gains (losses) on derivatives | **(13)** | | 46 | **(23)** | | | 30 | |
| Net change in unrealized gains (losses) on available-for-sale debt securities | **(21)** | | 16 | **(40)** | | | 46 | |
| Net change in pension and other benefit liabilities | **(2)** | | 32 | **45** | | | 100 | |
| **Total Comprehensive Income** | **2,756** | | 1,723 | **3,993** | | | 6,417 | |
| Less: Comprehensive income (loss) attributable to noncontrolling interests | **5** | | (145) | **(396)** | | | (88) | |
| **Total Comprehensive Income Attributable to Shareowners of The Coca-Cola Company** | **$ 2,751** $ | | 1,868 | **$ 4,389** $ | | | 6,505 | |
| Refer to Notes to Condensed Consolidated Financial Statements. |  | |  |  | | |  | |

3

## THE COCA-COLA COMPANY AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)

(In millions except par value)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | | | **September 25,** | December 31, | |
| **2020** | 2019 | |
|  | **ASSETS** | |  |  | |
| **Current Assets** |  | |  |  | |
| Cash and cash equivalents |  | | **$ 11,385** | $ 6,480 | |
| Short-term investments |  | | **7,347** | 1,467 | |
| **Total Cash, Cash Equivalents and Short-Term Investments** |  | | **18,732** | 7,947 | |
| Marketable securities |  | | **2,396** | 3,228 | |
| Trade accounts receivable, less allowances of $546 and $524, respectively |  | | **3,827** | 3,971 | |
| Inventories |  | | **3,264** | 3,379 | |
| Prepaid expenses and other assets |  | | **2,191** | 1,886 | |
| **Total Current Assets** |  | | **30,410** | 20,411 | |
| Equity method investments |  | | **18,875** | 19,025 | |
| Other investments |  | | **712** | 854 | |
| Other assets |  | | **6,161** | 6,075 | |
| Deferred income tax assets  Property, plant and equipment, less accumulated depreciation of |  | | **2,439** | 2,412 | |
| $8,877 and $8,083, respectively | **10,667** | | | 10,838 | |
| Trademarks with indefinite lives | **10,333** | | | 9,266 | |
| Goodwill | **16,887** | | | 16,764 | |
| Other intangible assets | **700** | | | 736 | |
| **Total Assets** | **$ 97,184** | | | $ 86,381 | |
| **LIABILITIES AND EQUITY** | | | | | |
| **Current Liabilities** | |  |  | |  |
| Accounts payable and accrued expenses | |  | **$ 12,750** $ | | 11,312 |
| Loans and notes payable | |  | **5,857** | | 10,994 |
| Current maturities of long-term debt | |  | **7,508** | | 4,253 |
| Accrued income taxes | |  | **776** | | 414 |
| **Total Current Liabilities** | |  | **26,891** | | 26,973 |
| Long-term debt | |  | **39,502** | | 27,516 |
| Other liabilities | |  | **8,530** | | 8,510 |
| Deferred income tax liabilities | |  | **1,945** | | 2,284 |
| **The Coca-Cola Company Shareowners' Equity** | |  |  | |  |
| Common stock, $0.25 par value; authorized — 11,200 shares; issued — 7,040 shares | |  | **1,760** | | 1,760 |
| Capital surplus | |  | **17,463** | | 17,154 |
| Reinvested earnings | |  | **66,863** | | 65,855 |
| Accumulated other comprehensive income (loss) | |  | **(15,446)** | | (13,544) |
| Treasury stock, at cost — 2,743 and 2,760 shares, respectively | |  | **(52,033)** | | (52,244) |
| **Equity Attributable to Shareowners of The Coca-Cola Company** | |  | **18,607** | | 18,981 |
| Equity attributable to noncontrolling interests | |  | **1,709** | | 2,117 |
| **Total Equity** | |  | **20,316** | | 21,098 |
| **Total Liabilities and Equity** | |  | **$ 97,184** $ | | 86,381 |
| Refer to Notes to Condensed Consolidated Financial Statements. | |  |  | |  |
|  | | 4 |  | |  |

## THE COCA-COLA COMPANY AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

(In millions)

Nine Months Ended

|  |  |  |
| --- | --- | --- |
|  | **September 25,**  **2020** | September 27,  2019 |
| **Operating Activities** |  |  |
| Consolidated net income | **$ 6,294** $ | 6,920 |
| Depreciation and amortization | **1,106** | 965 |
| Stock-based compensation expense | **88** | 146 |
| Deferred income taxes | **10** | (326) |
| Equity (income) loss — net of dividends | **(565)** | (336) |
| Foreign currency adjustments | **(145)** | 79 |
| Significant (gains) losses — net | **(899)** | (389) |
| Other operating charges | **671** | 147 |
| Other items | **562** | 444 |
| Net change in operating assets and liabilities | **(902)** | 121 |
| **Net Cash Provided by Operating Activities** | **6,220** | 7,771 |
| **Investing Activities** |  |  |
| Purchases of investments | **(12,051)** | (4,113) |
| Proceeds from disposals of investments | **6,482** | 5,674 |
| Acquisitions of businesses, equity method investments and nonmarketable securities | **(989)** | (5,376) |
| Proceeds from disposals of businesses, equity method investments and nonmarketable securities | **46** | 266 |
| Purchases of property, plant and equipment | **(759)** | (1,206) |
| Proceeds from disposals of property, plant and equipment | **156** | 944 |
| Other investing activities | **43** | (90) |
| **Net Cash Provided by (Used in) Investing Activities** | **(7,072)** | (3,901) |
| **Financing Activities** |  |  |
| Issuances of debt | **26,898** | 19,598 |
| Payments of debt | **(17,977)** | (21,716) |
| Issuances of stock | **514** | 923 |
| Purchases of stock for treasury | **(93)** | (690) |
| Dividends | **(3,522)** | (3,419) |
| Other financing activities | **153** | (33) |
| **Net Cash Provided by (Used in) Financing Activities** | **5,973** | (5,337) |
| **Effect of Exchange Rate Changes on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents** | **(36)** | (75) |
| **Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents** |  |  |
| Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalents during the period | **5,085** | (1,542) |
| Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period | **6,737** | 9,318 |
| **Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents at End of Period** | **11,822** | 7,776 |
| Less: Restricted cash and restricted cash equivalents at end of period | **437** | 245 |
| **Cash and Cash Equivalents at End of Period** | **$ 11,385** $ | 7,531 |
| Refer to Notes to Condensed Consolidated Financial Statements. |  |  |

5

## THE COCA-COLA COMPANY AND SUBSIDIARIES

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

(UNAUDITED)

## NOTE 1: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

### Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("U.S. GAAP") for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. They do not include all information and notes required by U.S. GAAP for complete financial statements. However, except as disclosed herein, there has been no material change in the information disclosed in the Notes to Consolidated Financial Statements included in the Annual Report on Form 10-K of The Coca-Cola Company for the year ended December 31, 2019.

When used in these notes, the terms "The Coca-Cola Company," "Company," "we," "us" and "our" mean The Coca-Cola Company and all entities included in our condensed consolidated financial statements. In the opinion of management, all adjustments (including normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and nine months ended September 25, 2020 are not necessarily indicative of the results that may be expected for the year ending December 31, 2020. Sales of our nonalcoholic ready-to-drink beverages are somewhat seasonal, with the second and third calendar quarters typically accounting for the highest sales volumes. The volume of sales in the beverage business may be affected by weather conditions.

Each of our interim reporting periods, other than the fourth interim reporting period, ends on the Friday closest to the last day of the corresponding quarterly calendar period. The third quarter of 2020 and the third quarter of 2019 ended on September 25, 2020 and September 27, 2019, respectively. Our fourth interim reporting period and our fiscal year end on December 31 regardless of the day of the week on which December 31 falls.

### Advertising Costs

The Company's accounting policy related to advertising costs for annual reporting purposes is to expense production costs of print, radio, television and other advertisements as of the first date the advertisements take place. All other marketing expenditures are expensed in the annual period in which the expenditure is incurred.

For interim reporting purposes, we allocate our estimated full year marketing expenditures that benefit multiple interim periods to each of our interim reporting periods. We use the proportion of each interim period's actual unit case volume to the estimated full year unit case volume as the basis for the allocation. This methodology results in our marketing expenditures being recognized at a standard rate per unit case. At the end of each interim reporting period, we review our estimated full year unit case volume and our estimated full year marketing expenditures that benefit multiple interim periods in order to evaluate if a change in estimate is necessary. The impact of any change in the full year estimate is recognized in the interim period in which the change in estimate occurs. Our full year marketing expenditures are not impacted by this interim accounting policy.

### Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents

We classify time deposits and other investments that are highly liquid and have maturities of three months or less at the date of purchase as cash equivalents or restricted cash equivalents, as applicable. Restricted cash and restricted cash equivalents generally consist of amounts held by our captive insurance companies, which are included in the line item other assets in our consolidated balance sheet. We manage our exposure to counterparty credit risk through specific minimum credit standards, diversification of counterparties and procedures to monitor our concentrations of credit risk.

6

The following tables provide a summary of cash, cash equivalents, restricted cash and restricted cash equivalents that constitute the total amounts shown in the condensed consolidated statements of cash flows (in millions):

|  |  |  |
| --- | --- | --- |
|  | **September 25,**  **2020** | December 31,  2019 |
| Cash and cash equivalents | **$ 11,385** $ | 6,480 |
| Cash and cash equivalents included in other assets1 | **437** | 257 |
| Cash, cash equivalents, restricted cash and restricted cash equivalents | **$ 11,822** $ | 6,737 |
| 1 Amounts represent cash and cash equivalents in our solvency capital portfolio set aside primarily to cover pension obligations in certain of our European and Canadian pension plans. Refer to Note 4. |  |  |
|  | September 27,  2019 | December 31,  2018 |
| Cash and cash equivalents | $ 7,531 $ | 9,077 |
| Cash and cash equivalents included in other assets1 | 245 | 241 |
| Cash, cash equivalents, restricted cash and restricted cash equivalents | $ 7,776 $ | 9,318 |

1 Amounts represent cash and cash equivalents in our solvency capital portfolio set aside primarily to cover pension obligations in certain of our European and Canadian pension plans. Refer to Note 4.

### Recently Issued Accounting Guidance

In December 2019, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2019-12,*Simplifying the Accounting for Income Taxes*, which eliminates certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating taxes during the quarters and the recognition of deferred tax liabilities for outside basis differences. This guidance also simplifies aspects of the accounting for franchise taxes and changes in tax laws or rates, as well as clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. ASU 2019-12 is effective for the Company beginning January 1, 2021 and would require us to recognize a cumulative effect adjustment to the opening balance of reinvested earnings, if applicable. We are currently evaluating the impact that ASU 2019-12 may have on our consolidated financial statements.

## NOTE 2: ACQUISITIONS AND DIVESTITURES

### Acquisitions

During the nine months ended September 25, 2020, our Company's acquisitions of businesses, equity method investments and nonmarketable securities totaled $989 million, which primarily related to the acquisition of the remaining equity ownership interest in fairlife, LLC ("fairlife").

During the nine months ended September 27, 2019, our Company's acquisitions of businesses, equity method investments and nonmarketable securities totaled $5,376 million, which primarily related to the acquisition of Costa Limited ("Costa"), the remaining equity ownership interest in C.H.I. Limited ("CHI") and controlling interests in bottling operations in Zambia.

*fairlife, LLC*

In January 2020, the Company acquired the remaining 57.5 percent interest in, and now owns100 percent of, fairlife. fairlife offers a broad portfolio of products in the value- added dairy category across North America. A significant portion of fairlife's revenues was already reflected in our consolidated financial statements, as we have operated as the sales and distribution organization for certain fairlife products. Upon consolidation, we recognized a gain of $902 million resulting from the remeasurement of our previously held equity interest in fairlife to fair value. The fair value of our previously held interest was determined using a discounted cash flow model based on Level 3 inputs. The gain was recorded in the line item other income (loss) — net in our condensed consolidated statement of income. We acquired the remaining interest in exchange for $979 million of cash, net of cash acquired, and effectively settled our $306 million note receivable from fairlife at the recorded amount. Under the terms of the agreement, we are subject to making future milestone payments which are contingent on fairlife achieving certain financial targets through 2024 and, if achieved, are payable in 2021, 2023 and 2025. These milestone payments are based on agreed-upon formulas related to fairlife's operating results, the resulting value of which is not subject to a ceiling. Under the applicable accounting guidance, we recorded a $270 million liability representing our best estimate of the fair value of this contingent consideration. The fair value of this contingent consideration was determined using a Monte Carlo valuation model based on Level 3 inputs. We will be required to remeasure this liability to fair value quarterly with any changes in the fair value recorded in income until the final milestone payments are made. During the three and nine months ended September 25, 2020, we recorded charges of

$18 million and $47 million, respectively, related to this remeasurement in the line item other operating charges in our condensed consolidated statements of income. As of September 25, 2020, $1.3 billion of the purchase price was allocated to the fairlife trademark and $0.8 billion was preliminarily allocated to goodwill. The goodwill

7

recognized as part of this acquisition is primarily related to synergistic value created from the opportunity for additional expansion. It also includes certain other intangible assets that do not qualify for separate recognition, such as an assembled workforce. The goodwill is not tax deductible and has been preliminarily assigned to the North America operating segment. The preliminary allocation of the purchase price is subject to refinement when valuations are finalized. As of September 25, 2020, the valuations that have not been finalized primarily relate to other intangible assets as well as operating lease right-of-use assets and operating lease liabilities. The final purchase price allocation will be completed no later than the first quarter of 2021.

*Costa Limited*

In January 2019, the Company acquired Costa in exchange for $4.9 billion of cash, net of cash acquired. Costa is a coffee business with retail outlets in more than 30 countries, the Costa Express vending system and a state-of-the-art roastery. We believe this acquisition will allow us to increase our presence in the hot beverage market as Costa has a scalable platform across multiple formats and channels, including opportunities to introduce ready-to-drink products. Upon finalization of purchase accounting, $2.4 billion of the purchase price was allocated to the Costa trademark and $2.5 billion was allocated to goodwill. The goodwill recognized as part of this acquisition is primarily related to synergistic value created from the opportunity for additional expansion as well as our ability to market and distribute Costa in ready-to-drink form throughout our bottling system. It also includes certain other intangible assets that do not qualify for separate recognition, such as an assembled workforce. The goodwill is not tax deductible and has been assigned to the Global Ventures operating segment, except for $108 million, which has been assigned to the Europe, Middle East and Africa operating segment.

*C.H.I. Limited*

In January 2019, the Company acquired the remaining 60 percent interest in CHI, a Nigerian producer of value-added dairy and juice beverages and iced tea, in exchange for

$260 million of cash, net of cash acquired, under the terms of the agreement for our original investment in CHI. Upon consolidation, we recognized a net charge of $121 million during the nine months ended September 27, 2019, which included the remeasurement of our previously held equity interest in CHI to fair value and the reversal of the related cumulative translation adjustments. The fair value of our previously held equity investment was determined using a discounted cash flow model based on Level 3 inputs. The net charge was recorded in the line item other income (loss) — net in our condensed consolidated statement of income.

### Divestitures

During the nine months ended September 25, 2020, proceeds from disposals of businesses, equity method investments and nonmarketable securities totaled $46 million, which primarily related to the sale of a portion of our ownership interest in one of our equity method investments. We recognized a net gain of $18 million as a result of the sale, which was recorded in the line item other income (loss) — net in our condensed consolidated statement of income.

During the nine months ended September 27, 2019, proceeds from disposals of businesses, equity method investments and nonmarketable securities totaled $266 million, which primarily related to the sale of a portion of our equity method investment in Embotelladora Andina S.A. ("Andina"). We recognized a gain of $39 million as a result of the sale, which was recorded in the line item other income (loss) — net in our condensed consolidated statement of income. We continue to account for our remaining interest in Andina as an equity method investment as a result of our representation on Andina's Board of Directors and other governance rights.

*North America Refranchising — United States*

In conjunction with implementing a new beverage partnership model in North America, in 2018 the Company completed the refranchising of all of our bottling territories in the United States that were previously managed by Coca-Cola Refreshments

("CCR") to certain of our unconsolidated bottling partners. During the three and nine months ended September 27, 2019, we recognized net gains of 1$9 million and $15

million, respectively. These net gains were included in the line item other income (loss) — net in our condensed consolidated statements of income and were primarily related to post-closing adjustments as contemplated by the related agreements.

*North America Refranchising — Canada*

During the three and nine months ended September 27, 2019, we recognized a charge of $122 million related to post-closing adjustments related to the sale of our Canadian bottling operations as contemplated by the related agreements. This charge was included in the line item other income (loss) — net in our condensed consolidated statements of income.

### Coca-Cola Beverages Africa Proprietary Limited

Due to the Company's original intent to refranchise Coca-Cola Beverages Africa Proprietary Limited ("CCBA"), CCBA was accounted for as held for sale and a discontinued operation from October 2017, when the Company became the controlling shareowner of CCBA, through the first quarter of 2019. While the Company had discussions with a number of potential partners throughout the period CCBA was held for sale, during the second quarter of 2019, the Company updated its plans for

8

CCBA and now intends to maintain its controlling stake in CCBA for the foreseeable future. As a result, CCBA no longer qualifies as held for sale or as a discontinued operation, and CCBA's financial results are now presented within the Company's continuing operations. The financial results for prior periods have also been retrospectively reclassified herein. As of the date we changed our plans, the Company was required to measure CCBA's property, plant and equipment and definite-lived intangible assets at the lower of their current fair values or their carrying amounts before they were classified as held for sale, adjusted for depreciation and amortization expense that would have been recognized had the business been classified as held and used during the period that CCBA was classified as held for sale. As a result, the Company reallocated the allowance for reduction of assets held for sale balance that was originally recorded during the third quarter of 2018 to reduce the carrying value of CCBA's property, plant and equipment by

$225 million and CCBA's definite-lived intangible assets by $329 million based on the relative amount of depreciation and amortization that would have been recognized during the periods they were held for sale. We also recorded a $160 million adjustment to reduce the carrying value of CCBA's property, plant and equipment and definite-lived intangible assets by an additional $34 million and $126 million, respectively, during the nine months ended September 27, 2019. These additional adjustments were included in the line item other income (loss) — net in our condensed consolidated statement of income.

## NOTE 3: REVENUE RECOGNITION

The following tables present net operating revenues disaggregated between the United States and International and further by line of business (in millions):

|  |  |  |  |
| --- | --- | --- | --- |
|  | United States | International | Total |
| **Three Months Ended September 25, 2020** |  |  |  |
| Concentrate operations | **$ 1,523 $** | **3,556 $** | **5,079** |
| Finished product operations | **1,503** | **2,070** | **3,573** |
| Total | **$ 3,026 $** | **5,626 $** | **8,652** |
| Three Months Ended September 27, 2019 |  |  |  |
| Concentrate operations | $ 1,414 $ | 4,026 $ | 5,440 |
| Finished product operations | 1,676 | 2,391 | 4,067 |
| Total | $ 3,090 $ | 6,417 $ | 9,507 |
|  | United States | International | Total |
| **Nine Months Ended September 25, 2020** |  |  |  |
| Concentrate operations | **$ 4,117 $** | **9,966 $** | **14,083** |
| Finished product operations | **4,299** | **6,021** | **10,320** |
| Total | **$ 8,416 $** | **15,987 $** | **24,403** |
| Nine Months Ended September 27, 2019 |  |  |  |
| Concentrate operations | $ 4,014 $ | 11,782 $ | 15,796 |
| Finished product operations | 4,824 | 7,578 | 12,402 |
| Total | $ 8,838 $ | 19,360 $ | 28,198 |
| Refer to Note 16 for additional revenue disclosures by operating segment and Corporate. |  |  |  |

9

## NOTE 4: INVESTMENTS

### Equity Securities

The carrying values of our equity securities were included in the following line items in our condensed consolidated balance sheets (in millions):

Fair Value with Changes Recognized in Income

Measurement Alternative — No Readily Determinable Fair

Value

|  |  |  |  |
| --- | --- | --- | --- |
| **September 25, 2020** |  | | |
| Marketable securities | **$** | **296 $** | **—** |
| Other investments |  | **662** | **50** |
| Other assets |  | **1,097** | **—** |
| Total equity securities | **$** | **2,055 $** | **50** |
| December 31, 2019 |  |  |  |
| Marketable securities | $ | 329 $ | — |
| Other investments |  | 772 | 82 |
| Other assets |  | 1,118 | — |
| Total equity securities | $ | 2,219 $ | 82 |

The calculation of net unrealized gains and losses recognized during the period related to equity securities still held at the end of the period is as follows (in millions):

Three Months Ended

|  |  |  |  |
| --- | --- | --- | --- |
|  | | **September 25,**  **2020** | September 27,  2019 |
| Net gains (losses) recognized during the period related to equity securities | **$** | **17** $ | 29 |
| Less: Net gains (losses) recognized during the period related to equity securities sold during the period |  | **—** | — |
| Net unrealized gains (losses) recognized during the period related to equity securities still held at the end of the period | **$** | **17** $ | 29 |

Nine Months Ended

**September 25,**

**2020**

September 27,

2019

Net gains (losses) recognized during the period related to equity securities **$ (137)** $ 163

Less: Net gains (losses) recognized during the period related to equity securities sold

during the period **(24)** 16

Net unrealized gains (losses) recognized during the period related to equity securities still held at the end of the period

**$**

**(113)** $

147

### Debt Securities

Our debt securities consisted of the following (in millions):

Gross Unrealized Estimated Fair

Cost Gains Losses Value

**September 25, 2020**

Trading securities **$ 34 $ 1 $ — $ 35**

Total debt securities **$ 2,645 $ 64 $ (16) $ 2,693**

December 31, 2019

Available-for-sale securities

**2,611**

**63**

**(16)**

**2,658**

|  |  |  |  |
| --- | --- | --- | --- |
| Trading securities $ 46 $ | 1 $ | — $ | 47 |
| Available-for-sale securities 3,172 | 113 | (4) | 3,281 |
| Total debt securities $ 3,218 $ | 114 $ | (4) $ | 3,328 |

10

The carrying values of our debt securities were included in the following line items in our condensed consolidated balance sheets (in millions):

**September 25, 2020** December 31, 2019

**Trading Securities**

**Available-for-**

**Sale Securities** Trading Securities

Available-for- Sale Securities

Cash and cash equivalents

**$**

**— $**

**305** $

— $

123

Marketable securities **35 2,065** 47 2,852

Other assets **— 288** — 306

Total debt securities **$ 35 $ 2,658** $ 47 $ 3,281

The contractual maturities of these available-for-sale debt securities as of September 25, 2020 were as follows (in millions):

Cost

Estimated Fair Value

Within 1 year $ 1,186 $ 1,212

After 1 year through 5 years 1,140 1,134

After 5 years through 10 years 89 102

After 10 years 196 210

Total $ 2,611 $ 2,658

The Company expects that actual maturities may differ from the contractual maturities above because borrowers have the right to call or prepay certain obligations. The sale and/or maturity of available-for-sale debt securities resulted in the following realized activity (in millions):

Three Months Ended Nine Months Ended

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | | **September 25,** | September 27, |  |  | **September 25,** | September 27, |
| **2020** | 2019 |  |  | **2020** | 2019 |
| Gross gains | **$** | **2** $ | 9 |  | **$** | **19** $ | 37 |
| Gross losses |  | **(3)** | (1) |  |  | **(11)** | (5) |
| Proceeds |  | **233** | 1,284 |  |  | **1,419** | 3,074 |

### Captive Insurance Companies

In accordance with local insurance regulations, our captive insurance companies are required to meet and maintain minimum solvency capital requirements. The Company elected to invest a majority of its solvency capital in a portfolio of marketable equity and debt securities. These securities are included in the disclosures above. The Company uses one of its consolidated captive insurance companies to reinsure group annuity insurance contracts that cover the pension obligations of certain of our European and Canadian pension plans. This captive's solvency capital funds included equity and debt securities of $1,227 million and $1,266 million as of September 25, 2020 and December 31, 2019, respectively, which are classified in the line item other assets in our condensed consolidated balance sheets because the assets are not available to satisfy our current obligations.

|  |  |  |
| --- | --- | --- |
| **NOTE 5: INVENTORIES** |  | |
| Inventories consisted of the following (in millions): |
|  | **September 25,**  **2020** | December 31,  2019 |
| Raw materials and packaging | **$ 2,069** $ | 2,180 |
| Finished goods | **802** | 851 |
| Other | **393** | 348 |
| Total inventories | **$ 3,264** $ | 3,379 |

11

## NOTE 6: HEDGING TRANSACTIONS AND DERIVATIVE FINANCIAL INSTRUMENTS

The following table presents the fair values of the Company's derivative instruments that were designated and qualified as part of a hedging relationship (in millions):

Fair Value1,2

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Derivatives Designated as Hedging Instruments | Balance Sheet Location1 |  | **September 25,**  **2020** |  | December 31, 2019 |
| Assets: |  |  |  |  |  |
| Foreign currency contracts | Prepaid expenses and other assets | **$** | **17** | $ | 24 |
| Foreign currency contracts | Other assets |  | **73** |  | 91 |
| Interest rate contracts | Prepaid expenses and other assets |  | **4** |  | 10 |
| Interest rate contracts | Other assets |  | **683** |  | 427 |
| Total assets |  | **$** | **777** | $ | 552 |
| Liabilities: | | | | | |
| Foreign currency contracts | Accounts payable and accrued expenses | **$** | **46** | $ | 40 |
| Foreign currency contracts | Other liabilities |  | **10** |  | 48 |
| Commodity contracts | Accounts payable and accrued expenses |  | **1** |  | — |
| Interest rate contracts | Other liabilities |  | **—** |  | 21 |
| Total liabilities |  | **$** | **57** | $ | 109 |

1 All of the Company's derivative instruments are carried at fair value in our condensed consolidated balance sheets after considering the impact of legally enforceable master netting agreements and cash collateral held or placed with the same counterparties, as applicable. Current disclosure requirements mandate that derivatives must also be disclosed without reflecting the impact of master netting agreements and cash collateral. Refer to Note 15 for the net presentation of the Company's derivative instruments.

2 Refer to Note 15 for additional information related to the estimated fair value.

The following table presents the fair values of the Company's derivative instruments that were not designated as hedging instruments (in millions):

Fair Value1,2

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Derivatives Not Designated as Hedging Instruments | Balance Sheet Location1 |  | **September 25,**  **2020** |  | December 31, 2019 |
| Assets: |  |  |  |  |  |
| Foreign currency contracts | Prepaid expenses and other assets | **$** | **34** | $ | 13 |
| Commodity contracts | Prepaid expenses and other assets |  | **19** |  | 8 |
| Commodity contracts | Other assets |  | **4** |  | 2 |
| Other derivative instruments | Prepaid expenses and other assets |  | **8** |  | 12 |
| Other derivative instruments | Other assets |  | **3** |  | 1 |
| Total assets |  | **$** | **68** | $ | 36 |
| Liabilities: |  |  |  |  |  |
| Foreign currency contracts | Accounts payable and accrued expenses | **$** | **41** | $ | 39 |
| Commodity contracts | Accounts payable and accrued expenses |  | **36** |  | 13 |
| Commodity contracts | Other liabilities |  | **11** |  | 1 |
| Other derivative instruments | Accounts payable and accrued expenses |  | **5** |  | — |
| Total liabilities |  | **$** | **93** | $ | 53 |

1 All of the Company's derivative instruments are carried at fair value in our condensed consolidated balance sheets after considering the impact of legally enforceable master netting agreements and cash collateral held or placed with the same counterparties, as applicable. Current disclosure requirements mandate that derivatives must also be disclosed without reflecting the impact of master netting agreements and cash collateral. Refer to Note 15 for the net presentation of the Company's derivative instruments.

2 Refer to Note 15 for additional information related to the estimated fair value.

### Credit Risk Associated with Derivatives

We have established strict counterparty credit guidelines and enter into transactions only with financial institutions of investment grade or better. We monitor counterparty exposures regularly and review any downgrade in credit rating

12

immediately. If a downgrade in the credit rating of a counterparty were to occur, we have provisions requiring collateral for substantially all of our transactions. To mitigate presettlement risk, minimum credit standards become more stringent as the duration of the derivative financial instrument increases. In addition, the Company's master netting agreements reduce credit risk by permitting the Company to net settle for transactions with the same counterparty. To minimize the concentration of credit risk, we enter into derivative transactions with a portfolio of financial institutions. Based on these factors, we consider the risk of counterparty default to be minimal.

### Cash Flow Hedging Strategy

The Company uses cash flow hedges to minimize the variability in cash flows of assets or liabilities or forecasted transactions caused by fluctuations in foreign currency exchange rates, commodity prices or interest rates. The changes in the fair values of derivatives designated as cash flow hedges are recorded in accumulated other comprehensive income (loss) ("AOCI") and are reclassified into the line item in our consolidated statement of income in which the hedged items are recorded in the same period the hedged items affect earnings. The changes in the fair values of hedges that are determined to be ineffective are immediately reclassified from AOCI into earnings. The maximum length of time for which the Company hedges its exposure to the variability in future cash flows is typically four years.

The Company maintains a foreign currency cash flow hedging program to reduce the risk that our eventual U.S. dollar net cash inflows from sales outside the United States and

U.S. dollar net cash outflows from procurement activities will be adversely affected by fluctuations in foreign currency exchange rates. We enter into forward contracts and purchase foreign currency options and collars (principally euro, British pound sterling and Japanese yen) to hedge certain portions of forecasted cash flows denominated in foreign currencies. When the U.S. dollar strengthens against the foreign currencies, the decline in the present value of future foreign currency cash flows is partially offset by gains in the fair value of the derivative instruments. Conversely, when the U.S. dollar weakens, the increase in the present value of future foreign currency cash flows is partially offset by losses in the fair value of the derivative instruments. The total notional values of derivatives that were designated and qualify for the Company's foreign currency cash flow hedging program were $8,809 million and $6,957 million as of September 25, 2020 and December 31, 2019, respectively.

The Company uses cross-currency swaps to hedge the changes in cash flows of certain of its foreign currency denominated debt and other monetary assets or liabilities due to changes in foreign currency exchange rates. For this hedging program, the Company records the changes in carrying value of these foreign currency denominated assets and liabilities due to changes in exchange rates into earnings each period. The changes in fair value of the cross-currency swap derivatives are recorded in AOCI with an immediate reclassification into earnings for the change in fair value attributable to fluctuations in foreign currency exchange rates. The total notional values of derivatives that have been designated as cash flow hedges for the Company's foreign currency denominated assets and liabilities were $2,700 million and $3,028 million as of September 25, 2020 and December 31, 2019, respectively.

The Company has entered into commodity futures contracts and other derivative instruments on various commodities to mitigate the price risk associated with forecasted purchases of materials used in our manufacturing process. These derivative instruments have been designated and qualify as part of the Company's commodity cash flow hedging program. The objective of this hedging program is to reduce the variability of cash flows associated with future purchases of certain commodities. The total notional values of derivatives that have been designated and qualify for this program were $11 million and $2 million as of September 25, 2020 and December 31, 2019, respectively.

Our Company monitors our mix of short-term debt and long-term debt regularly. From time to time, we manage our risk to interest rate fluctuations through the use of derivative financial instruments. The Company has entered into interest rate swap agreements and has designated these instruments as part of the Company's interest rate cash flow hedging program. The objective of this hedging program is to mitigate the risk of adverse changes in benchmark interest rates on the Company's future interest payments. As of September 25, 2020 and December 31, 2019, we did not have any interest rate swaps designated as a cash flow hedge.

13

The following tables present the pretax impact that changes in the fair values of derivatives designated as cash flow hedges had on other comprehensive income ("OCI"), AOCI and earnings (in millions):

|  |  |  |  |
| --- | --- | --- | --- |
|  | Gain (Loss)  Recognized  in OCI | Location of Gain (Loss) Recognized in Income | Gain (Loss) Reclassified from AOCI into Income |
| **Three Months Ended September 25, 2020** |  |  |  |
| Foreign currency contracts | **$ (84)** | Net operating revenues | **$ (21)** |
| Foreign currency contracts | **(4)** | Cost of goods sold | **2** |
| Foreign currency contracts | **—** | Interest expense | **(6)** |
| Foreign currency contracts | **122** | Other income (loss) — net | **100** |
| Interest rate contracts | **9** | Interest expense | **(14)** |
| Commodity contracts | **(2)** | Cost of goods sold | **(1)** |
| Total | **$ 41** |  | **$ 60** |
| Three Months Ended September 27, 2019 |  |  |  |
| Foreign currency contracts | $ 71 | Net operating revenues | $ (5) |
| Foreign currency contracts | 3 | Cost of goods sold | 2 |
| Foreign currency contracts | — | Interest expense | (3) |
| Foreign currency contracts | (46) | Other income (loss) — net | (46) |
| Interest rate contracts | (30) | Interest expense | (10) |
| Commodity contracts | 1 | Cost of goods sold | — |
| Total | $ (1) |  | $ (62) |

Gain (Loss)

Recognized

in OCI Location of Gain (Loss) Recognized in Income

Gain (Loss) Reclassified from AOCI into Income

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Nine Months Ended September 25, 2020** |  | | | | |
| Foreign currency contracts | **$** | **(61)** | Net operating revenues | **$** | **(22)** |
| Foreign currency contracts |  | **6** | Cost of goods sold |  | **7** |
| Foreign currency contracts |  | **—** | Interest expense |  | **(10)** |
| Foreign currency contracts |  | **21** | Other income (loss) — net |  | **71** |
| Interest rate contracts |  | **21** | Interest expense |  | **(35)** |
| Commodity contracts |  | **(2)** | Cost of goods sold |  | **(1)** |
| Total | **$** | **(15)** |  | **$** | **10** |
| Nine Months Ended September 27, 2019 |  |  |  |  |  |
| Foreign currency contracts | $ | 44 | Net operating revenues | $ | 2 |
| Foreign currency contracts |  | 1 | Cost of goods sold |  | 9 |
| Foreign currency contracts |  | — | Interest expense |  | (7) |
| Foreign currency contracts |  | (99) | Other income (loss) — net |  | (139) |
| Interest rate contracts |  | (47) | Interest expense |  | (30) |
| Commodity contracts |  | 1 | Cost of goods sold |  | — |
| Total | $ | (100) |  | $ | (165) |

As of September 25, 2020, the Company estimates that it will reclassify into earnings during the next 12 months net losses of $119 million from the pretax amount recorded in AOCI as the anticipated cash flows occur.

### Fair Value Hedging Strategy

The Company uses interest rate swap agreements designated as fair value hedges to minimize exposure to changes in the fair value of fixed-rate debt that results from fluctuations in benchmark interest rates. The Company also uses cross-currency interest rate swaps to hedge the changes in the fair value of foreign currency denominated debt relating to changes in foreign currency exchange rates and benchmark interest rates. The changes in the fair values of derivatives designated as fair value hedges and the offsetting changes in the fair values of the hedged items are recognized in earnings. The ineffective portions of

14

these hedges are immediately recognized in earnings. When a derivative is no longer designated as a fair value hedge for any reason, including termination and maturity, the remaining unamortized difference between the carrying value of the hedged item at that time and the face value of the hedged item is amortized to earnings over the remaining life of the hedged item, or immediately if the hedged item has matured or has been extinguished. The total notional values of derivatives related to fair value hedges of this type were $12,212 million and $12,523 million as of September 25, 2020 and December 31, 2019, respectively.

The Company also uses fair value hedges to minimize exposure to changes in the fair values of certain available-for-sale securities from fluctuations in foreign currency exchange rates. The changes in the fair values of derivatives designated as fair value hedges and the offsetting changes in the fair values of the hedged items due to changes in foreign currency exchange rates are recognized in earnings. As a result, any difference is reflected in earnings as ineffectiveness. The total notional value of derivatives related to fair value hedges of this type was $499 million as of September 25, 2020. As of December 31, 2019, we did not have any fair value hedges of this type.

The following tables summarize the pretax impact that changes in the fair values of derivatives designated as fair value hedges had on earnings (in millions):

Gain (Loss) Recognized in Income

Three Months Ended

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Hedging Instruments and Hedged Items | Location of Gain (Loss) Recognized in Income |  | **September 25,**  **2020** | September 27,  2019 |
| Interest rate contracts | Interest expense | **$** | **94** $ | 206 |
| Fixed-rate debt | Interest expense |  | **(97)** | (200) |
| Net impact to interest expense |  | **$** | **(3)** $ | 6 |
| Foreign currency contracts | Other income (loss) — net | **$** | **3** $ | — |
| Available-for-sale securities | Other income (loss) — net |  | **(3)** | — |
| Net impact to other income (loss) — net |  | **$** | **—** $ | — |
| Net impact of fair value hedging instruments |  | **$** | **(3)** $ | 6 |

Gain (Loss) Recognized in Income

Nine Months Ended

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Hedging Instruments and Hedged Items | Location of Gain (Loss) Recognized in Income |  | **September 25,**  **2020** | September 27,  2019 |
| Interest rate contracts | Interest expense | **$** | **284** $ | 647 |
| Fixed-rate debt | Interest expense |  | **(281)** | (637) |
| Net impact to interest expense |  | **$** | **3** $ | 10 |
| Foreign currency contracts | Other income (loss) — net | **$** | **3** $ | — |
| Available-for-sale securities | Other income (loss) — net |  | **(3)** | — |
| Net impact to other income (loss) — net |  | **$** | **—** $ | — |
| Net impact of fair value hedging instruments |  | **$** | **3** $ | 10 |

The following table summarizes the amounts recorded in the condensed consolidated balance sheets related to hedged items in fair value hedging relationships (in millions):

Cumulative Amount of Fair Value Hedging Adjustments Included in Carrying Value of Hedged

Carrying Value of Hedged Items Items1

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | | **September 25,** | December 31, |  |  | **September 25,** | December 31, |
| Balance Sheet Location of Hedged Items |  | **2020** | 2019 |  |  | **2020** | 2019 |
| Cash and cash equivalents | **$** | **294** $ | — |  | **$** | **—** $ | — |
| Marketable securities |  | **201** | — |  |  | **—** | — |
| Current maturities of long-term debt |  | **2,038** | 1,004 |  |  | **(2)** | 5 |
| Long-term debt |  | **10,685** | 12,087 |  |  | **670** | 448 |

1 Cumulative amount of fair value hedging adjustments does not include changes due to foreign currency exchange rates.

15

### Hedges of Net Investments in Foreign Operations Strategy

The Company uses forward contracts and a portion of its foreign currency denominated debt, a non-derivative financial instrument, to protect the value of our net investments in a number of foreign operations. For derivative instruments that are designated and qualify as hedges of net investments in foreign operations, the changes in the fair values of the derivative instruments are recognized in net foreign currency translation adjustments, a component of AOCI, to offset the changes in the values of the net investments being hedged. For non-derivative financial instruments that are designated and qualify as hedges of net investments in foreign operations, the change in the carrying value of the designated portion of the non-derivative financial instrument due to changes in foreign currency exchange rates is recorded in net foreign currency translation adjustments. Any ineffective portions of net investment hedges are reclassified from AOCI into earnings during the period of change.

The following table summarizes the notional values and pretax impact of changes in the fair values of instruments designated as net investment hedges (in millions):

Notional Amount Gain (Loss) Recognized in OCI

as of Three Months Ended Nine Months Ended

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **September 25,** | December 31, |  | **September 25,** | September 27, |  | **September 25,** | September 27, |
| **2020** | 2019 |  | **2020** | 2019 |  | **2020** | 2019 |
| Foreign currency contracts | **$ —** $ | — |  | **$ (23)** $ | 13 |  | **$ (4)** $ | 42 |
| Foreign currency denominated debt | **12,699** | 12,334 |  | **(445)** | 476 |  | **(452)** | 444 |
| Total | **$ 12,699** $ | 12,334 |  | **$ (468)** $ | 489 |  | **$ (456)** $ | 486 |

The Company did not reclassify any gains or losses related to net investment hedges from AOCI into earnings during the three and nine months ended September 25, 2020 and September 27, 2019. In addition, the Company did not have any ineffectiveness related to net investment hedges during the three and nine months ended September 25, 2020 and September 27, 2019. The cash inflows and outflows associated with the Company's derivative contracts designated as net investment hedges are classified in the line item other investing activities in our consolidated statement of cash flows.

### Economic (Non-Designated) Hedging Strategy

In addition to derivative instruments that are designated and qualify for hedge accounting, the Company also uses certain derivatives as economic hedges of foreign currency, interest rate and commodity exposure. Although these derivatives were not designated and/or did not qualify for hedge accounting, they are effective economic hedges. The changes in the fair values of economic hedges are immediately recognized in earnings.

The Company uses foreign currency economic hedges to offset the earnings impact that fluctuations in foreign currency exchange rates have on certain monetary assets and liabilities denominated in nonfunctional currencies. The changes in the fair values of economic hedges used to offset those monetary assets and liabilities are immediately recognized in earnings in the line item other income (loss) — net in our consolidated statement of income. In addition, we use foreign currency economic hedges to minimize the variability in cash flows associated with fluctuations in foreign currency exchange rates, including those related to certain acquisition and divestiture activities. The changes in the fair values of economic hedges used to offset the variability in U.S. dollar net cash flows are recognized in earnings in the line items net operating revenues, cost of goods sold or other income (loss) — net in our consolidated statement of income, as applicable. The total notional values of derivatives related to our foreign currency economic hedges were $6,069 million and $4,291 million as of September 25, 2020 and December 31, 2019, respectively.

The Company also uses certain derivatives as economic hedges to mitigate the price risk associated with the purchase of materials used in the manufacturing process and vehicle fuel. The changes in the fair values of these economic hedges are immediately recognized in earnings in the line items net operating revenues, cost of goods sold, or selling, general and administrative expenses in our consolidated statement of income, as applicable. The total notional values of derivatives related to our economic hedges of this type were $511 million and $425 million as of September 25, 2020 and December 31, 2019, respectively.

The following tables present the pretax impact that changes in the fair values of derivatives not designated as hedging instruments had on earnings (in millions):

16

Gain (Loss) Recognized in Income

Three Months Ended

|  |  |  |  |
| --- | --- | --- | --- |
| Derivatives Not Designated as Hedging Instruments | Location of Gain (Loss) Recognized in Income | **September 25,**  **2020** | September 27,  2019 |
| Foreign currency contracts | Net operating revenues | **$ 2** $ | 15 |
| Foreign currency contracts | Cost of goods sold | **(17)** | 2 |
| Foreign currency contracts | Other income (loss) — net | **53** | (21) |
| Interest rate contracts | Interest expense | **2** | — |
| Commodity contracts | Cost of goods sold | **34** | (60) |
| Other derivative instruments | Selling, general and administrative expenses | **20** | 4 |
| Other derivative instruments | Other income (loss) — net | **—** | 5 |
| Total |  | **$ 94** $ | (55) |
|  |  | Gain (Lo Recognized in | ss) Income |
|  |  | Nine Months | Ended |
| Derivatives Not Designated as Hedging Instruments | Location of Gain (Loss) Recognized in Income | **September 25,**  **2020** | September 27,  2019 |
| Foreign currency contracts | Net operating revenues | **$ 64** $ | 2 |
| Foreign currency contracts | Cost of goods sold | **10** | 4 |
| Foreign currency contracts | Other income (loss) — net | **(33)** | (46) |
| Interest rate contracts | Interest expense | **2** | — |
| Commodity contracts | Cost of goods sold | **(33)** | (58) |
| Other derivative instruments | Selling, general and administrative expenses | **(12)** | 32 |
| Other derivative instruments | Other income (loss) — net | **(55)** | 39 |
| Total |  | **$ (57)** $ | (27) |

## NOTE 7: DEBT AND BORROWING ARRANGEMENTS

During the nine months ended September 25, 2020, the Company issued U.S. dollar- and euro-denominated debt of $15,600 million and €2,600 million, respectively. The carrying value of this debt as of September 25, 2020 was $17,461 million. The general terms of the notes issued are as follows:

* $1,000 million total principal amount of notes due March 25, 2025, at a fixed interest rate of2.950 percent;
* $1,000 million total principal amount of notes due March 25, 2027, at a fixed interest rate of3.375 percent;
* $1,500 million total principal amount of notes due June 1, 2027, at a fixed interest rate of1.450 percent;
* $1,300 million total principal amount of notes due March 15, 2028, at a fixed interest rate of1.000 percent;
* €1,000 million total principal amount of notes due March 15, 2029, at a fixed interest rate of0.125 percent;
* $1,250 million total principal amount of notes due March 25, 2030, at a fixed interest rate of3.450 percent;
* $1,500 million total principal amount of notes due June 1, 2030, at a fixed interest rate of1.650 percent;
* $1,300 million total principal amount of notes due March 15, 2031, at a fixed interest rate of1.375 percent;
* €750 million total principal amount of notes due March 15, 2033, at a fixed interest rate of0.375 percent;
* €850 million total principal amount of notes due March 15, 2040, at a fixed interest rate of0.800 percent;
* $500 million total principal amount of notes due March 25, 2040, at a fixed interest rate of4.125 percent;
* $1,000 million total principal amount of notes due June 1, 2040, at a fixed interest rate of2.500 percent;
* $1,250 million total principal amount of notes due March 25, 2050, at a fixed interest rate of4.200 percent;
* $1,500 million total principal amount of notes due June 1, 2050, at a fixed interest rate of2.600 percent;

17

* $1,500 million total principal amount of notes due March 15, 2051, at a fixed interest rate of2.500 percent; and
* $1,000 million total principal amount of notes due June 1, 2060, at a fixed interest rate of2.750 percent.

During the nine months ended September 25, 2020, the Company retired upon maturity Australian dollar- and U.S. dollar-denominated notes. The general terms of the notes retired are as follows:

* AUD450 million total principal amount of notes due June 9, 2020, at a fixed interest rate of2.600 percent; and
* $171 million total principal amount of zero coupon notes due June 20, 2020.

During the nine months ended September 25, 2020, the Company also extinguished prior to maturity U.S. dollar- and euro-denominated debt of $1,954 million and

€1,448 million, respectively, resulting in associated charges of $397 million recorded in the line item interest expense in our condensed consolidated statement of income. These charges included the difference between the reacquisition price and the net carrying amount of the debt extinguished, including the impact of the related fair value hedging relationships. We also incurred charges of $8 million as a result of the reclassification of related cash flow hedging balances from AOCI into income. The general terms of the notes that were extinguished are as follows:

* €379 million total principal amount of notes due March 8, 2021, at a variable interest rate equal to thethree-month Euro Interbank Offered Rate ("EURIBOR") plus

0.200 percent;

* €152 million total principal amount of notes due March 9, 2021, at a fixed interest rate of0.000 percent;
* $444 million total principal amount of notes due September 1, 2021, at a fixed interest rate of3.300 percent;
* $335 million total principal amount of notes due September 1, 2021, at a fixed interest rate of1.550 percent;
* $184 million total principal amount of notes due May 25, 2022, at a fixed interest rate of2.200 percent;
* €598 million total principal amount of notes due September 22, 2022, at a fixed interest rate of0.125 percent;
* €319 million total principal amount of notes due September 22, 2022, at a fixed interest rate of1.125 percent;
* $282 million total principal amount of notes due March 25, 2040, at a fixed interest rate of4.125 percent; and
* $709 million total principal amount of notes due March 25, 2050, at a fixed interest rate of4.200 percent.

## NOTE 8: COMMITMENTS AND CONTINGENCIES

### Guarantees

As of September 25, 2020, we were contingently liable for guarantees of indebtedness owed by third parties of $443 million, of which $138 million was related to variable interest entities. Our guarantees are primarily related to third-party customers, bottlers and vendors and have arisen through the normal course of business. These guarantees have various terms, and none of these guarantees is individually significant. These amounts represent the maximum potential future payments that we could be required to make under the guarantees; however, we do not consider it probable that we will be required to satisfy these guarantees.

We believe our exposure to concentrations of credit risk is limited due to the diverse geographic areas covered by our operations.

### Legal Contingencies

The Company is involved in various legal proceedings. We establish reserves for specific legal proceedings when we determine that the likelihood of an unfavorable outcome is probable and the amount of loss can be reasonably estimated. Management has also identified certain other legal matters where we believe an unfavorable outcome is reasonably possible and/or for which no estimate of possible losses can be made. Management believes that the total liabilities of the Company that may arise as a result of currently pending legal proceedings will not have a material adverse effect on the Company taken as a whole.

### Tax Audits

The Company is involved in various tax matters, some of which have an uncertain outcome. We establish reserves to remove some or all of the tax benefit of any of our tax positions at the time we determine that it becomes uncertain based upon one of the following conditions: (1) the tax position is not "more likely than not" to be sustained; (2) the tax position is "more likely than not" to be sustained but for a lesser amount; or (3) the tax position is "more likely than not" to be sustained but not in the financial period in which the tax position was originally taken. For purposes of evaluating whether or not a tax position is uncertain, (1) we presume the tax position will be examined by the relevant taxing authority that has full knowledge of all relevant information; (2) the technical merits of a tax position are derived from authorities, such as legislation and statutes, legislative intent, regulations, rulings and case law and their applicability to the facts and circumstances of the tax position; and

18

1. each tax position is evaluated without consideration of the possibility of offset or aggregation with other tax positions taken. A number of years may elapse before a particular uncertain tax position is audited and finally resolved. The number of years subject to tax audits or tax assessments varies depending on the tax jurisdiction. The tax benefit that has been previously reserved because of a failure to meet the "more likely than not" recognition threshold would be recognized in our income tax expense in the first interim period when the uncertainty disappears under any one of the following conditions: (1) the tax position is "more likely than not" to be sustained; (2) the tax position, amount, and/or timing is ultimately settled through negotiation or litigation; or (3) the statute of limitations for the tax position has expired. Refer to Note 14.

On September 17, 2015, the Company received a Statutory Notice of Deficiency (the "Notice") from the Internal Revenue Service ("IRS") for the tax years 2007 through 2009 after a five-year audit. In the Notice, the IRS claimed that the Company's U.S. taxable income should be increased by an amount that creates a potential additional federal income tax liability of approximately $3.3 billion for the period plus interest. No penalties were asserted in the Notice. The disputed amounts largely relate to a transfer pricing matter involving the appropriate amount of taxable income the Company should report in the United States in connection with its licensing of intangible property to certain related foreign licensees regarding the manufacturing, distribution, sale, marketing, and promotion of products in certain foreign markets.

During the 2007-2009 audit period, the Company followed the same transfer pricing methodology for these licenses that had consistently been followed since the methodology was agreed with the IRS in a 1996 closing agreement (the "Closing Agreement") that applied back to 1987. The Closing Agreement provided prospective penalty protection conditioned on the Company's continued adherence to the prescribed methodology absent a change in material facts or circumstances or relevant federal tax law. Although the IRS subsequently asserted, without explanation, that material facts and circumstances and relevant federal tax law had changed, it has not asserted penalties. The Company's compliance with the Closing Agreement was audited and confirmed by the IRS in five successive audit cycles covering the subsequent 11 years through 2006, with the last audit concluding as recently as 2009.

The Notice represents a repudiation of the methodology previously adopted in the Closing Agreement. The IRS designated the matter for litigation on October 15, 2015. Due to the fact that the matter remains designated, the Company is prevented from pursuing any administrative settlement at IRS Appeals or under the IRS Advance Pricing and Mutual Agreement Program.

The Company firmly believes that the IRS' claims are without merit and is pursuing, and will continue to pursue, all available administrative and judicial remedies necessary to vigorously defend its position. To that end, the Company filed a petition in the U.S. Tax Court on December 14, 2015, and the IRS filed its answer on February 12, 2016. On October 4, 2017, the IRS filed an amended answer to the Company's petition in which it increased its transfer pricing adjustment by $385 million resulting in an additional tax adjustment of $135 million.

On June 20, 2017, the Company filed a motion for summary judgment on the portion of the IRS' adjustments related to our licensee in Mexico. On December 14, 2017, the U.S.

Tax Court issued a decision on the summary judgment motion in favor of the Company. This decision effectively reduced the IRS' potential tax adjustment by approximately $138 million.

The U.S. Tax Court trial was held from March 8, 2018 through May 11, 2018. The Company and the IRS filed and exchanged final post-trial briefs in April 2019. It is not known how much time will elapse thereafter prior to the issuance of the court's opinion. In the interim, or subsequent to the court's opinion, the IRS may propose similar adjustments for years subsequent to the 2007-2009 litigation period. While the Company continues to strongly disagree with the IRS' position, there is no assurance that the court will rule in the Company's favor, and it is possible that all or some portion of the adjustment proposed by the Notice ultimately could be sustained. In that event, the Company may be subject to significant additional liabilities for the years at issue and potentially also for subsequent periods, which could have a material adverse impact on the Company's financial position, results of operations, and cash flows.

The Company regularly assesses the likelihood of adverse outcomes resulting from tax disputes such as this and other examinations for all open years to determine the adequacy of its tax reserves. Any such adjustments related to years prior to 2018, either in the litigation period or later, may have an impact on the transition tax payable as part of the Tax Cuts and Jobs Act of 2017 ("Tax Reform Act").

### Risk Management Programs

The Company has numerous global insurance programs in place to help protect the Company from the risk of loss. In general, we are self-insured for large portions of many different types of claims; however, we do use commercial insurance above our self-insured retentions to reduce the Company's risk of catastrophic loss. Our reserves for the Company's self-insured losses are estimated using actuarial methods and assumptions of the insurance industry, adjusted for our specific expectations based on our claim history. Our self-insurance reserves totaled $271 million and $301 million as of September 25, 2020 and December 31, 2019, respectively.

19

## NOTE 9: OTHER COMPREHENSIVE INCOME

AOCI attributable to shareowners of The Coca-Cola Company is separately presented in our condensed consolidated balance sheets as a component of The Coca-Cola Company's shareowners' equity, which also includes our proportionate share of equity method investees' AOCI. OCI attributable to noncontrolling interests is allocated to, and included in, our condensed consolidated balance sheets as part of the line item equity attributable to noncontrolling interests.

AOCI attributable to shareowners of The Coca-Cola Company consisted of the following, net of tax (in millions):

**September 25,**

|  |  |  |
| --- | --- | --- |
|  | **2020** | December 31, 2019 |
| Foreign currency translation adjustments | **$ (13,154)** | $ (11,270) |
| Accumulated derivative net gains (losses) | **(232)** | (209) |
| Unrealized net gains (losses) on available-for-sale debt securities | **35** | 75 |
| Adjustments to pension and other benefit liabilities | **(2,095)** | (2,140) |
| Accumulated other comprehensive income (loss) | **$ (15,446)** | $ (13,544) |

The following table summarizes the allocation of total comprehensive income between shareowners of The Coca-Cola Company and noncontrolling interests (in millions):

Nine Months Ended September 25, 2020

Shareowners of The Coca-Cola Company

Noncontrolling

Interests Total

Consolidated net income $ 6,291 $ 3 $ 6,294 Other comprehensive income:

Net foreign currency translation adjustments (1,884) (399) (2,283)

Net gains (losses) on derivatives1 (23) — (23)

Net change in unrealized gains (losses) on available-for-sale debt securities2

(40)

—

(40)

Net change in pension and other benefit liabilities

Total comprehensive income (loss)

$

45

4,389 $

—

(396) $

45

3,993

1 Refer to Note 6 for additional information related to the net gains or losses on derivative instruments.

2 Refer to Note 4 for additional information related to the net unrealized gains or losses on available-for-sale debt securities.

20

The following tables present OCI attributable to shareowners of The Coca-Cola Company, including our proportionate share of equity method investees' OCI (in millions):

Before-Tax

Three Months Ended September 25, 2020 Amount Income Tax After-Tax Amount

Foreign currency translation adjustments:

Translation adjustments arising during the period $ 548 $ (30) $ 518

Gains (losses) on intra-entity transactions that are of a long-term investment nature 883 — 883

Gains (losses) on net investment hedges arising during the period1 (468) 117 (351)

Reclassification adjustments recognized in net income — — —

Net foreign currency translation adjustments $ 963 $ 87 $ 1,050

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Derivatives: | | | | | |
| Gains (losses) arising during the period | $ 41 | | $ (9) | | $ 32 |
| Reclassification adjustments recognized in net income | (60) | | 15 | | (45) |
| Net gains (losses) on derivatives1 | $ (19) | | $ 6 | | $ (13) |
| Available-for-sale debt securities: | | | | | |
| Unrealized gains (losses) arising during the period | $ (32) | | $ 10 | | $ (22) |
| Reclassification adjustments recognized in net income | 1 | | — | | 1 |
| Net change in unrealized gains (losses) on available-for-sale debt securities2 | $ (31) | | $ 10 | | $ (21) |
| Pension and other benefit liabilities: | | | | | |
| Net pension and other benefit liabilities arising during the period | $ (44) | | $ 9 | | $ (35) |
| Reclassification adjustments recognized in net income | 44 | | (11) | | 33 |
| Net change in pension and other benefit liabilities | $ — | | $ (2) | | $ (2) |
| Other comprehensive income (loss) attributable to shareowners of The Coca-Cola Company | $ | 913 | $ | 101 $ 1,014 | |
| 1 Refer to Note 6 for additional information related to the net gains or losses on derivative instruments. |  |  |  |  | |
| 2 Refer to Note 4 for additional information related to the net unrealized gains or losses on available-for-sale debt securities. |  |  |  |  | |
| Nine Months Ended September 25, 2020 |  | Before-Tax Amount |  | Income Tax After-Tax Amount | |
| Foreign currency translation adjustments: |  |  |  |  | |
| Translation adjustments arising during the period | $ (2,627) | | $ 196 | | $ (2,431) |
| Reclassification adjustments recognized in net income | 3 | | — | | 3 |
| Gains (losses) on intra-entity transactions that are of a long-term investment nature | 886 | | — | | 886 |
| Gains (losses) on net investment hedges arising during the period1 | (456) | | 114 | | (342) |
| Net foreign currency translation adjustments | $ (2,194) | | $ 310 | | $ (1,884) |
| Derivatives: | | | | | |
| Gains (losses) arising during the period | $ (24) | | $ 8 | | $ (16) |
| Reclassification adjustments recognized in net income | (10) | | 3 | | (7) |
| Net gains (losses) on derivatives1 | $ (34) | | $ 11 | | $ (23) |
| Available-for-sale debt securities: | | | | | |
| Unrealized gains (losses) arising during the period | $ (54) | | $ 20 | | $ (34) |
| Reclassification adjustments recognized in net income | (8) | | 2 | | (6) |
| Net change in unrealized gains (losses) on available-for-sale debt securities2 | $ (62) | | $ 22 | | $ (40) |
| Pension and other benefit liabilities: | | | | | |
| Net pension and other benefit liabilities arising during the period | $ (68) | | $ 15 | | $ (53) |
| Reclassification adjustments recognized in net income | 130 | | (32) | | 98 |
| Net change in pension and other benefit liabilities | $ 62 | | $ (17) | | $ 45 |
| Other comprehensive income (loss) attributable to shareowners of The Coca-Cola Company | $ (2,228) | | $ 326 | | $ (1,902) |
| 1 Refer to Note 6 for additional information related to the net gains or losses on derivative instruments. |  | |  | |  |
| 2 Refer to Note 4 for additional information related to the net unrealized gains or losses on available-for-sale debt securities. |  | |  | |  |

21

Three Months Ended September 27, 2019

Before-Tax

Amount Income Tax After-Tax Amount

Foreign currency translation adjustments:

Translation adjustments arising during the period $ (256) $ (6) $ (262)

Gains (losses) on intra-entity transactions that are of a long-term investment nature (924) — (924)

Gains (losses) on net investment hedges arising during the period1 489 (122) 367

Net foreign currency translation adjustments $ (691) $ (128) $ (819)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Derivatives: |  | | | | |
| Gains (losses) arising during the period | $ (2) | | $ 1 | | $ (1) |
| Reclassification adjustments recognized in net income | 62 | | (15) | | 47 |
| Net gains (losses) on derivatives1 | $ 60 | | $ (14) | | $ 46 |
| Available-for-sale debt securities: |  | |  | |  |
| Unrealized gains (losses) arising during the period | $ 29 | | $ (7) | | $ 22 |
| Reclassification adjustments recognized in net income | (8) | | 2 | | (6) |
| Net change in unrealized gains (losses) on available-for-sale debt securities2 | $ 21 | | $ (5) | | $ 16 |
| Pension and other benefit liabilities: |  | |  | |  |
| Net pension and other benefit liabilities arising during the period | $ 4 | | $ — | | $ 4 |
| Reclassification adjustments recognized in net income | 37 | | (9) | | 28 |
| Net change in pension and other benefit liabilities | $ 41 | | $ (9) | | $ 32 |
| Other comprehensive income (loss) attributable to shareowners of The Coca-Cola Company | $ | (569) | $ | (156) $ (725) | |
| 1 Refer to Note 6 for additional information related to the net gains or losses on derivative instruments. |  |  |  |  | |
| 2 Refer to Note 4 for additional information related to the net unrealized gains or losses on available-for-sale debt securities. |  |  |  |  | |
| Nine Months Ended September 27, 2019 |  | Before-Tax Amount |  | Income Tax After-Tax Amount | |
| Foreign currency translation adjustments: |  |  |  |  | |
| Translation adjustments arising during the period | $ (141) | | $ (77) | | $ (218) |
| Reclassification adjustments recognized in net income | 192 | | — | | 192 |
| Gains (losses) on intra-entity transactions that are of a long-term investment nature | (888) | | — | | (888) |
| Gains (losses) on net investment hedges arising during the period1 | 486 | | (121) | | 365 |
| Net foreign currency translation adjustments | $ (351) | | $ (198) | | $ (549) |
| Derivatives: | | | | | |
| Gains (losses) arising during the period | $ (119) | | $ 24 | | $ (95) |
| Reclassification adjustments recognized in net income | 166 | | (41) | | 125 |
| Net gains (losses) on derivatives1 | $ 47 | | $ (17) | | $ 30 |
| Available-for-sale debt securities: | | | | | |
| Unrealized gains (losses) arising during the period | $ 88 | | $ (17) | | $ 71 |
| Reclassification adjustments recognized in net income | (32) | | 7 | | (25) |
| Net change in unrealized gains (losses) on available-for-sale debt securities2 | $ 56 | | $ (10) | | $ 46 |
| Pension and other benefit liabilities: | | | | | |
| Net pension and other benefit liabilities arising during the period | $ 11 | | $ 5 | | $ 16 |
| Reclassification adjustments recognized in net income | 111 | | (27) | | 84 |
| Net change in pension and other benefit liabilities | $ 122 | | $ (22) | | $ 100 |
| Other comprehensive income (loss) attributable to shareowners of The Coca-Cola Company | $ (126) | | $ (247) | | $ (373) |
| 1 Refer to Note 6 for additional information related to the net gains or losses on derivative instruments. |  | |  | |  |
| 2 Refer to Note 4 for additional information related to the net unrealized gains or losses on available-for-sale debt securities. |  | |  | |  |

22

The following table presents the amounts and line items in our condensed consolidated statements of income where adjustments reclassified from AOCI into income were recorded (in millions):

Amount Reclassified from AOCI into Income

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Description of AOCI Component | Financial Statement Line Item |  | Three Months Ended September 25, 2020 |  | Nine Months Ended September 25, 2020 |
| Foreign currency translation adjustments: |  |  |  |  |  |
| Divestitures, deconsolidations and other1 | Other income (loss) — net | $ | — | $ | 3 |
|  | Income before income taxes |  | — |  | 3 |
|  | Income taxes |  | — |  | — |
|  | Consolidated net income | $ | — | $ | 3 |
| Derivatives: |  |  |  |  |  |
| Foreign currency contracts | Net operating revenues | $ | 21 | $ | 22 |
| Foreign currency and commodity contracts | Cost of goods sold |  | (1) |  | (6) |
| Foreign currency contracts | Other income (loss) — net |  | (100) |  | (71) |
| Foreign currency and interest rate contracts | Interest expense |  | 20 |  | 45 |
|  | Income before income taxes |  | (60) |  | (10) |
|  | Income taxes |  | 15 |  | 3 |
|  | Consolidated net income | $ | (45) | $ | (7) |
| Available-for-sale debt securities: |  |  |  |  |  |
| Sale of debt securities | Other income (loss) — net | $ | 1 | $ | (8) |
|  | Income before income taxes |  | 1 |  | (8) |
|  | Income taxes |  | — |  | 2 |
|  | Consolidated net income | $ | 1 | $ | (6) |
| Pension and other benefit liabilities: |  |  |  |  |  |
| Recognized net actuarial loss | Other income (loss) — net | $ | 45 | $ | 132 |
| Recognized prior service cost (credit) | Other income (loss) — net |  | (1) |  | (2) |
|  | Income before income taxes |  | 44 |  | 130 |
|  | Income taxes |  | (11) |  | (32) |
|  | Consolidated net income | $ | 33 | $ | 98 |

1 Related to the sale of a portion of our ownership interest in one of our equity method investments. Refer to Note 2.

## NOTE 10: CHANGES IN EQUITY

The following tables provide a reconciliation of the beginning and ending carrying amounts of total equity, equity attributable to shareowners of The Coca-Cola Company and equity attributable to noncontrolling interests (in millions):

**Shareowners of The Coca-Cola Company**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Three Months Ended September 25, 2020 | Common Shares Outstanding | Total | Reinvested Earnings | Accumulated  Other Comprehensive Income (Loss) | Common Stock | Capital Surplus | Treasury Stock | **Non- controlling Interests** |
| June 26, 2020 | 4,295 $ | 19,189 $ | 66,888 $ | (16,460) $ | 1,760 $ | 17,367 $ | (52,071) $ | 1,705 |
| Comprehensive income (loss) | — | 2,756 | 1,737 | 1,014 | — | — | — | 5 |
| Dividends paid/payable to |  |  |  |  |  |  |  |  |
| shareowners of The Coca-Cola |  |  |  |  |  |  |  |  |
| Company ($0.41 per share) | — | (1,762) | (1,762) | — | — | — | — | — |
| Dividends paid to noncontrolling interests | — | (1) | — | — | — | — | — | (1) |
| Impact related to stock-based |  |  |  |  |  |  |  |  |
| compensation plans | 2 | 134 | — | — | — | 96 | 38 | — |
| September 25, 2020 | 4,297 $ | 20,316 $ | 66,863 $ | (15,446) $ | 1,760 $ | 17,463 $ | (52,033) $ | 1,709 |

23

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Shareowners of The Coca-Cola Company** | | | | | | | | |
|  |  |  |  | Accumulated |  |  |  |  |
|  |  |  |  | Other |  |  |  | **Non-** |
|  | Common Shares |  | Reinvested | Comprehensive | Common | Capital | Treasury | **controlling** |
| Nine Months Ended September 25, 2020 | Outstanding | Total | Earnings | Income (Loss) | Stock | Surplus | Stock | **Interests** |
| December 31, 2019 | 4,280 $ | 21,098 $ | 65,855 $ | (13,544) $ | 1,760 $ | 17,154 $ | (52,244) $ | 2,117 |
| Comprehensive income (loss) | — | 3,993 | 6,291 | (1,902) | — | — | — | (396) |
| Dividends paid/payable to |  |  |  |  |  |  |  |  |
| shareowners of The Coca-Cola |  |  |  |  |  |  |  |  |
| Company ($1.23 per share) | — | (5,283) | (5,283) | — | — | — | — | — |
| Dividends paid to noncontrolling |  |  |  |  |  |  |  |  |
| interests | — | (12) | — | — | — | — | — | (12) |
| Impact related to stock-based |  |  |  |  |  |  |  |  |
| compensation plans | 17 | 520 | — | — | — | 309 | 211 | — |
| September 25, 2020 | 4,297 $ | 20,316 $ | 66,863 $ | (15,446) $ | 1,760 $ | 17,463 $ | (52,033) $ | 1,709 |
| **Shareowners of The Coca-Cola Company** | | | | | | | | |
|  |  |  |  | Accumulated |  |  |  |  |
|  |  |  |  | Other |  |  |  | **Non-** |
|  | Common Shares |  | Reinvested | Comprehensive | Common | Capital | Treasury | **controlling** |
| Three Months Ended September 27, 2019 | Outstanding | Total | Earnings | Income (Loss) | Stock | Surplus | Stock | **Interests** |
| June 28, 2019 | 4,275 $ | 20,295 $ | 64,602 $ | (12,981) $ | 1,760 $ | 16,833 $ | (52,033) $ | 2,114 |
| Comprehensive income (loss) | — | 1,723 | 2,593 | (725) | — | — | — | (145) |
| Dividends paid/payable to |  |  |  |  |  |  |  |  |
| shareowners of The Coca-Cola |  |  |  |  |  |  |  |  |
| Company ($0.40 per share) | — | (1,714) | (1,714) | — | — | — | — | — |
| Dividends paid to noncontrolling |  |  |  |  |  |  |  |  |
| interests | — | (7) | — | — | — | — | — | (7) |
| Business combinations including purchase accounting adjustments | — | 8 | — | — | — | — | — | 8 |
| Impact related to stock-based |  |  |  |  |  |  |  |  |
| compensation plans | 9 | 378 | — | — | — | 206 | 172 | — |
| September 27, 2019 | 4,284 $ | 20,683 $ | 65,481 $ | (13,706) $ | 1,760 $ | 17,039 $ | (51,861) $ | 1,970 |
| **Shareowners of The Coca-Cola Company** | | | | | | | | |
|  |  |  |  | Accumulated |  |  |  |  |
|  |  |  |  | Other |  |  |  | **Non-** |
|  | Common Shares |  | Reinvested | Comprehensive | Common | Capital | Treasury | **controlling** |
| Nine Months Ended September 27, 2019 | Outstanding | Total | Earnings | Income (Loss) | Stock | Surplus | Stock | **Interests** |
| December 31, 2018 | 4,268 $ | 19,058 $ | 63,234 $ | (12,814) $ | 1,760 $ | 16,520 $ | (51,719) $ | 2,077 |
| Adoption of accounting standards | — | (18) | 501 | (519) | — | — | — | — |
| Comprehensive income (loss) | — | 6,417 | 6,878 | (373) | — | — | — | (88) |
| Dividends paid/payable to |  |  |  |  |  |  |  |  |
| shareowners of The Coca-Cola |  |  |  |  |  |  |  |  |
| Company ($1.20 per share) | — | (5,132) | (5,132) | — | — | — | — | — |
| Dividends paid to noncontrolling |  |  |  |  |  |  |  |  |
| interests | — | (27) | — | — | — | — | — | (27) |
| Business combinations including purchase accounting adjustments | — | 8 | — | — | — | — | — | 8 |
| Purchases of treasury stock | (14) | (635) | — | — | — | — | (635) | — |
| Impact related to stock-based |  |  |  |  |  |  |  |  |
| compensation plans | 30 | 1,012 | — | — | — | 519 | 493 | — |
| September 27, 2019 | 4,284 $ | 20,683 $ | 65,481 $ | (13,706) $ | 1,760 $ | 17,039 $ | (51,861) $ | 1,970 |

24

## NOTE 11: SIGNIFICANT OPERATING AND NONOPERATING ITEMS

### Other Operating Charges

During the three months ended September 25, 2020, the Company recorded other operating charges of $372 million. These charges primarily consisted of $332 million due to the Company's strategic realignment initiatives and $10 million related to the Company's productivity and reinvestment program. In addition, other operating charges included

$18 million related to the remeasurement of our contingent consideration liability to fair value in conjunction with the fairlife acquisition and $12 million related to the restructuring of our manufacturing operations in the United States. Refer to Note 2 for additional information on the fairlife acquisition. Refer to Note 12 for additional information on the Company's strategic realignment initiatives and productivity and reinvestment program. Refer to Note 16 for the impact these charges had on our operating segments and Corporate.

During the nine months ended September 25, 2020, the Company recorded other operating charges of $747 million. These charges primarily consisted of $332 million related to the Company's strategic realignment initiatives and $71 million related to the Company's productivity and reinvestment program. In addition, other operating charges included impairment charges of $160 million related to the Odwalla trademark and charges of $35 million related to discontinuing the Odwalla juice business. Other operating charges also included an impairment charge of $55 million related to a trademark in North America, which was primarily driven by the impact of the COVID-19 pandemic, revised projections of future operating results and a change in brand focus in the Company's portfolio. Other operating charges also included $47 million related to the

remeasurement of our contingent consideration liability to fair value in conjunction with the fairlife acquisition and $24 million related to the restructuring of our manufacturing operations in the United States. Refer to Note 2 for additional information on the fairlife acquisition. Refer to Note 12 for additional information on the Company's strategic realignment initiatives and productivity and reinvestment program. Refer to Note 15 for additional information on the impairment charges. Refer to Note 16 for the impact these charges had on our operating segments and Corporate.

During the three months ended September 27, 2019, the Company recorded other operating charges of $125 million. These charges primarily consisted of $61 million related to the Company's productivity and reinvestment program and $42 million related to the impairment of a trademark in Asia Pacific. In addition, other operating charges included

$21 million for costs incurred to refranchise certain of our North America bottling operations. Costs related to refranchising include, among other items, internal and external costs for individuals directly working on the refranchising efforts, severance, and costs associated with the implementation of information technology systems to facilitate consistent data standards and availability throughout our North America bottling system. Refer to Note 12 for additional information on the Company's productivity and reinvestment program. Refer to Note 15 for additional information on the trademark impairment charge. Refer to Note 16 for the impact these charges had on our operating segments and Corporate.

During the nine months ended September 27, 2019, the Company recorded other operating charges of $344 million. These charges primarily consisted of $184 million related to the Company's productivity and reinvestment program and $42 million related to the impairment of a trademark in Asia Pacific. In addition, other operating charges included

$46 million of transaction costs associated with the purchase of Costa, which we acquired in January 2019, and $61 million for costs incurred to refranchise certain of our North America bottling operations. Refer to Note 2 for additional information on the acquisition of Costa. Refer to Note 12 for additional information on the Company's productivity and reinvestment program. Refer to Note 15 for additional information on the trademark impairment charge. Refer to Note 16 for the impact these charges had on our operating segments and Corporate.

### Other Nonoperating Items

*Interest Expense*

During the three and nine months ended September 25, 2020, the Company recorded charges of $405 million related to the extinguishment of long-term debt. Refer to Note 7.

*Equity Income (Loss) — Net*

During the three and nine months ended September 25, 2020, the Company recorded net charges of $27 million and $128 million, respectively. During the three and nine months ended September 27, 2019, the Company recorded net charges of $39 million and $107 million, respectively. These amounts represent the Company's proportionate share of significant operating and nonoperating items recorded by certain of our equity method investees. Refer to Note 16 for the impact these items had on our operating segments and Corporate.

25

*Other Income (Loss) — Net*

During the three months ended September 25, 2020, the Company recognized a net gain of $13 million related to realized and unrealized gains and losses on equity securities and trading debt securities as well as realized gains and losses on available-for-sale debt securities. The Company also recorded other postretirement benefit plan curtailment charges of $11 million related to its strategic realignment initiatives. Refer to Note 4 for additional information on equity and debt securities. Refer to Note 12 for additional information on the Company's strategic realignment initiatives. Refer to Note 16 for the impact these items had on our operating segments and Corporate.

During the nine months ended September 25, 2020, the Company recognized a gain of $902 million in conjunction with the fairlife acquisition, which resulted from the remeasurement of our previously held equity interest in fairlife to fair value and a gain of $18 million related to the sale of a portion of our ownership interest in one of our equity method investments. These gains were partially offset by a net loss of $55 million related to economic hedging activities, an other-than-temporary impairment charge of

$38 million related to one of our equity method investees in Latin America and an impairment charge of $26 million associated with an investment in an equity security without a readily determinable fair value, which were primarily driven by revised projections of future operating results. The Company also recorded a charge of $21 million related to the restructuring of our manufacturing operations in the United States, other postretirement benefit plan curtailment charges of $11 million related to the Company's strategic realignment initiatives, and a net loss of $127 million related to realized and unrealized gains and losses on equity securities and trading debt securities as well as realized gains and losses on available-for-sale debt securities. Refer to Note 2 for additional information on the fairlife acquisition. Refer to Note 4 for additional information on equity and debt securities. Refer to Note 6 for additional information on our economic hedging activities. Refer to Note 12 for additional information on the Company's strategic realignment initiatives. Refer to Note 15 for additional information on the impairment charges. Refer to Note 16 for the impact these items had on our operating segments and Corporate.

During the three months ended September 27, 2019, the Company recognized a gain of $739 million on the sale of a retail and office building in New York City. The Company also recognized a net gain of $38 million related to realized and unrealized gains and losses on equity securities and trading debt securities as well as realized gains and losses on available-for-sale debt securities. In addition, the Company recorded an other-than-temporary impairment charge of $120 million related to Coca-Cola Bottlers Japan Holdings Inc. ("CCBJHI"), an equity method investee, and other-than-temporary impairment charges of $255 million related to certain equity method investees in the Middle East. The Company also recorded net charges of $103 million primarily related to post-closing adjustments as contemplated by the related agreements associated with the refranchising of certain bottling territories in North America. Refer to Note 2 for additional information on refranchising activities. Refer to Note 4 for additional information on equity and debt securities. Refer to Note 15 for information on the impairment charges. Refer to Note 16 for the impact these items had on our operating segments and Corporate.

During the nine months ended September 27, 2019, the Company recognized a gain of $739 million on the sale of a retail and office building in New York City. The Company also recognized a net gain of $197 million related to realized and unrealized gains and losses on equity securities and trading debt securities as well as realized gains and losses on available-for-sale debt securities and a gain of $39 million related to the sale of a portion of our equity ownership interest in Andina. These gains were partially offset by other-than-temporary impairment charges of $406 million related to CCBJHI, an equity method investee, $255 million related to certain equity method investees in the Middle East, $57 million related to one of our equity method investees in North America and $49 million related to one of our equity method investees in Latin America. The Company also recorded an adjustment to reduce the carrying amount of CCBA's fixed assets and definite-lived intangible assets by $160 million and recognized a $121 million loss in conjunction with our acquisition of the remaining equity ownership interest in CHI. Additionally, the Company recognized net charges of $107 million primarily related to post- closing adjustments as contemplated by the related agreements associated with the refranchising of certain bottling territories in North America. Refer to Note 2 for additional information on the CCBA asset adjustment, refranchising activities, the acquisition of the remaining equity ownership interest in CHI and the sale of a portion of our equity ownership interest in Andina. Refer to Note 4 for additional information on equity and debt securities. Refer to Note 15 for additional information on the impairment charges.

Refer to Note 16 for the impact these items had on our operating segments and Corporate.

26

## NOTE 12: RESTRUCTURING

### Strategic Realignment

In August 2020, the Company announced strategic steps to transform our organizational structure in an effort to better enable us to capture growth in the fast-changing marketplace. The Company is building a networked global organization designed to combine the power of scale with the deep knowledge required to win locally. We are creating new operating units focused on regional and local execution. The operating units, which will sit under the four existing geographic segments, will be highly interconnected with more consistency in the structure and a focus on eliminating duplication of resources and scaling new products more quickly. The operating units will work closely with five global marketing category leadership teams to rapidly scale ideas. The global marketing category leadership teams will primarily focus on innovation, marketing efficiency and effectiveness. The organizational structure will also include the center that will provide strategy, governance and scale for global initiatives. The operating units, global marketing category leadership teams and the center will be supported by a platform services organization, which will focus on providing efficient and scaled global services and capabilities including, but not limited to, governance, transactional work, data management, consumer analytics, digital commerce and social/digital hubs.

The expenses related to these strategic realignment initiatives were recorded in the line items other operating charges and other income (loss) — net in our condensed consolidated statements of income. Refer to Note 16 for the impact these expenses had on our operating segments and Corporate. Outside services reported in the table below primarily relate to expenses in connection with legal and consulting activities. The Company currently expects the total cost of the strategic realignment initiatives to range from approximately $350 million to $550 million. We expect the new networked organization to be established and functioning at the beginning of 2021, and the platform services activities will be integrated, standardized and scaled over the course of 2021.

The following table summarizes the balance of accrued expenses related to these strategic realignment initiatives as of September 25, 2020 (in millions):

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Costs Incurred | Payments | Noncash and Exchange | Accrued Balance September 25, 2020 |
| Severance pay and benefits | $ 327 $ | — $ | (23) 1 $ | 304 |
| Outside services | 16 | (15) | — | 1 |
| Total | $ 343 $ | (15) $ | (23) $ | 305 |

1 Includes stock-based compensation modification and other postretirement benefit plan curtailment charges.

### Productivity and Reinvestment Program

In February 2012, the Company announced a productivity and reinvestment program designed to further enable our efforts to strengthen our brands and reinvest our resources to drive long-term profitable growth. This program is focused on the following initiatives: global supply chain optimization; global marketing and innovation effectiveness; operating expense leverage and operational excellence; data and information technology systems standardization; and the integration of Coca-Cola Enterprises Inc.'s former North America business.

In February 2014, the Company announced the expansion of our productivity and reinvestment program to drive incremental productivity that will primarily be redirected into increased media investments. Our incremental productivity goal consists of two relatively equal components. First, we will expand savings through global supply chain optimization, data and information technology systems standardization, and resource and cost reallocation. Second, we will increase the effectiveness of our marketing investments by transforming our marketing and commercial model to redeploy resources into more consumer-facing marketing investments to accelerate growth.

In October 2014, the Company announced that we were further expanding our productivity and reinvestment program and extending it through 2019. The expansion of the productivity initiatives focused on four key areas: restructuring the Company's global supply chain; implementing zero-based work, an evolution of zero-based budget principles, across the organization; streamlining and simplifying the Company's operating model; and further driving increased discipline and efficiency in direct marketing investments.

In April 2017, the Company announced another expansion of our productivity and reinvestment program. This expansion is focused on achieving additional efficiencies in both our supply chain and our marketing expenditures as well as transitioning to a new, more agile operating model to enable growth. Under this operating model, our business units are supported by an expanded enabling services organization and a corporate center focused on a few strategic initiatives, policy and governance. The expanded enabling services organization focuses on both simplifying and standardizing key transactional processes and providing support to business units through global centers of excellence.

Certain productivity initiatives included in this program, primarily related to our enabling services organization, will continue until the initiatives have been completed.

27

The Company has incurred total pretax expenses of $3,901 million related to our productivity and reinvestment program since it commenced. These expenses were recorded in the line items other operating charges and other income (loss) — net in our condensed consolidated statements of income. Refer to Note 16 for the impact these charges had on our operating segments and Corporate. Outside services reported in the tables below primarily relate to expenses in connection with legal, outplacement and consulting activities. Other direct costs reported in the tables below include, among other items, internal and external costs associated with the development, communication, administration and implementation of these initiatives; accelerated depreciation on certain fixed assets; contract termination fees; and relocation costs.

The following tables summarize the balance of accrued expenses related to these productivity and reinvestment initiatives and the changes in the accrued amounts as of and for the three and nine months ended September 25, 2020 (in millions):

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | | Accrued Balance June 26, 2020 | Costs Incurred | Payments | Noncash and Exchange | Accrued Balance September 25, 2020 |
| Severance pay and benefits | $ | 46 $ | (2) $ | (10) $ | — $ | 34 |
| Outside services |  | — | 5 | (5) | — | — |
| Other direct costs |  | 1 | 7 | (6) | — | 2 |
| Total | $ | 47 $ | 10 $ | (21) $ | — $ | 36 |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | Accrued Balance December 31, 2019 | Costs Incurred | Payments | Noncash and Exchange | Accrued Balance September 25, 2020 |
| Severance pay and benefits | $ 58 $ | (1) $ | (23) $ | — $ | 34 |
| Outside services | 1 | 42 | (43) | — | — |
| Other direct costs | 7 | 30 | (30) | (5) | 2 |
| Total | $ 66 $ | 71 $ | (96) $ | (5) $ | 36 |

## NOTE 13: PENSION AND OTHER POSTRETIREMENT BENEFIT PLANS

Net periodic benefit cost (income) for our pension and other postretirement benefit plans consisted of the following (in millions):

Pension Benefit Plans

Three Months Ended

Other Postretirement Benefit Plans

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | | **September 25,**  **2020** | September 27,  2019 |  | **September 25,**  **2020** | September 27,  2019 |
| Service cost | **$** | **28** $ | 26 | **$** | **2** $ | 2 |
| Interest cost |  | **58** | 73 |  | **6** | 7 |
| Expected return on plan assets1 |  | **(148)** | (138) |  | **(4)** | (3) |
| Amortization of prior service credit |  | **—** | (1) |  | **(1)** | (1) |
| Amortization of net actuarial loss |  | **43** | 38 |  | **2** | 1 |
| Net periodic benefit cost (income) |  | **(19)** | (2) |  | **5** | 6 |
| Curtailment charges2 |  | **—** | — |  | **11** | — |
| Total cost (income) recognized in condensed consolidated statements of income | **$** | **(19)** $ | (2) | **$** | **16** $ | 6 |

1 The weighted-average expected long-term rates of return on plan assets used in computing 2020 net periodic benefit cost (income) are 7.50 percent for pension benefit plans and 4.50 percent for other postretirement benefit plans.

2 The curtailment charges were related to the strategic realignment initiatives. Refer to Note 12.

28

Pension Benefit Plans

Nine Months Ended

Other Postretirement Benefit Plans

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  |  | **September 25,**  **2020** | September 27,  2019 |  | **September 25,**  **2020** | September 27,  2019 |
| Service cost | **$** | **84** $ | 78 | **$** | **8** $ | 7 |
| Interest cost |  | **176** | 218 |  | **17** | 20 |
| Expected return on plan assets1 |  | **(440)** | (414) |  | **(12)** | (10) |
| Amortization of prior service credit |  | **—** | (3) |  | **(2)** | (2) |
| Amortization of net actuarial loss |  | **128** | 114 |  | **4** | 2 |
| Net periodic benefit cost (income) |  | **(52)** | (7) |  | **15** | 17 |
| Curtailment charges2 |  | **—** | — |  | **11** | — |
| Total cost (income) recognized in condensed consolidated statements of income | **$** | **(52)** $ | (7) | **$** | **26** $ | 17 |

1 The weighted-average expected long-term rates of return on plan assets used in computing 2020 net periodic benefit cost (income) are 7.50 percent for pension benefit plans and 4.50 percent for other postretirement benefit plans.

2 The curtailment charges were related to the strategic realignment initiatives. Refer to Note 12.

All amounts in the tables above, other than service cost, were recorded in the line item other income (loss) — net in our condensed consolidated statements of income. During the nine months ended September 25, 2020, the Company contributed $25 million to our pension trusts, and we anticipate making additional contributions of approximately $4 million during the remainder of 2020. The Company contributed $29 million to our pension trusts during the nine months ended September 27, 2019.

## NOTE 14: INCOME TAXES

The Company recorded income taxes of $441 million (20.2 percent effective tax rate) and $503 million (16.3 percent effective tax rate) during the three months ended September 25, 2020 and September 27, 2019, respectively. The Company recorded income taxes of $1,094 million (14.8 percent effective tax rate) and $1,446 million (17.3 percent effective tax rate) during the nine months ended September 25, 2020 and September 27, 2019, respectively.

The Company's effective tax rates for the three and nine months ended September 25, 2020 and September 27, 2019 vary from the statutory U.S. federal income tax rate o2f 1.0 percent primarily due to the tax impact of significant operating and nonoperating items, along with the tax benefits of having significant operations outside the United States and significant earnings generated in investments accounted for under the equity method, both of which are generally taxed at rates lower than the statutory U.S. rate.

The Company's effective tax rates for the three and nine months ended September 25, 2020 included $15 million of net tax expense and $138 million of net tax benefit, respectively, associated with various discrete tax items, including return to provision adjustments, excess tax benefits associated with the Company's stock-based compensation arrangements, the net tax impact of tax law changes in certain foreign jurisdictions, and net tax charges for changes to our uncertain tax positions, including interest and penalties. The Company's effective tax rate for the nine months ended September 25, 2020 also included a tax benefit of $40 million associated with the gain recorded upon the acquisition of the remaining interest in fairlife. Refer to Note 2 for additional information on the fairlife acquisition.

The Company's effective tax rates for the three and nine months ended September 27, 2019 included $213 million and $245 million, respectively, of net tax benefits recorded. These net tax benefits were primarily associated with return to provision adjustments, but also included excess tax benefits associated with the Company's stock-based compensation arrangements, net tax charges for various resolved tax audit issues, and net tax charges for changes to our uncertain tax positions, including interest and penalties. The Company's effective tax rate for the nine months ended September 27, 2019 also included a tax benefit of $199 million recorded as a result of CCBA no longer qualifying as a discontinued operation. Refer to Note 2 for additional information on CCBA.

On September 17, 2015, the Company received a Statutory Notice of Deficiency from the IRS for the tax years 2007 through 2009, after a five-year audit. The Company contested the proposed adjustments in U.S. Tax Court and is currently awaiting a decision. Refer to Note 8.

29

## NOTE 15: FAIR VALUE MEASUREMENTS

### Recurring Fair Value Measurements

The following tables summarize assets and liabilities measured at fair value on a recurring basis (in millions):

Netting

Fair Value

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 25, 2020 Level 1 | | | Level 2 | Level 3 | Other3 | | Adjustment | 4 |  | Measurements |  |
| Assets: | | |  |  |  | |  |  |  |  |
| Equity securities with readily determinable values1 $ 1,750 $ | | | 193 $ | 11 | $ 101 $ | | — |  | $ | 2,055 |
| Debt securities1 | — | | 2,647 | 46 | — | | — |  | 2,693 | |
| Derivatives2 | 14 | | 831 | — | — | | (617) | 6 | 228 | | 8 |
| Total assets | $ 1,764 $ | | 3,671 $ | 57 | $ 101 $ | | (617) |  | $ 4,976 | |  |
| Liabilities: |  | |  |  |  | |  |  |  |  |  |
| Contingent consideration liability | $ | — $ | — $ | (317) | 5 $ | — $ | — | $ | | (317) |  |
| Derivatives2 | (2) | | (148) | — | — | | 134 | 7 | (16) | | 8 |
| Total liabilities | $ (2) $ | | (148) $ | (317) | $ — $ | | 134 |  | $ (333) | |  |

1 Refer to Note 4 for additional information related to the composition of our equity securities with readily determinable values and debt securities.

2 Refer to Note 6 for additional information related to the composition of our derivative portfolio.

3 Certain investments that are measured at fair value using the net asset value per share (or its equivalent) practical expedient have not been categorized in the fair value hierarchy but are included to reconcile to the amounts presented in Note 4.

4 Amounts represent the impact of legally enforceable master netting agreements that allow the Company to settle net positive and negative positions and also cash collateral held or placed with the same counterparties. There are no amounts subject to legally enforceable master netting agreements that management has chosen not to offset or that do not meet the offsetting requirements. Refer to Note 6.

5 Refer to Note 2 for additional information related to the contingent consideration liability resulting from the fairlife acquisition.

6 The Company is obligated to return $ 485 million in cash collateral it has netted against its derivative position.

7 The Company does not have the right to reclaim any cash collateral it has netted against its derivative position.

8 The Company's derivative financial instruments are recorded at fair value in our condensed consolidated balance sheet as follows:

$228 million in the line item other assets and $16 million in the line item other liabilities. Refer to Note 6 for additional information related to the composition of our derivative portfolio.

Netting Fair Value

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| December 31, 2019 Level 1 | | Level 2 | Level 3 | Other3 | Adjustment | 4 |  | Measurements |  |
| Assets: | |  |  |  |  |  |  |  |
| Equity securities with readily determinable values1 $ 1,877 $ | | 219 $ | 14 | $ 109 $ | — |  | $ | 2,219 |
| Debt securities1 | — | 3,291 | 37 | — | — |  | 3,328 | |
| Derivatives2 | 9 | 579 | — | — | (392) | 5 | 196 | | 7 |
| Total assets | $ 1,886 $ | 4,089 $ | 51 | $ 109 $ | (392) |  | $ 5,743 | |  |
| Liabilities: |  |  |  |  |  |  |  |  |  |
| Derivatives2 | $ — $ | (162) $ | — $ — $ | | 130 | 6 | $ (32) | | 7 |
| Total liabilities | $ — $ | (162) $ | — $ — $ | | 130 |  | $ (32) | |  |

1 Refer to Note 4 for additional information related to the composition of our equity securities with readily determinable values and debt securities.

2 Refer to Note 6 for additional information related to the composition of our derivative portfolio.

3 Certain investments that are measured at fair value using the net asset value per share (or its equivalent) practical expedient have not been categorized in the fair value hierarchy but are included to reconcile to the amounts presented in Note 4.

4 Amounts represent the impact of legally enforceable master netting agreements that allow the Company to settle net positive and negative positions and also cash collateral held or placed with the same counterparties. There are no amounts subject to legally enforceable master netting agreements that management has chosen not to offset or that do not meet the offsetting requirements. Refer to Note 6.

5 The Company is obligated to return $ 261 million in cash collateral it has netted against its derivative position.

6 The Company does not have the right to reclaim any cash collateral it has netted against its derivative position.

7 The Company's derivative financial instruments are recorded at fair value in our condensed consolidated balance sheet as follows: $ 196 million in the line item other assets and $32 million in the line item other liabilities. Refer to Note 6 for additional information related to the composition of our derivative portfolio.

30

Gross realized and unrealized gains and losses on Level 3 assets and liabilities were not significant for the three and nine months ended September 25, 2020 and September 27, 2019.

The Company recognizes transfers between levels within the hierarchy as of the beginning of the reporting period. Gross transfers between levels within the hierarchy were not significant for the three and nine months ended September 25, 2020 and September 27, 2019.

### Nonrecurring Fair Value Measurements

The gains and losses on assets measured at fair value on a nonrecurring basis are summarized in the table below (in millions):

Gains (Losses)

Three Months Ended Nine Months Ended

**September 25,**

**2020**

September 27,

2019

**September 25,**

**2020**

September 27,

2019

Impairment of intangible assets **$ —** $ (42) 1 **$ (215) 2** $ (42)

1

Other-than-temporary impairment charges **—** (375) 3 **(38) 3** (767) 3

Impairment of equity investment without a readily determinable fair value

**—**

—

**(26) 4**

—

CCBA asset adjustments **—** — **—** (160) 5

Total **$ —** $ (417) **$ (279)** $ (969)

1 During the three and nine months ended September 27, 2019, the Company recorded an impairment charge of $42 million related to a trademark in Asia Pacific, which was primarily driven by revised projections of future operating results for the trademark. The fair value of this trademark was derived using discounted cash flow analyses based on Level 3 inputs.

2 The Company recorded impairment charges of $160 million during the nine months ended September 25, 2020 related to its Odwalla trademark in North America, as the Company decided in June 2020 to discontinue its Odwalla juice business. The Company recorded an impairment charge of $55 million during the nine months ended September 25, 2020 related to a trademark in North America, which was primarily driven by the impact of the COVID-19 pandemic, revised projections of future operating results and a change in brand focus in the Company's portfolio. The fair value of this trademark was derived using discounted cash flow analyses based on Level 3 inputs.

3 During the three and nine months ended September 27, 2019, the Company recognized other-than-temporary impairment charges of $ 120 million and $406 million, respectively, related to our investment in CCBJHI, an equity method investee. Based on the length of time and the extent to which the market value of our investment in CCBJHI had been less than our carrying value as well as the financial condition and near-term prospects of the issuer, management determined that the decline in fair value was other than temporary in nature. This impairment charge was determined using the quoted market prices (a Level 1 measurement) of CCBJHI. The Company also recorded other-than-temporary impairment charges of $255 million related to certain equity method investees in the Middle East. These impairment charges were derived using Level 3 inputs and were primarily driven by revised projections of future operating results largely related to instability in the region and recent changes in local excise taxes. During the nine months ended September 25, 2020 and September 27, 2019, the Company recognized other- than-temporary impairment charges of $38 million and $49 million, respectively, related to certain of our equity method investees in Latin America, primarily driven by revised projections of future operating results. The fair values of these investments were derived using discounted cash flow analyses based on Level 3 inputs. During the nine months ended September 27, 2019, the Company also recorded an other-than-temporary impairment charge of $57 million related to one of our equity method investees in North America. This impairment charge was derived using Level 3 inputs and was primarily driven by revised projections of future operating results.

4 The Company recorded an impairment charge of $26 million related to an investment in an equity security without a readily determinable fair value. This impairment charge was derived using Level 3 inputs and was primarily driven by revised projections of future operating results.

5 As a result of CCBA no longer being classified as held for sale, the Company was required to measure CCBA's property, plant and equipment and definite-lived intangible assets at the lower of their current fair values or their carrying amounts before they were classified as held for sale, adjusted for depreciation and amortization expense that would have been recognized had the business been classified as held and used during the period that CCBA was classified as held for sale. As a result, we reduced the carrying value of CCBA's property, plant and equipment and definite-lived intangible assets by $34 million and $126 million, respectively, based on Level 3 inputs. Refer to Note 2.

### Other Fair Value Disclosures

The carrying amounts of cash and cash equivalents; short-term investments; trade accounts receivable; accounts payable and accrued expenses; and loans and notes payable approximate their fair values because of the relatively short-term maturities of these financial instruments. The fair value of our long-term debt is estimated using Level 2 inputs based on quoted prices for those instruments. Where quoted prices are not available, fair value is estimated using discounted cash flows and market-based expectations for interest rates, credit risk and the contractual terms of the debt instruments. As of September 25, 2020, the carrying amount and fair value of our long-term debt, including the current portion, were $47,010 million and $49,436 million, respectively. As of December 31, 2019, the carrying amount and fair value of our long-term debt, including the current portion, were $31,769 million and $32,725 million, respectively.

31

## NOTE 16: OPERATING SEGMENTS

Information about our Company's operations by operating segment and Corporate is as follows (in millions):

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | Europe, Middle  East & Africa | Latin  America | North  America | Asia Pacific |  | Global  Ventures | Bottling  Investments | Corporate | Eliminations | Consolidated |
| **As of and for the Three Months Ended September 25, 2020** |  |  |  |  |  |  |  |  |  |  |
| Net operating revenues: |  |  |  |  |  |  |  |  |  |  |
| Third party | **$ 1,556** | **$ 809 $** | **3,087 $** | **1,207** |  | **$ 513 $** | **1,474** | **$ 6 $** | **— $** | **8,652** |
| Intersegment | **137** | **—** | **1** | **127** |  | **—** | **1** | **—** | **(266)** | **—** |
| Total net operating revenues | **1,693** | **809** | **3,088** | **1,334** |  | **513** | **1,475** | **6** | **(266)** | **8,652** |
| Operating income (loss) | **903** | **483** | **727** | **564** |  | **(31)** | **55** | **(403)** | **—** | **2,298** |
| Income (loss) before income taxes | **925** | **476** | **738** | **575** |  | **(29)** | **398** | **(902)** | **—** | **2,181** |
| Identifiable operating assets | **8,283 1** | **1,647** | **19,983** | **2,143** | **2** | **7,453** | **9,851 1,2** | **28,237** | **—** | **77,597** |
| Investments3 | **544** | **577** | **356** | **236** |  | **6** | **13,765** | **4,103** | **—** | **19,587** |
| As of and for the Three Months Ended September 27, 2019 |  |  |  |  |  |  |  |  |  |  |
| Net operating revenues: |  |  |  |  |  |  |  |  |  |  |
| Third party | $ 1,672 | $ 1,045 $ | 3,137 $ | 1,319 |  | $ 629 $ | 1,681 | $ 24 $ | — $ | 9,507 |
| Intersegment | 156 | — | 1 | 143 |  | — | 3 | — | (303) | — |
| Total net operating revenues | 1,828 | 1,045 | 3,138 | 1,462 |  | 629 | 1,684 | 24 | (303) | 9,507 |
| Operating income (loss) | 886 | 603 | 641 | 594 |  | 77 | 7 | (309) | — | 2,499 |
| Income (loss) before income taxes | 651 | 605 | 658 | 603 |  | 80 | 55 | 440 | — | 3,092 |
| Identifiable operating assets | 8,363 1 | 1,895 | 17,895 | 2,118 |  | 6,935 | 10,456 1 | 20,204 | — | 67,866 |
| Investments3 | 483 | 719 | 365 | 223 |  | 14 | 13,892 | 3,871 | — | 19,567 |
| As of December 31, 2019 |  |  |  |  |  |  |  |  |  |  |
| Identifiable operating assets | $ 8,143 1 | $ 1,801 $ | 17,687 $ | 2,060 |  | $ 7,265 $ | 11,170 1 | $ 18,376 $ | — $ | 66,502 |
| Investments3 | 543 | 716 | 358 | 224 |  | 14 | 14,093 | 3,931 | — | 19,879 |

1 Property, plant and equipment — net in South Africa represented 14 percent, 14 percent and 16 percent of consolidated property, plant and equipment — net as of September 25, 2020, September 27, 2019 and December 31, 2019, respectively.

2 Property, plant and equipment — net in the Philippines represented 10 percent of consolidated property, plant and equipment — net as of September 25, 2020.

3 Principally equity method investments and other investments in bottling companies.

During the three months ended September 25, 2020, the results of our operating segments and Corporate were impacted by the following items:

* + Operating income (loss) and income (loss) before income taxes were reduced by $41 million for Europe, Middle East and Africa, $22 million for Latin America,

$121 million for North America and $32 million for Asia Pacific, and operating income (loss) and income (loss) before income taxes were reduced by $116 million and

$127 million, respectively, for Corporate due to the Company's strategic realignment initiatives. Refer to Note 12.

* + Operating income (loss) and income (loss) before income taxes were reduced by $23 million and $25 million, respectively, for North America related to the restructuring of our manufacturing operations in the United States.
* Operating income (loss) and income (loss) before income taxes were reduced by $18 million for Corporate related to the remeasurement of our contingent consideration liability to fair value in conjunction with the fairlife acquisition. Refer to Note 2.
* Operating income (loss) and income (loss) before income taxes were reduced by $13 million for Corporate due to the Company's productivity and reinvestment program. Operating income (loss) and income (loss) before income taxes were increased by $3 million for Europe, Middle East and Africa due to the refinement of previously established accruals related to the Company's productivity and reinvestment program. Refer to Note 12.
* Operating income (loss) and income (loss) before income taxes were increased by $2 million for North America due to the refinement of previously established accruals related to discontinuing the Odwalla juice business.

32

* Income (loss) before income taxes was increased by $13 million for Corporate related to realized and unrealized gains and losses on equity securities and trading debt securities as well as realized gains and losses on available-for-sale debt securities. Refer to Note 4.
* Income (loss) before income taxes was reduced by $405 million for Corporate related to charges associated with the extinguishment of long-term debt. Refer to Note 7.
* Income (loss) before income taxes was reduced by $27 million for Bottling Investments due to the Company's proportionate share of significant operating and nonoperating items recorded by certain of our equity method investees.

During the three months ended September 27, 2019, the results of our operating segments and Corporate were impacted by the following items:

* Operating income (loss) and income (loss) before income taxes were reduced by $42 million for Asia Pacific due to an impairment charge related to a trademark.
* Operating income (loss) and income (loss) before income taxes were reduced by $21 million for Bottling Investments related to costs incurred to refranchise certain of our North America bottling operations.
* Operating income (loss) and income (loss) before income taxes were reduced by $1 million for Europe, Middle East and Africa, $12 million for North America and $48 million for Corporate due to the Company's productivity and reinvestment program. Refer to Note 12.
* Income (loss) before income taxes was increased by $739 million for Corporate as a result of the sale of a retail and office building in New York City.
* Income (loss) before income taxes was reduced by $255 million for Europe, Middle East and Africa due to other-than-temporary impairment charges related to certain of our equity method investees in the Middle East. Refer to Note 15.
* Income (loss) before income taxes was reduced by $120 million for Bottling Investments due to an other-than-temporary impairment charge related to CCBJHI, an equity method investee. Refer to Note 15.
* Income (loss) before income taxes was reduced by $103 million for Bottling Investments due to the refranchising of certain bottling territories in North America. Refer to Note 11.
* Income (loss) before income taxes was reduced by $39 million for Bottling Investments due to the Company's proportionate share of significant operating and nonoperating items recorded by certain of our equity method investees.

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | Europe, Middle  East & Africa | Latin  America | North  America | Asia Pacific | Global  Ventures | Bottling  Investments | Corporate | Eliminations | Consolidated |
| **Nine Months Ended September 25, 2020** |  |  |  |  |  |  |  |  |  |
| Net operating revenues: |  |  |  |  |  |  |  |  |  |
| Third party | **$ 4,264** | **$ 2,494 $** | **8,583 $** | **3,264** | **$ 1,381** | **$ 4,392** | **$ 25 $** | **— $** | **24,403** |
| Intersegment | **364** | **—** | **3** | **381** | **—** | **4** | **—** | **(752)** | **—** |
| Total net operating revenues | **4,628** | **2,494** | **8,586** | **3,645** | **1,381** | **4,396** | **25** | **(752)** | **24,403** |
| Operating income (loss) | **2,578** | **1,526** | **1,603** | **1,727** | **(114)** | **130** | **(791)** | **—** | **6,659** |
| Income (loss) before income taxes | **2,632** | **1,455** | **1,623** | **1,749** | **(114)** | **762** | **(719)** | **—** | **7,388** |
| Nine Months Ended September 27, 2019 |  |  |  |  |  |  |  |  |  |
| Net operating revenues: |  |  |  |  |  |  |  |  |  |
| Third party | $ 5,110 | $ 2,944 $ | 8,976 $ | 3,729 | $ 1,847 | $ 5,513 | $ 79 $ | — $ | 28,198 |
| Intersegment | 420 | — | 7 | 460 | 2 | 7 | — | (896) | — |
| Total net operating revenues | 5,530 | 2,944 | 8,983 | 4,189 | 1,849 | 5,520 | 79 | (896) | 28,198 |
| Operating income (loss) | 2,902 | 1,687 | 1,938 | 1,867 | 216 | 226 | (914) | — | 7,922 |
| Income (loss) before income taxes | 2,701 | 1,636 | 1,924 | 1,891 | 223 | 348 | (357) | — | 8,366 |

33

During the nine months ended September 25, 2020, the results of our operating segments and Corporate were impacted by the following items:

* Operating income (loss) and income (loss) before income taxes for North America were reduced by $160 million related to the impairment of the Odwalla trademark and

$37 million related to the cost of discontinuing the Odwalla juice business.

* Operating income (loss) and income (loss) before income taxes were reduced by $41 million for Europe, Middle East and Africa, $22 million for Latin America,

$121 million for North America and $32 million for Asia Pacific, and operating income (loss) and income (loss) before income taxes were reduced by $116 million and

$127 million, respectively, for Corporate due to the Company's strategic realignment initiatives. Refer to Note 12.

* Operating income (loss) and income (loss) before income taxes were reduced by $74 million for Corporate due to the Company's productivity and reinvestment program. Operating income (loss) and income (loss) before income taxes were increased by $3 million for Europe, Middle East and Africa due to the refinement of previously established accruals related to the Company's productivity and reinvestment program. Refer to Note 12.
* Operating income (loss) and income (loss) before income taxes were reduced by $55 million for North America related to the impairment of a trademark. Refer to Note 15.
* Operating income (loss) and income (loss) before income taxes were reduced by $48 million and $69 million, respectively, for North America related to the restructuring of our manufacturing operations in the United States.
* Operating income (loss) and income (loss) before income taxes were reduced by $47 million for Corporate related to the remeasurement of our contingent consideration liability to fair value in conjunction with the fairlife acquisition. Refer to Note 2.
* Income (loss) before income taxes was increased by $902 million for Corporate in conjunction with our fairlife acquisition, which resulted from the remeasurement of our previously held equity interest in fairlife to fair value. Refer to Note 2.
* Income (loss) before income taxes was increased by $18 million for Corporate related to the sale of a portion of our ownership interest in one of our equity method investments.
* Income (loss) before income taxes was reduced by $405 million for Corporate related to charges associated with the extinguishment of long-term debt. Refer to Note 7.
* Income (loss) before income taxes was reduced by $127 million for Corporate related to realized and unrealized gains and losses on equity securities and trading debt securities as well as realized gains and losses on available-for-sale debt securities. Refer to Note 4.
* Income (loss) before income taxes was reduced by $28 million for Latin America, $1 million for North America and $99 million for Bottling Investments due to the Company's proportionate share of significant operating and nonoperating items recorded by certain of our equity method investees.
* Income (loss) before income taxes was reduced by $38 million for Latin America due to an other-than-temporary impairment charge related to one of our equity method investees. Refer to Note 15.
* Income (loss) before income taxes was reduced by $26 million for Corporate due to an impairment charge associated with an investment in an equity security without a readily determinable fair value. Refer to Note 15.

During the nine months ended September 27, 2019, the results of our operating segments and Corporate were impacted by the following items:

* Operating income (loss) and income (loss) before income taxes were reduced by $2 million for Europe, Middle East and Africa, $42 million for North America, $3 million for Bottling Investments and $137 million for Corporate due to the Company's productivity and reinvestment program. Refer to Note 12.
* Operating income (loss) and income (loss) before income taxes were reduced by $61 million for Bottling Investments due to costs incurred to refranchise certain of our North America bottling operations. Refer to Note 2.
* Operating income (loss) and income (loss) before income taxes were reduced by $46 million for Corporate related to transaction costs associated with the purchase of Costa, which we acquired in January 2019. Refer to Note 2.
* Operating income (loss) and income (loss) before income taxes were reduced by $42 million for Asia Pacific due to an impairment charge related to a trademark.

34

* Income (loss) before income taxes was increased by $739 million for Corporate as a result of the sale of a retail and office building in New York City.
* Income (loss) before income taxes was increased by $39 million for Corporate related to the sale of a portion of our equity ownership interest in Andina. Refer to Note 2.
* Income (loss) before income taxes was reduced by $406 million for Bottling Investments due to an other-than-temporary impairment charge related to CCBJHI, an equity method investee. Refer to Note 15.
* Income (loss) before income taxes was reduced by $255 million for Europe, Middle East and Africa due to other-than-temporary impairment charges related to certain of our equity method investees in the Middle East. Refer to Note 15.
* Income (loss) before income taxes was reduced by $160 million for Corporate as result of CCBA asset adjustments. Refer to Note 2.
* Income (loss) before income taxes was reduced by $121 million for Corporate resulting from a loss in conjunction with our acquisition of the remaining equity ownership interest in CHI. Refer to Note 2.
* Income (loss) before income taxes was reduced by $107 million for Bottling Investments due to the refranchising of certain bottling territories in North America. Refer to Note 11.
* Income (loss) before income taxes was reduced by $105 million for Bottling Investments and $2 million for Corporate due to the Company's proportionate share of significant operating and nonoperating items recorded by certain of our equity method investees.
* Income (loss) before income taxes was reduced by $57 million for North America due to an other-than-temporary impairment charge related to one of our equity method investees.
* Income (loss) before income taxes was reduced by $49 million for Latin America due to an other-than-temporary impairment charge related to one of our equity method investees.

## NOTE 17: SUBSEQUENT EVENT

In October 2020, the Company extinguished a portion of its long-term debt. As of September 25, 2020, the extinguished notes had a carrying value of $3,306 million. The general terms of the notes that were extinguished are as follows:

* €348 million total principal amount of notes due March 9, 2021, at a fixed interest rate of0.000 percent;
* $880 million total principal amount of notes due September 1, 2021, at a fixed interest rate of3.300 percent;
* $665 million total principal amount of notes due September 1, 2021, at a fixed interest rate of1.550 percent;
* $316 million total principal amount of notes due May 25, 2022, at a fixed interest rate of2.200 percent;
* €481 million total principal amount of notes due September 22, 2022, at a fixed interest rate of1.125 percent; and
* €402 million total principal amount of notes due September 22, 2022, at a fixed interest rate of0.125 percent.

The notes were redeemed at a redemption price of 100 percent of the principal amount of the applicable notes, plus accrued and unpaid interest and the applicable make-whole premiums. As a result of the extinguishment, the Company incurred charges of approximately $80 million.

35

### Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

When used in this report, the terms "The Coca-Cola Company," "Company," "we," "us" and "our" mean The Coca-Cola Company and all entities included in our condensed consolidated financial statements.

During the nine months ended September 25, 2020, the effects of a novel strain of coronavirus ("COVID-19") pandemic and the related actions by governments around the world to attempt to contain the spread of the virus have impacted our business globally. In particular, the outbreak and preventive measures taken to contain COVID-19 negatively impacted our unit case volume and our price, product and geographic mix in all of our operating segments, primarily due to unfavorable channel and product mix as consumer demand has shifted to more at-home consumption versus away from home.

In response to the COVID-19 outbreak and business disruption, we have five priorities:

* To ensure the health and safety of our employees
* To support and make a difference in the communities we serve
* To keep our brands in supply and to maintain the quality and safety of our products
* To best serve our customers across all channels as they adapt to the shifting demands of consumers during the crisis
* To best position ourselves to emerge stronger when this crisis ends

We have deployed global and regional teams to monitor the rapidly evolving situation in each of our local markets and recommend risk mitigation actions; we have implemented travel restrictions; and we are following social distancing practices. Around the world, we are endeavoring to follow guidance from authorities and health officials including, but not limited to, checking the temperature of associates when entering our facilities, requiring associates to wear masks and other protective clothing as appropriate, and implementing additional cleaning and sanitization routines at system facilities. In addition, most office-based employees around the world are required to work remotely.

We are grateful to the people throughout the world who are providing essential services, keeping communities safe and ensuring access to food, medicine and many other essential goods. We have made contributions of money, products and materials to support relief efforts in impacted local communities across the globe.

During times of crisis, business continuity and adapting to the needs of our customers is critical. We have developed systemwide knowledge-sharing routines and processes which include the management of any supply chain challenges. As of the date of this filing, there has been no material impact and we do not foresee a material impact on our and our bottling partners' ability to manufacture or distribute our products. We are moving with speed to best serve our customers impacted by COVID-19. In partnership with our bottlers and retail customers, we are working to ensure adequate inventory levels in key channels while prioritizing core brands, key packages and consumer affordability. We are increasing investments in e-commerce to support retailer and meal delivery services, shifting toward package sizes that are fit-for-purpose for online sales, and shifting more consumer and trade promotions to digital.

Although we are experiencing a time of crisis, we are not losing sight of long-term opportunities for our business. We believe that we will come out of this situation a better and stronger company. We are leveraging the crisis as a catalyst to accelerate our strategy by focusing on the following: prioritizing stronger global brands across various consumer needs while, at the same time, doing a better job of nurturing and growing regional and scaled local brands; establishing a more disciplined innovation framework and increasing marketing effectiveness and efficiency; strengthening our revenue growth management capabilities; enhancing our system collaboration and capturing supply chain efficiencies; and investing in new capabilities and evolving our organization to support the accelerated strategy. In August 2020, the Company announced strategic steps to transform our organizational structure in an effort to better enable us to capture growth in the fast-changing marketplace. The Company is building a networked global organization designed to combine the power of scale with the deep knowledge required to win locally. These organizational changes will require a reallocation of resources, along with both voluntary and involuntary reductions of associates. Refer to Note 12 of Notes to Condensed Consolidated Financial Statements for additional information about our strategic realignment initiatives.

36

## CRITICAL ACCOUNTING POLICIES AND ESTIMATES

### Recoverability of Current and Noncurrent Assets

Our Company faces many uncertainties and risks related to various economic, political and regulatory environments in the countries in which we operate, particularly in developing and emerging markets. Refer to the heading "Item 1A. Risk Factors" in Part I and "Our Business — Challenges and Risks" in Part II of our Annual Report on Form 10-K for the year ended December 31, 2019. As a result, management must make numerous assumptions, which involve a significant amount of judgment, when completing recoverability and impairment tests of current and noncurrent assets in various regions around the world.

Factors that management must estimate include, among others, the economic lives of the assets, sales volume, pricing, cost of raw materials, delivery costs, inflation, cost of capital, marketing spending, foreign currency exchange rates, tax rates, capital spending, proceeds from the sale of assets and customers' financial condition. These factors are even more difficult to estimate as a result of uncertainties associated with the global COVID-19 pandemic, including, but not limited to, the continued number of people contracting the virus, the impact of social distancing requirements and reopening plans across the globe, and the substance and pace of the post-pandemic economic recovery. The estimates we use when assessing the recoverability of assets are consistent with those we use in our internal planning. When performing impairment tests, we estimate the fair values of the assets using management's best assumptions, which we believe would be consistent with what a market participant would use. The variability of these factors depends on a number of conditions, including uncertainties associated with COVID-19, and thus our accounting estimates may change from period to period. Our current estimates reflect our belief that the second quarter of 2020 will be the most severely impacted quarter of the year; however, we still anticipate that the continued number of people testing positive for the virus and the reopening plans and social distancing practices across the globe will have a negative impact on our business in the fourth quarter of 2020. We also anticipate that many smaller customers throughout the world may permanently close. The Company has certain intangible and other long-lived assets that are more dependent on cash flows generated in the away-from-home channels and/or that generate cash flows in geographic areas that are more heavily impacted by the COVID-19 pandemic and are therefore more susceptible to impairment. In addition, intangible and other long-lived assets we acquired in recent transactions are naturally more susceptible to impairment, because they are recorded at fair value based on recent operating plans and macroeconomic conditions at the time of acquisition. If we had used other assumptions and estimates when tests of these assets were performed, impairment charges could have resulted. Furthermore, if management uses different assumptions or if different conditions exist in future periods, future impairment charges could result. The total future impairment charges we may be required to record could be material. Refer to Note 2 of Notes to Condensed Consolidated Financial Statements for a discussion of recent acquisitions. Refer to Note 11 of Notes to Condensed Consolidated Financial Statements for the discussion of impairment charges.

We perform recoverability and impairment tests of current and noncurrent assets in accordance with accounting principles generally accepted in the United States ("U.S. GAAP"). For certain assets, recoverability and/or impairment tests are required only when conditions exist that indicate the carrying value may not be recoverable. For other assets, impairment tests are required at least annually, or more frequently if events or circumstances indicate that an asset may be impaired.

During the third quarter of 2020, we conducted a portfolio rationalization process with the objective of reducing our product offerings to a tailored collection of global, regional and local brands with the potential for greater growth. As a result, the Company elected to discontinue selling certain brands over the next 1 to 2 years. While the portfolio rationalization process did not result in any impairment charges, we reclassified a net $80 million from indefinite-lived intangible assets to definite-lived intangible assets. We are amortizing the carrying values of the brands we elected to discontinue over their remaining useful lives.

As of September 25, 2020, the carrying value of our investment in Coca-Cola Bottlers Japan Holdings Inc. ("CCBJHI") exceeded its fair value by $207 million, or 37 percent, and the carrying value of our investment in Coca-Cola European Partners plc exceeded its fair value by $461 million, or 14 percent. Based on the length of time and the extent to which the fair values have been less than our carrying values and our intent and ability to retain the investments for a period of time sufficient to allow for any anticipated recovery in market value, management determined that the declines in fair values were temporary in nature. Therefore, we did not record an impairment charge related to either investment.

Our equity method investees also perform such recoverability and/or impairment tests. If an impairment charge is recorded by one of our equity method investees, the Company records its proportionate share of such charge as a reduction of equity income (loss) — net in our consolidated statement of income. However, the actual amount we record with respect to our proportionate share of such charge may be impacted by items such as basis differences, deferred taxes and deferred gains.

## OPERATIONS REVIEW

Sales of our nonalcoholic ready-to-drink beverages are somewhat seasonal, with the second and third calendar quarters typically accounting for the highest sales volumes. The volume of sales in the beverage business may be affected by weather conditions.

37

### Structural Changes, Acquired Brands and Newly Licensed Brands

In order to continually improve upon the Company's operating performance, from time to time, we engage in buying and selling ownership interests in bottling partners and other manufacturing operations. In addition, we also acquire brands and their related operations or enter into license agreements for certain brands to supplement our beverage offerings. These items impact our operating results and certain key metrics used by management in assessing the Company's performance.

Unit case volume growth is a metric used by management to evaluate the Company's performance because it measures demand for our products at the consumer level. The Company's unit case volume represents the number of unit cases (or unit case equivalents) of Company beverage products directly or indirectly sold by the Company and its bottling partners to customers or consumers and, therefore, reflects unit case volume for both consolidated and unconsolidated bottlers. Refer to the heading "Beverage Volume" below.

Concentrate sales volume represents the amount of concentrates, syrups, source waters and powders/minerals (in all instances expressed in unit case equivalents) sold by, or used in finished products sold by, the Company to its bottling partners or other customers. For Costa Limited ("Costa") non-ready-to-drink beverage products, concentrate sales volume represents the amount of coffee beans and finished beverages (in all instances expressed in unit case equivalents) sold by the Company to customers or consumers.

Refer to the heading "Beverage Volume" below.

When we analyze our net operating revenues we generally consider the following factors: (1) volume growth (concentrate sales volume or unit case volume, as applicable); (2) changes in price, product and geographic mix; (3) foreign currency fluctuations; and (4) acquisitions and divestitures (including structural changes defined below), as applicable. Refer to the heading "Net Operating Revenues" below. The Company sells concentrates and syrups to both consolidated and unconsolidated bottling partners. The ownership structure of our bottling partners impacts the timing of recognizing concentrate revenue and concentrate sales volume. When we sell concentrates or syrups to our consolidated bottling partners, we are not able to recognize the concentrate revenue or concentrate sales volume until the bottling partner has sold finished products manufactured from the concentrates or syrups to a third party or independent customer. When we sell concentrates or syrups to our unconsolidated bottling partners, we recognize the concentrate revenue and concentrate sales volume when the concentrates or syrups are sold to the bottling partner. The subsequent sale of the finished products manufactured from the concentrates or syrups to a third party or independent customer does not impact the timing of recognizing the concentrate revenue or concentrate sales volume. When we account for an unconsolidated bottling partner as an equity method investment, we eliminate the intercompany profit related to these transactions to the extent of our ownership interest until the equity method investee has sold finished products manufactured from the concentrates or syrups to a third party or independent customer. We typically report unit case volume when finished products manufactured from the concentrates or syrups are sold to a third party or independent customer regardless of our ownership interest in the bottling partner.

We generally refer to acquisitions and divestitures of bottling operations as structural changes, which are a component of acquisitions and divestitures. Typically, structural changes do not impact the Company's unit case volume or concentrate sales volume on a consolidated basis or at the geographic operating segment level. We recognize unit case volume for all sales of Company beverage products, regardless of our ownership interest in the bottling partner, if any. However, the unit case volume reported by our Bottling Investments operating segment is generally impacted by structural changes because it only includes the unit case volume of our consolidated bottling operations. Refer to Note 2 of Notes to Condensed Consolidated Financial Statements for additional information on the Company's acquisitions and divestitures.

"Acquired brands" refers to brands acquired during the past 12 months. Typically, the Company has not reported unit case volume or recognized concentrate sales volume related to acquired brands in periods prior to the closing of a transaction. Therefore, the unit case volume and concentrate sales volume related to these brands is incremental to prior year volume. We generally do not consider the acquisition of a brand to be a structural change.

"Licensed brands" refers to brands not owned by the Company but for which we hold certain rights, generally including, but not limited to, distribution rights, and from which we derive an economic benefit when the products are sold. Typically, the Company has not reported unit case volume or recognized concentrate sales volume related to these brands in periods prior to the beginning of the term of a license agreement. Therefore, in the year a license agreement is entered into, the unit case volume and concentrate sales volume related to the brand is incremental to prior year volume. We generally do not consider the licensing of a brand to be a structural change.

In 2020, the Company acquired the remaining interest in fairlife, LLC ("fairlife"). The impact on revenues for fairlife products not previously sold by the Company has been included in acquisitions and divestitures in our analysis of net operating revenues on a consolidated basis as well as for the North America operating segment.

Also in 2020, the Company discontinued our Odwalla juice business. The impact of discontinuing our Odwalla juice business has been included in acquisitions and divestitures in our analysis of net operating revenues on a consolidated basis as well as for the North America operating segment.

38

In 2019, the Company acquired the remaining interest in C.H.I. Limited ("CHI"). The impact of this acquisition has been included in acquisitions and divestitures in our analysis of net operating revenues on a consolidated basis as well as for the Europe, Middle East and Africa operating segment. Other acquisitions by the Company in 2019 included controlling interests in bottling operations in Zambia, Kenya and Eswatini. The impact of these acquisitions has been included as a structural change in our analysis of net operating revenues on a consolidated basis as well as for the Bottling Investments and Europe, Middle East and Africa operating segments.

Also in 2019, the Company refranchised certain of its bottling operations in India. The impact of these refranchising activities has been included as a structural change in our analysis of net operating revenues on a consolidated basis as well as for the Bottling Investments and Asia Pacific operating segments.

### Beverage Volume

We measure the volume of Company beverage products sold in two ways: (1) unit cases of finished products and (2) concentrate sales. As used in this report, "unit case" means a unit of measurement equal to 192 U.S. fluid ounces of finished beverage (24 eight-ounce servings), with the exception of unit case equivalents for Costa non-ready-to-drink beverage products which are primarily measured in number of transactions; and "unit case volume" means the number of unit cases (or unit case equivalents) of Company beverage products directly or indirectly sold by the Company and its bottling partners to customers or consumers. Unit case volume primarily consists of beverage products bearing Company trademarks. Also included in unit case volume are certain products licensed to, or distributed by, our Company, and brands owned by Coca-Cola system bottlers for which our Company provides marketing support and from the sale of which we derive economic benefit. In addition, unit case volume includes sales by certain joint ventures in which the Company has an equity interest. We believe unit case volume is one of the measures of the underlying strength of the Coca-Cola system because it measures trends at the consumer level. The unit case volume numbers used in this report are derived based on estimates received by the Company from its bottling partners and distributors. Concentrate sales volume represents the amount of concentrates, syrups, source waters and powders/minerals (in all instances expressed in unit case equivalents) sold by, or used in finished beverages sold by, the Company to its bottling partners or other customers. For Costa non-ready-to-drink beverage products, concentrate sales volume represents the amount of coffee beans and finished beverages (in all instances expressed in unit case equivalents) sold by the Company to customers or consumers. Unit case volume and concentrate sales volume growth rates are not necessarily equal during any given period. Factors such as seasonality, bottlers' inventory practices, supply point changes, timing of price increases, new product introductions and changes in product mix can create differences between unit case volume and concentrate sales volume growth rates. In addition to the items mentioned above, the impact of unit case volume from certain joint ventures in which the Company has an equity interest, but to which the Company does not sell concentrates, syrups, source waters or powders/minerals, may give rise to differences between unit case volume and concentrate sales volume growth rates.

39

Information about our volume growth worldwide and by operating segment is as follows:

Percent Change 2020 versus 2019

Three Months Ended September 25, 2020

Concentrate

Nine Months Ended September 25, 2020

Concentrate

Unit Cases 1,2,3

Sales4 Unit Cases 1,2,3

Sales4

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Worldwide | (4) % |  | (3) % | 6 | (7) % |  | (9) | % |  |
| Europe, Middle East & Africa | (3) % |  | — % |  | (7) % |  | (10) | % |
| Latin America | (4) |  | (2) |  | (4) |  | (6) |  |
| North America | (6) |  | (7) |  | (7) |  | (7) |  | 7 |
| Asia Pacific | (4) |  | (4) |  | (10) |  | (9) |  | 8 |
| Global Ventures | (11) |  | (14) |  | (15) |  | (17) |  |  |
| Bottling Investments | (10) 5 | N/A |  |  | (19) | 5 | N/A |  |  |

1 Bottling Investments operating segment data reflects unit case volume growth for consolidated bottlers only.

2 Geographic and Global Ventures operating segment data reflects unit case volume growth for all bottlers, both consolidated and unconsolidated, and distributors in the applicable geographic areas.

3 Unit case volume percent change is based on average daily sales. Unit case volume growth based on average daily sales is computed by comparing the average daily sales in each of the corresponding periods. Average daily sales are the unit cases sold during the period divided by the number of days in the period.

4 Concentrate sales volume represents the amount of concentrates, syrups, source waters and powders/minerals (in all instances expressed in unit case equivalents) sold by, or used in finished beverages sold by, the Company to its bottling partners or other customers and is not based on average daily sales. For Costa non-ready-to-drink products, concentrate sales volume represents the amount of coffee beans and finished beverages (in all instances expressed in unit case equivalents) sold by the Company to customers or consumers and is not based on average daily sales. Each of our interim reporting periods, other than the fourth interim reporting period, ends on the Friday closest to the last day of the corresponding quarterly calendar period. As a result, the first quarter of 2020 had one less day when compared to the first quarter of 2019, and the fourth quarter of 2020 will have two additional days when compared to the fourth quarter of 2019.

5 After considering the impact of structural changes, unit case volume for Bottling Investments declined 9 percent and 16 percent for the three and nine months ended September 25, 2020, respectively.

6 After considering the impact of structural changes, worldwide concentrate sales volume declined 4 percent for the three months ended September 25, 2020.

7 After considering the impact of structural changes, concentrate sales volume for North America declined 8 percent for the nine months ended September 25, 2020.

8 After considering the impact of structural changes, concentrate sales volume for Asia Pacific declined 10 percent for the nine months ended September 25, 2020.

### Unit Case Volume

Although a significant portion of our Company's revenues is not based directly on unit case volume, we believe unit case

volume is one of the measures of the underlying strength of the Coca-Cola system because it measures trends at the consumer level.

*Three Months Ended September 25, 2020 versus Three Months Ended September 27, 2019*

Unit case volume in Europe, Middle East and Africa declined 3 percent, which included a 1 percent decline in sparkling soft drinks, a 16 percent decline in water, enhanced water and sports drinks, and an 8 percent decline in tea and coffee, with even performance in juice, dairy and plant-based beverages. The group's sparkling soft drinks volume performance included 2 percent growth in Trademark Coca-Cola. The group reported decreases in unit case volume in the Western Europe; South & East Africa; Middle East & North Africa and Turkey, Caucasus & Central Asia business units. The decreases in these business units were partially offset by an increase in the West Africa business unit and even performance in the Central & Eastern Europe business unit.

In Latin America, unit case volume declined 4 percent, which included a 2 percent decline in sparkling soft drinks, a 10 percent decline in water, enhanced water and sports drinks, and a 9 percent decline in juice, dairy and plant-based beverages. These decreases were partially offset by a 14 percent increase in tea and coffee. The group reported declines in unit case volume of 6 percent in the Mexico business unit, 8 percent in the South Latin business unit and 6 percent in the Latin Center business unit. The decreases in these business units were partially offset by an 8 percent increase in the Brazil business unit.

40

Unit case volume in North America declined 6 percent, which included a 14 percent decline in tea and coffee, a 4 percent decline in water, enhanced water and sports drinks, and a 5 percent decline in juice, dairy and plant-based beverages. The group's sparkling soft drinks volume declined 7 percent, which included a 4 percent decline in Trademark Coca-Cola.

In Asia Pacific, unit case volume declined 4 percent, which included a 12 percent decline in water, enhanced water and sports drinks, a 10 percent decline in juice, dairy and plant-based beverages, and a 9 percent decline in tea and coffee, partially offset by a 2 percent increase in sparkling soft drinks. The group's sparkling soft drinks volume growth included 5 percent growth in Trademark Coca-Cola. The group reported declines in unit case volume of 11 percent in the India & South West Asia business unit, 8 percent in the Japan business unit, 2 percent in the ASEAN business unit and 1 percent in both the South Pacific and Greater China & Korea business units.

Unit case volume for Global Ventures declined 11 percent, driven by a 30 percent decrease in tea and coffee, partially offset by a 2 percent increase in juice, dairy and plant- based beverages and an increase in energy drinks.

Unit case volume for Bottling Investments declined 10 percent. The declines in unit case volume in the majority of our consolidated bottling operations were primarily the result of the impact of the COVID-19 pandemic.

*Nine Months Ended September 25, 2020 versus Nine Months Ended September 27, 2019*

Unit case volume in Europe, Middle East and Africa declined 7 percent, which included a 5 percent decline in sparkling soft drinks, a 17 percent decline in water, enhanced water and sports drinks, a 12 percent decline in juice, dairy and plant-based beverages, and an 18 percent decline in tea and coffee. The group's sparkling soft drinks volume performance reflected a decline of 3 percent in Trademark Coca-Cola. The group reported declines in all business units with the exception of the West Africa business unit, which was even.

In Latin America, unit case volume declined 4 percent, which included a 4 percent decline in sparkling soft drinks, a 5 percent decline in water, enhanced water and sports drinks, and a 9 percent decline in juice, dairy and plant-based beverages, partially offset by 1 percent growth in tea and coffee. The group reported declines in unit case volume of 11 percent in the South Latin business unit, 5 percent in the Mexico business unit and 1 percent in the Latin Center business unit. The Brazil business unit performance was even.

Unit case volume in North America declined 7 percent, which included a 16 percent decline in tea and coffee, a 4 percent decline in water, enhanced water and sports drinks, and a 5 percent decline in juice, dairy and plant-based beverages. The group's sparkling soft drinks volume declined 8 percent, which included a 5 percent decline in Trademark Coca-Cola.

In Asia Pacific, unit case volume declined 10 percent, which included a 6 percent decline in sparkling soft drinks, an 18 percent decline in water, enhanced water and sports drinks, a 19 percent decline in juice, dairy and plant-based beverages, and a 10 percent decline in tea and coffee. The group's sparkling soft drinks volume performance included 2 percent growth in Trademark Coca-Cola. The group reported a 31 percent decline in unit case volume in the India & South West Asia business unit, a 9 percent decline in the Japan business unit, a 7 percent decline in the ASEAN business unit, a 6 percent decline in the South Pacific business unit, and a 4 percent decline in the Greater China & Korea business unit.

Unit case volume for Global Ventures declined 15 percent, driven by a 31 percent decrease in tea and coffee, partially offset by growth in energy drinks. Performance was even in juice, dairy and plant-based beverages.

Unit case volume for Bottling Investments declined 19 percent. The declines in unit case volume in all of our consolidated bottling operations were primarily the result of the impact of the COVID-19 pandemic.

The ultimate impact that the COVID-19 pandemic will have on full year 2020 unit case volume is unknown at this time, as it will depend heavily on the impact of social distancing practices and the timing, pace and success of reopening plans, as well as the substance and pace of the post-pandemic recovery. While we believe the second quarter of 2020 will be the most severely impacted quarter of the year, we believe the fourth quarter will continue to be negatively impacted by the COVID-19 pandemic. The percentage decline in global unit case volume for October month-to-date was low single digits.

### Concentrate Sales Volume

During the three months ended September 25, 2020, worldwide concentrate sales volume declined 3 percent and unit case volume declined 4 percent compared to the three months ended September 27, 2019. During the nine months ended September 25, 2020, worldwide concentrate sales volume declined 9 percent and unit case volume declined 7 percent compared to the nine months ended September 27, 2019. Concentrate sales volume growth is calculated based on the amount of concentrate sold during the reporting periods, which is impacted by the number of days. Conversely, unit case volume growth is calculated based on average daily sales, which is not impacted by the number of days in the reporting periods. The first quarter of 2020 had one less day when compared to the first quarter of 2019, which contributed to the differences between concentrate sales volume and unit case sales volume growth rates on a consolidated basis and for the individual operating segments during the nine months ended September 25, 2020. In addition, the differences between concentrate sales volume and unit case volume

41

growth rates on a consolidated basis and for the Europe, Middle East and Africa operating segment during the nine months ended September 25, 2020 were impacted by the timing of concentrate shipments related to Brexit in the prior year. The differences between concentrate sales volume and unit case volume growth rates during the three months ended September 25, 2020 were impacted by the timing of concentrate shipments as bottlers adjusted inventory levels due to COVID-19 uncertainty in the current year and also by the timing of concentrate shipments in Brazil in the prior year.

### Net Operating Revenues

*Three Months Ended September 25, 2020 versus Three Months Ended September 27, 2019*

During the three months ended September 25, 2020, net operating revenues were $8,652 million compared to $9,507 million during the three months ended September 27, 2019, a decrease of $855 million, or 9 percent.

The following table illustrates, on a percentage basis, the estimated impact of key factors resulting in the increase (decrease) in net operating revenues on a consolidated basis and for each of our operating segments:

Percent Change 2020 versus 2019

Volume1

Price, Product & Geographic Mix

Foreign Currency

Fluctuations

Acquisitions &

Divestitures2 **Total**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Consolidated | (4) % | (3) | % | (3) | % | — % | **(9)%** |
| Europe, Middle East & Africa | — % | (6) | % | (1) | % | — % | **(7)%** |
| Latin America | (2) | (1) |  | (19) |  | — | **(23)** |
| North America | (7) | 4 |  | — |  | 1 | **(2)** |
| Asia Pacific | (4) | (4) |  | (1) |  | — | **(9)** |
| Global Ventures | (14) | (7) |  | 2 |  | — | **(19)** |
| Bottling Investments | (9) | 2 |  | (5) |  | (1) | **(12)** |

Note: Certain rows may not add due to rounding.

1 Represents the percent change in net operating revenues attributable to the increase (decrease) in concentrate sales volume for our geographic operating segments and our Global Ventures operating segment (expressed in unit case equivalents) after considering the impact of acquisitions and divestitures. For our Bottling Investments operating segment, this represents the percent change in net operating revenues attributable to the increase (decrease) in unit case volume computed by comparing the total sales (rather than the average daily sales) in each of the corresponding periods after considering the impact of structural changes. Our Bottling Investments operating segment data reflects unit case volume growth for consolidated bottlers only after considering the impact of structural changes. Refer to the heading "Beverage Volume" above.

2 Includes structural changes. Refer to the heading "Structural Changes, Acquired Brands and Newly Licensed Brands" above.

Refer to the heading "Beverage Volume" above for additional information related to changes in our unit case and concentrate sales volumes.

"Price, product and geographic mix" refers to the change in net operating revenues caused by factors such as price changes, the mix of products and packages sold, and the mix of channels and geographic territories where the sales occurred. The impact of price, product and geographic mix is calculated by subtracting the change in net operating revenues resulting from volume increases or decreases, changes in foreign currency exchange rates, and acquisitions and divestitures from the total change in net operating revenues. Management believes that providing investors with price, product and geographic mix enhances their understanding about the combined impact that the following items had on the Company's net operating revenues: (1) pricing actions taken by the Company and, where applicable, our bottling partners; (2) changes in the mix of products and packages sold; and (3) changes in the mix of channels and geographic territories where products were sold. Management uses this measure in making financial, operating and planning decisions and in evaluating the Company's performance.

Price, product and geographic mix had a 3 percent unfavorable impact on our consolidated net operating revenues. Price, product and geographic mix was impacted by a variety of factors and events including, but not limited to, the following:

* Europe, Middle East and Africa — unfavorable channel, package and geographic mix;
* Latin America — unfavorable channel, package and geographic mix and the timing of deductions from revenue, partially offset by pricing initiatives in Mexico and the impact of inflationary environments in certain markets;
* North America — favorable product mix, partially offset by unfavorable channel and package mix;
* Asia Pacific — unfavorable channel and package mix across a majority of the business units, partially offset by favorable geographic mix;

42

* Global Ventures — unfavorable product and channel mix primarily due to the impact of social distancing measures and gradual reopenings of the Costa retail stores as a result of the impact of the COVID-19 pandemic; and
* Bottling Investments — favorable pricing, partially offset by unfavorable channel and package mix.

Fluctuations in foreign currency exchange rates decreased our consolidated net operating revenues by 3 percent. This unfavorable impact was primarily due to a stronger U.S. dollar compared to certain foreign currencies, including the Mexican peso, Brazilian real, Chilean peso, Turkish lira, Russian ruble and Indian rupee, which had an unfavorable impact on our Latin America, Europe, Middle East and Africa, Asia Pacific and Bottling Investments operating segments. The unfavorable impact of a stronger U.S. dollar compared to the currencies listed above was partially offset by the impact of a weaker U.S. dollar compared to certain other foreign currencies, including the euro, British pound sterling, South African rand and Australian dollar, which had a favorable impact on our Europe, Middle East and Africa, Global Ventures and Asia Pacific operating segments. Refer to the heading "Liquidity, Capital Resources and Financial Position — Foreign Exchange" below.

"Acquisitions and divestitures" refers to acquisitions and divestitures of brands or businesses, some of which the Company considers to be structural changes. The impact of acquisitions and divestitures is the difference between the change in net operating revenues and the change in what our net operating revenues would have been if we removed the net operating revenues associated with an acquisition or divestiture from either the current year or the prior year, as applicable. Management believes that quantifying the impact that acquisitions and divestitures had on the Company's net operating revenues provides investors with useful information to enhance their understanding of the Company's net operating revenue performance by improving their ability to compare our period-to-period results. Management considers the impact of acquisitions and divestitures when evaluating the Company's performance. Refer to the heading "Structural Changes, Acquired Brands and Newly Licensed Brands" above for additional information related to acquisitions and divestitures.

*Nine Months Ended September 25, 2020 versus Nine Months Ended September 27, 2019*

During the nine months ended September 25, 2020, net operating revenues were $24,403 million, compared to $28,198 million during the nine months ended September 27, 2019, a decrease of $3,795 million, or 13 percent.

The following table illustrates, on a percentage basis, the estimated impact of key factors resulting in the increase (decrease) in net operating revenues on a consolidated basis and for each of our operating segments:

Percent Change 2020 versus 2019

Volume1

Price, Product & Geographic Mix

Foreign Currency

Fluctuations

Acquisitions &

Divestitures2 **Total**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Consolidated | (9) % | (2) | % | (3) | % | — % | **(13)%** |
| Europe, Middle East & Africa | (10) % | (5) | % | (2) | % | — % | **(16)%** |
| Latin America | (6) | 4 |  | (13) |  | — | **(15)** |
| North America | (8) | 2 |  | — |  | 2 | **(4)** |
| Asia Pacific | (10) | (3) |  | (1) |  | 1 | **(13)** |
| Global Ventures | (17) | (8) |  | — |  | — | **(25)** |
| Bottling Investments | (16) | 1 |  | (4) |  | (2) | **(20)** |

Note: Certain rows may not add due to rounding.

1 Represents the percent change in net operating revenues attributable to the increase (decrease) in concentrate sales volume for our geographic operating segments and our Global Ventures operating segment (expressed in unit case equivalents) after considering the impact of acquisitions and divestitures. For our Bottling Investments operating segment, this represents the percent change in net operating revenues attributable to the increase (decrease) in unit case volume computed by comparing the total sales (rather than the average daily sales) in each of the corresponding periods after considering the impact of structural changes. Our Bottling Investments operating segment data reflects unit case volume growth for consolidated bottlers only after considering the impact of structural changes. Refer to the heading "Beverage Volume" above.

2 Includes structural changes. Refer to the heading "Structural Changes, Acquired Brands and Newly Licensed Brands" above.

Refer to the heading "Beverage Volume" above for additional information related to changes in our unit case and concentrate sales volumes.

Price, product and geographic mix had a 2 percent unfavorable impact on our consolidated net operating revenues. Price, product and geographic mix was impacted by a variety of factors and events including, but not limited to, the following:

* Europe, Middle East and Africa — unfavorable channel, package and geographic mix, including the impact of the Brexit inventory build in the prior year;

43

* Latin America — favorable pricing initiatives in Mexico and the impact of inflationary environments in certain markets, partially offset by unfavorable channel and package mix;
* North America — favorable product mix, partially offset by unfavorable channel and package mix;
* Asia Pacific — unfavorable channel and package mix, partially offset by favorable geographic mix;
* Global Ventures — unfavorable product and channel mix primarily due to the impact of the temporary closures, social distancing measures and gradual third quarter reopenings of the Costa retail stores as a result of the COVID-19 pandemic; and
* Bottling Investments — favorable price and geographic mix, partially offset by unfavorable channel and package mix.

The unfavorable channel and package mix for both the three and nine months ended September 25, 2020 in all operating segments was primarily a result of the shift in consumer demand due to the impact of the COVID-19 pandemic. Consumers are purchasing more products in the at-home channels and fewer in the away-from-home channels. We expect any shift in consumer demand back to the away-from-home channels during the fourth quarter of 2020 to be closely correlated with the success of reopening plans and social distancing practices.

Fluctuations in foreign currency exchange rates decreased our consolidated net operating revenues by 3 percent. This unfavorable impact was primarily due to a stronger U.S. dollar compared to certain foreign currencies, including the South African rand, Turkish lira, Mexican peso, Chilean peso, Brazilian real, Indian rupee and Australian dollar, which had an unfavorable impact on our Europe, Middle East and Africa, Latin America, Asia Pacific and Bottling Investments operating segments. The unfavorable impact of a stronger U.S. dollar compared to the currencies listed above was partially offset by the impact of a weaker U.S. dollar compared to certain other foreign currencies, including the euro, British pound sterling and Japanese yen, which had a favorable impact on our Europe, Middle East and Africa and Asia Pacific operating segments. Refer to the heading "Liquidity, Capital Resources and Financial Position — Foreign Exchange" below.

Net operating revenue growth rates are impacted by sales volume; price, product and geographic mix; foreign currency fluctuations; and acquisitions and divestitures. The size and timing of acquisitions and divestitures are not consistent from period to period. Based on current spot rates and our hedging coverage in place, we expect foreign currencies will have an unfavorable impact on our full year 2020 net operating revenues.

### Gross Profit Margin

Gross profit margin is a ratio calculated by dividing gross profit by net operating revenues. Management believes gross profit margin provides investors with useful information related to the profitability of our business prior to considering all of the operating costs incurred. Management uses this measure in making financial, operating and planning decisions and in evaluating the Company's performance.

Our gross profit margin decreased to 59.9 percent for the three months ended September 25, 2020, compared to 60.4 percent for the three months ended September 27, 2019. Our gross profit margin decreased to 59.6 percent for the nine months ended September 25, 2020, compared to 60.8 percent for the nine months ended September 27, 2019. These decreases were primarily related to unfavorable channel and package mix along with unfavorable manufacturing overhead variances, partially offset by the impact of acquisitions and divestitures. Refer to Note 2 of Notes to Condensed Consolidated Financial Statements for additional information related to acquisitions and divestitures.

### Selling, General and Administrative Expenses

The following table sets forth the components of selling, general and administrative expenses (in millions):

Three Months Ended Nine Months Ended

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **September 25,** | September 27, |  |  | **September 25,** September 27, |
| **2020** | 2019 |  |  | **2020** 2019 |
| Stock-based compensation expense | **$ 52** $ | 58 |  | **$** | **88** $ 146 |
| Advertising expenses | **870** | 1,201 |  |  | **2,142** 3,319 |
| Selling and distribution expenses | **635** | 733 |  |  | **1,902** 2,121 |
| Other operating expenses | **954** | 1,124 |  |  | **3,010** 3,293 |
| Selling, general and administrative expenses | **$ 2,511** $ | 3,116 |  | **$** | **7,142** $ 8,879 |

During the three and nine months ended September 25, 2020, selling, general and administrative expenses decreased $605 million, or 19 percent, and decreased $1,737 million, or 20 percent, respectively, versus the prior year comparable period. The decreases were primarily due to effective cost management and a reduction in marketing spending as a result of uncertainties related to the impact of the COVID-19 pandemic, the impact of savings from our productivity initiatives and a

44

foreign currency exchange rate impact of 2 percent. The decrease for the nine months ended September 25, 2020 was also impacted by a reduction in stock-based compensation expense resulting from a change in estimated payout.

The decreases in advertising expenses during the three and nine months ended September 25, 2020 included the impact of a reduction in our estimate of full year advertising expenses that benefit multiple interim periods. Based on our interim accounting policy for advertising costs, a change in estimate of full year advertising expense is recognized in the interim period in which the change in estimate occurs. The foreign currency exchange rate impact on advertising expenses was a decrease of 1 percent for both the three and nine months ended September 25, 2020.

The decrease in selling and distribution expenses during the three months ended September 25, 2020 was primarily due to effective cost management as a result of uncertainties related to the COVID-19 pandemic. The decrease in selling and distribution expenses during the nine months ended September 25, 2020 was primarily due to volume declines and effective cost management as a result of uncertainties related to the COVID-19 pandemic, partially offset by amortization and depreciation expense in the current year for Coca-Cola Beverages Africa Proprietary Limited ("CCBA"). During the first five months of 2019, CCBA was classified as held for sale, and therefore amortization and depreciation expense were not recorded.

As of September 25, 2020, we had $255 million of total unrecognized compensation cost related to nonvested stock-based compensation awards granted under our plans, which we expect to recognize over a weighted-average period of 2.1 years as stock-based compensation expense. This expected cost does not include the impact of any future stock- based compensation awards granted.

### Other Operating Charges

Other operating charges incurred by operating segment and Corporate were as follows (in millions):

Three Months Ended Nine Months Ended

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **September 25,** | September 27, |  |  | **September 25,** September 27, |
|  | **2020** | 2019 |  |  | **2020** 2019 |
| Europe, Middle East & Africa | **$ 38** $ | 1 |  | **$** | **38** $ 2 |
| Latin America | **22** | — |  |  | **32** — |
| North America | **133** | 12 |  |  | **395** 42 |
| Asia Pacific | **32** | 42 |  |  | **32** 42 |
| Global Ventures | **—** | — |  |  | **—** — |
| Bottling Investments | **—** | 21 |  |  | **13** 64 |
| Corporate | **147** | 49 |  |  | **237** 194 |
| Total | **$ 372** $ | 125 |  | **$** | **747** $ 344 |

During the three months ended September 25, 2020, the Company recorded other operating charges of $372 million. These charges primarily consisted of $332 million due to the Company's strategic realignment initiatives and $10 million related to the Company's productivity and reinvestment program. In addition, other operating charges included

$18 million related to the remeasurement of our contingent consideration liability to fair value in conjunction with the fairlife acquisition and $12 million related to the restructuring of our manufacturing operations in the United States. Refer to Note 2 of Notes to Condensed Consolidated Financial Statements for additional information on the fairlife acquisition. Refer to Note 12 of Notes to Condensed Consolidated Financial Statements for additional information on the Company's strategic realignment initiatives and the Company's productivity and reinvestment program. Refer to Note 16 of Notes to Condensed Consolidated Financial Statements for the impact these charges had on our operating segments and Corporate.

45

During the nine months ended September 25, 2020, the Company recorded other operating charges of $747 million. These charges primarily consisted of $332 million related to the Company's strategic realignment initiatives and $71 million related the Company's productivity and reinvestment program. In addition, other operating charges included impairment charges of $160 million related to the Odwalla trademark and charges of $35 million related to discontinuing the Odwalla juice business. Other operating charges also included an impairment charge of $55 million related to a trademark in North America, which was primarily driven by the impact of the COVID-19 pandemic, revised projections of future operating results and a change in brand focus in the Company's portfolio. Other operating charges also included $47 million related to the remeasurement of our contingent consideration liability to fair value in conjunction with the fairlife acquisition and $24 million related to the restructuring of our manufacturing operations in the United States. Refer to Note 2 of Notes to Condensed Consolidated Financial Statements for additional information on the fairlife acquisition. Refer to Note 12 of Notes to Condensed Consolidated Financial Statements for additional information on the Company's strategic realignment initiatives and the Company's productivity and reinvestment program. Refer to Note 15 of Notes to Condensed Consolidated Financial Statements for additional information on the impairment charges. Refer to Note 16 of Notes to Condensed Consolidated Financial Statements for the impact these charges had on our operating segments and Corporate.

During the three months ended September 27, 2019, the Company recorded other operating charges of $125 million. These charges primarily consisted of $61 million related to the Company's productivity and reinvestment program and $42 million related to the impairment of a trademark in Asia Pacific. In addition, other operating charges included

$21 million for costs incurred to refranchise certain of our North America bottling operations. Costs related to refranchising include, among other items, internal and external costs for individuals directly working on the refranchising efforts, severance, and costs associated with the implementation of information technology systems to facilitate consistent data standards and availability throughout our North America bottling system. Refer to Note 12 of Notes to Condensed Consolidated Financial Statements for additional information on the Company's productivity and reinvestment program. Refer to Note 15 of Notes to Condensed Consolidated Financial Statements for additional information on the trademark impairment charge. Refer to Note 16 of Notes to Condensed Consolidated Financial Statements for the impact these charges had on our operating segments and Corporate.

During the nine months ended September 27, 2019, the Company recorded other operating charges of $344 million. These charges primarily consisted of $184 million related to the Company's productivity and reinvestment program and $42 million related to the impairment of a trademark in Asia Pacific. In addition, other operating charges included

$46 million of transaction costs associated with the purchase of Costa, which we acquired in January 2019, and $61 million for costs incurred to refranchise certain of our North America bottling operations. Refer to Note 2 of Notes to Condensed Consolidated Financial Statements for additional information on the acquisition of Costa. Refer to Note 12 of Notes to Condensed Consolidated Financial Statements for additional information on the Company's productivity and reinvestment program. Refer to Note 15 of Notes to Condensed Consolidated Financial Statements for additional information on the trademark impairment charge. Refer to Note 16 of Notes to Condensed Consolidated Financial Statements for the impact these charges had on our operating segments and Corporate.

### Operating Income and Operating Margin

Information about our operating income contribution by operating segment and Corporate on a percentage basis is as follows:

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | Three Months Ended |  |  | Nine Months Ended |  |
| **September 25,**  **2020** | September 27,  2019 |  | **September 25,**  **2020** | September 27,  2019 |
| Europe, Middle East & Africa | **39.3%** | 35.4% |  | **38.7%** | 36.6% |
| Latin America | **21.0** | 24.1 |  | **22.9** | 21.3 |
| North America | **31.7** | 25.6 |  | **24.1** | 24.4 |
| Asia Pacific | **24.5** | 23.8 |  | **25.9** | 23.6 |
| Global Ventures | **(1.4)** | 3.1 |  | **(1.7)** | 2.7 |
| Bottling Investments | **2.4** | 0.3 |  | **2.0** | 2.9 |
| Corporate | **(17.5)** | (12.3) |  | **(11.9)** | (11.5) |
| Total | **100.0%** | 100.0% |  | **100.0%** | 100.0% |

Operating margin is a ratio calculated by dividing operating income by net operating revenues. Management believes operating margin provides investors with useful information related to the profitability of our business after considering all of the operating costs incurred. Management uses this measure in making financial, operating and planning decisions and in evaluating the Company's performance.

46

Information about our operating margin on a consolidated basis and by operating segment and Corporate is as follows:

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | Three Months Ended |  |  | Nine Months Ended |  |
|  | **September 25,**  **2020** | September 27,  2019 |  | **September 25,**  **2020** | September 27,  2019 |
| Consolidated | **26.6%** | 26.3% |  | **27.3%** | 28.1% |
| Europe, Middle East & Africa | **58.0%** | 53.0% |  | **60.5%** | 56.8% |
| Latin America | **59.7** | 57.7 |  | **61.2** | 57.3 |
| North America | **23.6** | 20.4 |  | **18.7** | 21.6 |
| Asia Pacific | **46.7** | 45.0 |  | **52.9** | 50.1 |
| Global Ventures | **(6.1)** | 12.2 |  | **(8.3)** | 11.7 |
| Bottling Investments | **3.7** | 0.4 |  | **3.0** | 4.1 |
| Corporate | **\*** | \* |  | **\*** | \* |

*\** Calculation is not meaningful.

*Three Months Ended September 25, 2020 versus Three Months Ended September 27, 2019*

During the three months ended September 25, 2020, operating income was $2,298 million, compared to $2,499 million during the three months ended September 27, 2019, a decrease of $201 million, or 8 percent. The decrease was primarily driven by a decline in net operating revenues due to the impact of the COVID-19 pandemic, an unfavorable foreign currency exchange rate impact and higher other operating charges, partially offset by lower selling, general and administrative expenses.

During the three months ended September 25, 2020, fluctuations in foreign currency exchange rates unfavorably impacted consolidated operating income by 9 percent due to a stronger U.S. dollar compared to certain foreign currencies, including the Mexican peso, Brazilian real, Chilean peso, Turkish lira, Russian ruble and Indian rupee, which had an unfavorable impact on our Latin America, Europe, Middle East and Africa, Asia Pacific and Bottling Investments operating segments. The unfavorable impact of a stronger

U.S. dollar compared to the currencies listed above was partially offset by the impact of a weaker U.S. dollar compared to certain other foreign currencies, including the euro, British pound sterling and Australian dollar, which had a favorable impact on our Europe, Middle East and Africa and Asia Pacific operating segments.

Operating income for all operating segments and Corporate was impacted by a decline in net operating revenues due to the impact of the COVID-19 pandemic. Operating income was also impacted by lower selling, general and administrative expenses. In addition, operating income for each operating segment and Corporate was impacted by the following:

* Europe, Middle East and Africa — higher other operating charges and an unfavorable foreign currency exchange rate impact of 3 percent;
* Latin America — higher other operating charges and an unfavorable foreign currency exchange rate impact of 28 percent;
* North America — higher other operating charges;
* Asia Pacific — an unfavorable foreign currency exchange rate impact of 2 percent, partially offset by lower other operating charges;
* Global Ventures — the impact of social distancing practices and the gradual reopenings of the Costa retail stores in Western Europe;
* Bottling Investments — lower other operating charges, partially offset by an unfavorable foreign currency exchange rate impact; and
* Corporate — operating loss in 2020 increased primarily as a result of higher other operating charges and unfavorable manufacturing overhead variances due to lower volume, partially offset by lower stock-based compensation expense, lower annual incentive expense and savings from productivity initiatives.

*Nine Months Ended September 25, 2020 versus Nine Months Ended September 27, 2019*

During the nine months ended September 25, 2020, operating income was $6,659 million, compared to $7,922 million during the nine months ended September 27, 2019, a decrease of $1,263 million, or 16 percent. The decrease in operating income was primarily driven by a decline in net operating revenues due to the impact of the COVID-19 pandemic, an unfavorable foreign currency exchange rate impact and higher other operating charges, partially offset by lower selling, general and administrative expenses.

47

During the nine months ended September 25, 2020, fluctuations in foreign currency exchange rates unfavorably impacted consolidated operating income by 6 percent due to a stronger U.S. dollar compared to certain foreign currencies, including the South African rand, Turkish lira, Mexican peso, Chilean peso, Brazilian real, Australian dollar and Indian rupee, which had an unfavorable impact on our Europe, Middle East and Africa, Latin America, Asia Pacific and Bottling Investments operating segments. The unfavorable impact of a stronger U.S. dollar compared to the currencies listed above was partially offset by the impact of a weaker U.S. dollar compared to certain other foreign currencies, including the euro, British pound sterling and Japanese yen, which had a favorable impact on our Europe, Middle East and Africa and Asia Pacific operating segments.

Operating income for all operating segments and Corporate was impacted by a decline in net operating revenues due to the impact of the COVID-19 pandemic. Operating income was also impacted by lower selling, general and administrative expenses. In addition, operating income for each operating segment and Corporate was impacted by the following:

* Europe, Middle East and Africa — higher other operating charges and an unfavorable foreign currency exchange rate impact of 3 percent;
* Latin America — higher other operating charges and an unfavorable foreign currency exchange rate impact of 20 percent;
* North America — higher other operating charges;
* Asia Pacific — an unfavorable foreign currency exchange rate impact of 2 percent, partially offset by lower other operating charges;
* Global Ventures — the temporary closures and gradual third quarter 2020 reopenings of the Costa retail stores;
* Bottling Investments — a favorable foreign currency exchange rate impact of 10 percent and lower other operating charges; and
* Corporate — operating loss in 2020 decreased primarily as a result of lower stock-based compensation expense, lower annual incentive expense and savings from productivity initiatives, partially offset by higher other operating charges, unfavorable manufacturing overhead variances due to lower volume and a loss on the disposal of certain assets.

Based on current spot rates and our hedging coverage in place, we expect foreign currency fluctuations will have an unfavorable impact on operating income through the end of the year.

### Interest Income

During the three months ended September 25, 2020, interest income was $82 million, compared to $153 million during the three months ended September 27, 2019, a decrease of $71 million, or 46 percent. During the nine months ended September 25, 2020, interest income was $294 million, compared to $428 million during the nine months ended September 27, 2019, a decrease of $134 million, or 31 percent. These decreases were primarily driven by lower returns in certain of our international locations, as well as the unfavorable impact of fluctuations in foreign currency exchange rates.

### Interest Expense

During the three months ended September 25, 2020, interest expense was $660 million, compared to $230 million during the three months ended September 27, 2019, an increase of $430 million, or 188 percent. During the nine months ended September 25, 2020, interest expense was $1,127 million, compared to $711 million during the nine months ended September 27, 2019, an increase of $416 million, or 59 percent. These increases were primarily due to charges of $405 million associated with the extinguishment of certain long-term debt. The increases in interest expense were also driven by higher average balances resulting from 2020 long-term debt issuances, partially offset by lower short-term U.S. interest rates and balances. Refer to Note 7 of Notes to Condensed Consolidated Financial Statements.

### Equity Income (Loss) — Net

*Three Months Ended September 25, 2020 versus Three Months Ended September 27, 2019*

During the three months ended September 25, 2020, equity income was $431 million, compared to equity income of $346 million during the three months ended September 27, 2019, an increase of $85 million, or 24 percent. This increase reflects, among other things, the impact of more favorable operating results reported by several of our equity method investees, partially offset by the unfavorable impact of foreign currency exchange rate fluctuations. In addition, the Company recorded net charges of $27 million and

$39 million in the line item equity income (loss) — net during the three months ended September 25, 2020 and September 27, 2019, respectively. These amounts represent the Company's proportionate share of significant operating and nonoperating items recorded by certain of our equity method investees.

48

*Nine Months Ended September 25, 2020 versus Nine Months Ended September 27, 2019*

During the nine months ended September 25, 2020, equity income was $774 million, compared to equity income of $808 million during the nine months ended September 27, 2019, a decrease of $34 million, or 4 percent. This decrease reflects the impact of the COVID-19 pandemic on operating results reported by our equity method investees and the unfavorable impact of foreign currency exchange rate fluctuations. In addition, the Company recorded net charges of $128 million and $107 million in the line item equity income (loss) — net during the nine months ended September 25, 2020 and September 27, 2019, respectively. These amounts represent the Company's proportionate share of significant operating and nonoperating items recorded by certain of our equity method investees.

### Other Income (Loss) — Net

*Three Months Ended September 25, 2020 versus Three Months Ended September 27, 2019*

Other income (loss) — net includes, among other things, dividend income; gains and losses related to the disposal of property, plant and equipment; gains and losses related to acquisitions and divestitures; non-service cost components of net periodic benefit cost for pension and other postretirement benefit plans; other charges and credits related to pension and other postretirement benefit plans; realized and unrealized gains and losses on equity securities and trading debt securities; realized gains and losses on available- for-sale debt securities; and the impact of foreign currency exchange gains and losses. The foreign currency exchange gains and losses are primarily the result of the remeasurement of monetary assets and liabilities from certain currencies into functional currencies. The effects of the remeasurement of these assets and liabilities are partially offset by the impact of our economic hedging program for certain exposures on our consolidated balance sheet. Refer to Note 6 of Notes to Condensed Consolidated Financial Statements.

During the three months ended September 25, 2020, other income (loss) — net was income of $30 million. The Company recognized a net gain of $13 million related to realized and unrealized gains and losses on equity securities and trading debt securities as well as realized gains and losses on available-for-sale debt securities. The Company also recorded other postretirement benefit plan curtailment charges of $11 million related to the strategic realignment initiatives. Other income (loss) — net also included income of $44 million related to the non-service cost components of net periodic benefit cost, $5 million of dividend income and net foreign currency exchange losses of $3 million. None of the other items included in other income (loss) — net was individually significant. Refer to Note 4 of Notes to Condensed Consolidated Financial Statements for additional information on equity and debt securities. Refer to Note 12 of Notes to Condensed Consolidated Financial Statements for additional information on the strategic realignment initiatives. Refer to Note 16 of Notes to Condensed Consolidated Financial Statements for the impact these items had on our operating segments and Corporate.

During the three months ended September 27, 2019, other income (loss) — net was income of $324 million. The Company recognized a gain of $739 million on the sale of a retail and office building in New York City and a net gain of $38 million related to realized and unrealized gains and losses on equity securities and trading debt securities as well as realized gains and losses on available-for-sale debt securities. In addition, the Company recorded an other-than-temporary impairment charge of $120 million related to CCBJHI, an equity method investee, and other-than-temporary impairment charges of $255 million related to certain equity method investees in the Middle East. The Company also recorded net charges of $103 million primarily related to post-closing adjustments as contemplated by the related agreements associated with the refranchising of certain bottling territories in North America. Other income (loss) — net also included income of $24 million related to the non-service cost components of net periodic benefit cost, $11 million of dividend income and net foreign currency exchange losses of $15 million. None of the other items included in other income (loss) — net was individually significant. Refer to Note 2 of Notes to Condensed Consolidated Financial Statements for additional information on refranchising activities. Refer to Note 4 of Notes to Condensed Consolidated Financial Statements for additional information on equity and debt securities. Refer to Note 15 of Notes to Condensed Consolidated Financial Statements for information on the impairment charges. Refer to Note 16 of Notes to Condensed Consolidated Financial Statements for the impact these items had on our operating segments and Corporate.

49

*Nine Months Ended September 25, 2020 versus Nine Months Ended September 27, 2019*

During the nine months ended September 25, 2020, other income (loss) — net was income of $788 million. The Company recognized a gain of $902 million in conjunction with the fairlife acquisition, which resulted from the remeasurement of our previously held equity interest in fairlife to fair value and a gain of $18 million related to the sale of a portion of our ownership interest in one of our equity method investments. These gains were partially offset by a net loss of $55 million related to economic hedging activities, an other-than-temporary impairment charge of $38 million related to one of our equity method investees in Latin America and an impairment charge of $26 million associated with an investment in an equity security without a readily determinable fair value, which were primarily driven by revised projections of future operating results. The Company also recorded a charge of $21 million related to the restructuring of our manufacturing operations in the United States, other postretirement benefit plan curtailment charges of

$11 million related to the Company's strategic realignment initiatives, and a net loss of $127 million related to realized and unrealized gains and losses on equity securities and trading debt securities as well as realized gains and losses on available-for-sale debt securities. Other income (loss) — net also included income of $129 million related to the non-service cost components of net periodic benefit cost, dividend income of $48 million and net foreign currency exchange losses of $36 million. None of the other items included in other income (loss) — net was individually significant. Refer to Note 2 of Notes to Condensed Consolidated Financial Statements for additional information on the fairlife acquisition. Refer to Note 4 of Notes to Condensed Consolidated Financial Statements for additional information on equity and debt securities. Refer to Note 6 of Notes to Condensed Consolidated Financial Statements for additional information on our economic hedging activities. Refer to Note 12 of Notes to Condensed Consolidated Financial Statements for additional information on the Company's strategic realignment initiatives. Refer to Note 15 of Notes to Condensed Consolidated Financial Statements for additional information on the impairment charges. Refer to Note 16 of Notes to Condensed Consolidated Financial Statements for the impact these items had on our operating segments and Corporate.

During the nine months ended September 27, 2019, other income (loss) — net was a loss of $81 million. The Company recognized a gain of $739 million on the sale of a retail and office building in New York City. The Company also recognized a net gain of $197 million related to realized and unrealized gains and losses on equity securities and trading debt securities as well as realized gains and losses on available-for-sale debt securities and a gain of $39 million related to the sale of a portion of our equity ownership interest in Embotelladora Andina S.A. ("Andina"). These gains were partially offset by other-than-temporary impairment charges of $406 million related to CCBJHI, an equity method investee, $255 million related to certain equity method investees in the Middle East, $57 million related to one of our equity method investees in North America and

$49 million related to one of our other equity method investees in Latin America. The Company also recorded an adjustment to reduce the carrying amount of CCBA's fixed assets and definite-lived intangible assets by $160 million and recognized a $121 million loss in conjunction with our acquisition of the remaining equity ownership interest in CHI. Additionally, the Company recognized net charges of $107 million primarily related to post-closing adjustments as contemplated by the related agreements associated with the refranchising of certain bottling territories in North America. Other income (loss) — net also included income of $75 million related to the non-service cost components of net periodic benefit cost and $51 million of dividend income, partially offset by net foreign currency exchange losses of $76 million. None of the other items included in other income (loss) — net was individually significant. Refer to Note 2 of Notes to Condensed Consolidated Financial Statements for additional information on the CCBA asset adjustment, refranchising activities, the acquisition of the remaining equity ownership interest in CHI and the sale of a portion of our equity ownership interest in Andina. Refer to Note 4 of Notes to Condensed Consolidated Financial Statements for additional information on equity and debt securities. Refer to Note 15 of Notes to Condensed Consolidated Financial Statements for additional information on the impairment charges. Refer to Note 16 of Notes to Condensed Consolidated Financial Statements for the impact these items had on our operating segments and Corporate.

### Income Taxes

The Company recorded income taxes of $441 million (20.2 percent effective tax rate) and $503 million (16.3 percent effective tax rate) during the three months ended September 25, 2020 and September 27, 2019, respectively. The Company recorded income taxes of $1,094 million (14.8 percent effective tax rate) and $1,446 million (17.3 percent effective tax rate) during the nine months ended September 25, 2020 and September 27, 2019, respectively.

The Company's effective tax rates for the three and nine months ended September 25, 2020 and September 27, 2019 vary from the statutory U.S. federal income tax rate of 21.0 percent primarily due to the tax impact of significant operating and nonoperating items, along with the tax benefits of having significant operations outside the United States and significant earnings generated in investments accounted for under the equity method, both of which are generally taxed at rates lower than the statutory U.S. rate.

The Company's effective tax rates for the three and nine months ended September 25, 2020 included $15 million of net tax expense and $138 million of net tax benefit, respectively, associated with various discrete tax items, including return to provision adjustments, excess tax benefits associated with the Company's stock-based compensation arrangements, the net tax impact of tax law changes in certain foreign jurisdictions, and net tax charges for changes to our uncertain tax positions,

50

including interest and penalties. The Company's effective tax rate for the nine months ended September 25, 2020 also included a tax benefit of $40 million associated with the gain recorded upon the acquisition of the remaining interest in fairlife. Refer to Note 2 of Notes to Condensed Consolidated Financial Statements for additional information on the fairlife acquisition.

The Company's effective tax rates for the three and nine months ended September 27, 2019 included $213 million and $245 million, respectively, of net tax benefits recorded. These net tax benefits were primarily associated with return to provision adjustments, but also included excess tax benefits associated with the Company's stock-based compensation arrangements, net tax charges for various resolved tax audit issues, and net tax charges for changes to our uncertain tax positions, including interest and penalties. The Company's effective tax rate for the nine months ended September 27, 2019 also included a tax benefit of $199 million recorded as a result of CCBA no longer qualifying as a discontinued operation. Refer to Note 2 of Notes to Condensed Consolidated Financial Statements for additional information on CCBA.

On September 17, 2015, the Company received a Statutory Notice of Deficiency from the Internal Revenue Service ("IRS") for the tax years 2007 through 2009, after a five- year audit. The Company contested the proposed adjustments in U.S. Tax Court and is currently awaiting a decision. Refer to Note 8 of Notes to Condensed Consolidated Financial Statements.

At the end of each interim period, we make our best estimate of the effective tax rate expected to be applicable for the full fiscal year. This estimate reflects, among other items, our best estimate of operating results and foreign currency exchange rates. Based on current tax laws, the Company's effective tax rate in 2020 is expected to be 19.5 percent before considering the potential impact of any significant operating and nonoperating items that may affect our effective tax rate.

## LIQUIDITY, CAPITAL RESOURCES AND FINANCIAL POSITION

As a result of uncertainties in the near-term outlook for our business caused by the COVID-19 pandemic, we are reevaluating all aspects of our spending. We recognize that marketing campaigns are often less effective at times like these; therefore, we have taken actions to adjust our marketing spending until we have more clarity and visibility into the impact of the pandemic on our business. We have reviewed all of our capital projects to ensure that we are only spending on projects that are deemed to be essential in the current environment. We have taken steps to limit spending on travel, third-party services and other operating expenses, and we continue to focus on cash flow generation. Our current capital allocation priorities are focused on investing wisely to support our business operations and continuing to prioritize our dividend payment. Currently, we have no intention of repurchasing shares under our Board of Directors' authorized plan during the year ending December 31, 2020, and we have no intention on changing our approach toward paying dividends. We also do not currently expect any significant mergers and acquisitions activity to occur during the remainder of this year. We will review and, when appropriate, adjust our overall approach to capital allocation as we know more about the length and severity of the COVID-19 pandemic and how the post-pandemic recovery will unfold. The Company does not typically raise capital through the issuance of stock. Instead, we use debt financing to lower our overall cost of capital and increase our return on shareowners' equity. Refer to the heading "Cash Flows from Financing Activities" below. We have a history of borrowing funds both domestically and internationally at reasonable interest rates, and we expect to be able to continue to borrow funds at reasonable rates over the long term. Our debt financing also includes the use of an extensive commercial paper program. While the COVID-19 pandemic initially caused a disruption in the commercial paper market, we currently still have the ability to borrow funds in this market and expect to continue to be able to do so in the future. The Company reviews its optimal mix of short-term and long-term debt regularly, and as a result of this review, during both the second and third quarter of 2020, we issued additional long-term debt with certain tranches having a longer duration than other recent long-term debt issuances. We used a portion of the proceeds from the long-term debt issuances to extinguish certain tranches of our previously issued long-term debt which had either near- term maturity dates and/or high coupon rates. While we intend to remain active in the commercial paper market, we also used a portion of the proceeds from the long-term debt issuances to reduce our commercial paper balance. We also intend to use a portion of the proceeds to extinguish additional tranches of our previously issued long-term debt.

Refer to Note 7 and Note 17 of Notes to Condensed Consolidated Financial Statements for additional information on the debt extinguishments.

On March 20, 2020 and April 29, 2020, we issued $5.0 billion and $6.5 billion, respectively, of long-term debt across various maturities. On September 14, 2020, we issued

U.S. dollar- and euro-denominated long-term debt of $4.1 billion and €2.6 billion, respectively, across various maturities. The Company's cash, cash equivalents, short-term investments and marketable securities totaled $21.1 billion as of September 25, 2020. In addition to these funds, our commercial paper program and our ability to issue long- term debt, we had $8.9 billion in unused lines of credit for general corporate purposes as of September 25, 2020. These backup lines of credit expire at various times from 2020 through 2025.

Based on all of the aforementioned factors, the Company believes its current liquidity position is strong and will continue to be sufficient to fund our operating activities and cash commitments for investing and financing activities for the foreseeable future.

51

### Cash Flows from Operating Activities

As part of our continued efforts to improve our working capital efficiency, we have worked with our suppliers over the past several years to revisit terms and conditions, including the extension of payment terms. Our current payment terms with the majority of our suppliers are 120 days. Additionally, two global financial institutions offer a voluntary supply chain finance ("SCF") program which enables our suppliers, at their sole discretion, to sell their receivables from the Company to these financial institutions on a non-recourse basis at a rate that leverages our credit rating and thus may be more beneficial to them. The SCF program is available to suppliers of goods and services included in cost of goods sold as well as suppliers of goods and services included in selling, general and administrative expenses in our consolidated statement of income. The Company and our suppliers agree on commercial terms for the goods and services we procure, including prices, quantities and payment terms, regardless of whether the supplier elects to participate in the SCF program. The suppliers sell goods or services, as applicable, to the Company and issue the associated invoices to the Company based on the agreed-upon contractual terms. Then, if they are participating in the SCF program, our suppliers, at their sole discretion, determine which invoices, if any, they want to sell to the financial institutions. Our suppliers' voluntary inclusion of invoices in the SCF program has no bearing on our payment terms. No guarantees are provided by the Company or any of our subsidiaries under the SCF program. We have no economic interest in a supplier's decision to participate in the SCF program, and we have no direct financial

relationship with the financial institutions, as it relates to the SCF program. Accordingly, amounts due to our suppliers that elected to participate in the SCF program are included in the line item accounts payable and accrued expenses in our consolidated balance sheet. All activity related to amounts due to suppliers that elected to participate in the SCF program is reflected in the line item cash flows from operating activities in our consolidated statement of cash flows. We have been informed by the financial institutions that as of September 25, 2020 and December 31, 2019, suppliers elected to sell $724 million and $784 million, respectively, of our outstanding payment obligations to the financial institutions. The amount settled through the SCF program was $2,076 million for the nine months ended September 25, 2020.

Net cash provided by operating activities for the nine months ended September 25, 2020 and September 27, 2019 was $6,220 million and $7,771 million, respectively, a decrease of $1,551 million, or 20 percent. This decrease was primarily driven by the decline in operating income, the extension of payment terms with certain of our suppliers in the prior year, one less selling day in the current year and the unfavorable impact of foreign currency exchange rate fluctuations. Net cash provided by operating activities included estimated benefits of $786 million and $869 million for the nine months ended September 27, 2019 and year ended December 31, 2019, respectively, from the extension of payment terms with certain of our suppliers. We do not believe there is a risk that our payment terms will be shortened in the near future, and we do not currently expect our net cash provided by operating activities to be significantly impacted by additional extensions of payment terms in 2020.

### Cash Flows from Investing Activities

Net cash used in investing activities for the nine months ended September 25, 2020 and September 27, 2019 was $7,072 million and $3,901 million, respectively.

*Purchases of Investments and Proceeds from Disposals of Investments*

During the nine months ended September 25, 2020, purchases of investments were $12,051 million and proceeds from disposals of investments were $6,482 million, resulting in a net cash outflow of $5,569 million. During the nine months ended September 27, 2019, purchases of investments were $4,113 million and proceeds from disposals of investments were $5,674 million, resulting in a net cash inflow of $1,561 million. This activity primarily represents the purchases of, and proceeds from the disposals of, investments in marketable securities and short-term investments that were made as part of the Company's overall cash management strategy. Also included in this activity are purchases of, and proceeds from the disposals of, insurance captive investments. Refer to Note 4 of Notes to Condensed Consolidated Financial Statements for additional information.

*Acquisitions of Businesses, Equity Method Investments and Nonmarketable Securities*

During the nine months ended September 25, 2020, the Company's acquisitions of businesses, equity method investments and nonmarketable securities totaled $989 million, which primarily related to the acquisition of the remaining interest in fairlife. Refer to Note 2 of Notes to Condensed Consolidated Financial Statements for additional information.

During the nine months ended September 27, 2019, the Company's acquisitions of businesses, equity method investments and nonmarketable securities totaled $5,376 million, which primarily related to the acquisition of Costa and the remaining interest in CHI. Refer to Note 2 of Notes to Condensed Consolidated Financial Statements for additional information.

52

*Proceeds from Disposals of Businesses, Equity Method Investments and Nonmarketable Securities*

During the nine months ended September 25, 2020, proceeds from disposals of businesses, equity method investments and nonmarketable securities were $46 million, which primarily related to the sale of a portion of our ownership interest in one of our equity method investments. Refer to Note 2 of Notes to Condensed Consolidated Financial Statements for additional information.

During the nine months ended September 27, 2019, proceeds from disposals of businesses, equity method investments and nonmarketable securities were $266 million, which primarily related to the proceeds from the sale of a portion of our equity ownership interest in Andina. Refer to Note 2 of Notes to Condensed Consolidated Financial Statements for additional information.

*Purchases of Property, Plant and Equipment*

Purchases of property, plant and equipment for the nine months ended September 25, 2020 and September 27, 2019 were $759 million and $1,206 million, respectively.

### Cash Flows from Financing Activities

Net cash provided by financing activities during the nine months ended September 25, 2020 was $5,973 million, and net cash used in financing activities during the nine months ended September 27, 2019 was $5,337 million.

*Debt Financing*

Issuances and payments of debt included both short-term and long-term financing activities. During the nine months ended September 25, 2020, the Company had issuances of debt of $26,898 million, which included $8,260 million of net issuances related to commercial paper and short-term debt with maturities greater than 90 days and long-term debt issuances of $18,638 million, net of related discounts and issuance costs.

The Company made payments of debt of $17,977 million during the nine months ended September 25, 2020, which included $11,464 million of payments of commercial paper and short-term debt with maturities greater than 90 days, $1,911 million of payments of commercial paper and short-term debt with maturities of 90 days or less, and payments of long-term debt of $4,602 million.

During the nine months ended September 25, 2020, the Company issued U.S. dollar- and euro-denominated debt of $15,600 million and €2,600 million, respectively. The carrying value of this debt as of September 25, 2020 was $17,461 million. During the nine months ended September 25, 2020, the Company retired upon maturity Australian dollar- and U.S. dollar-denominated notes of AUD450 million and $171 million, respectively. During the nine months ended September 25, 2020, the Company also extinguished prior to maturity U.S. dollar- and euro-denominated debt of $1,954 million and €1,448 million, respectively. Refer to Note 7 of Notes to Condensed Consolidated Financial Statements for the general terms of these notes.

*Issuances of Stock*

During the nine months ended September 25, 2020, the Company received cash proceeds from issuances of stock of $514 million, a decrease of $409 million when compared to cash proceeds from issuances of stock of $923 million during the nine months ended September 27, 2019.

*Share Repurchases*

During the nine months ended September 25, 2020, the Company did not repurchase common stock under the share repurchase plan authorized by our Board of Directors. The Company's treasury stock activity includes shares surrendered to the Company to pay the exercise price and/or to satisfy tax withholding obligations in connection with so- called stock swap exercises of employee stock options and/or the vesting of restricted stock issued to employees. The Company's treasury stock activity during the nine months ended September 25, 2020 resulted in a cash outflow of $93 million.

*Dividends*

During the nine months ended September 25, 2020 and September 27, 2019, the Company paid dividends of $3,522 million and $3,419 million, respectively. The Company paid the third quarter dividend in both 2020 and 2019 during the first week of October.

Our Board of Directors approved the Company's regular quarterly dividend of $0.41 per share at its October 2020 meeting. This dividend is payable on December 15, 2020 to shareowners of record as of the close of business on December 1, 2020.

53

### Foreign Exchange

Our international operations are subject to certain opportunities and risks, including currency fluctuations and governmental actions. We closely monitor our operations in each country and seek to adopt appropriate strategies that are responsive to changing economic and political environments as well as to fluctuations in foreign currencies.

Our Company conducts business in more than 200 countries and territories. Due to the geographic diversity of our operations, weakness in some foreign currencies may be offset by strength in others. Our foreign currency management program is designed to mitigate, over time, a portion of the potentially unfavorable impact of exchange rate changes on net income and earnings per share. Taking into account the effects of our hedging activities, the impact of changes in foreign currency exchange rates decreased our operating income for the three and nine months ended September 25, 2020 by 9 percent and 6 percent, respectively.

Based on current spot rates and our hedging coverage in place, we expect foreign currency fluctuations will have an unfavorable impact on operating income and cash flows from operations through the end of the year.

### Item 3. Quantitative and Qualitative Disclosures About Market Risk

We have no material changes to the disclosures on this matter made in our Annual Report on Form 10-K for the year ended December 31, 2019.

### Item 4. Controls and Procedures

*Evaluation of Disclosure Controls and Procedures*

The Company, under the supervision and with the participation of its management, including the Chief Executive Officer and the Chief Financial Officer, evaluated the effectiveness of the design and operation of the Company's "disclosure controls and procedures" (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act")) as of the end of the period covered by this report. Based on that evaluation, the Chief Executive Officer and the Chief Financial Officer concluded that the Company's disclosure controls and procedures were effective as of September 25, 2020.

*Changes in Internal Control Over Financial Reporting*

There have been no changes in the Company's internal control over financial reporting during the quarter ended September 25, 2020 that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

## Part II. Other Information

### Item 1. Legal Proceedings

Information regarding reportable legal proceedings is contained in Part I, "Item 3. Legal Proceedings" in our Annual Report on Form 10-K for the year ended December 31, 2019.

### Item 1A. Risk Factors

In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, "Item 1A. Risk Factors" in our Annual Report on

Form 10-K for the year ended December 31, 2019, as updated and supplemented in Part II, "Item 1A. Risk Factors" in our Quarterly Report on Form 10-Q for the quarter ended March 27, 2020 and in Part II, "Item 1A. Risk Factors" in our Quarterly Report on Form 10-Q for the quarter ended June 26, 2020 and as further updated and supplemented below, which could materially affect our business, financial condition or results of operations in future periods. These risks are not the only risks facing our Company.

Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition or results of operations in future periods.

### The COVID-19 pandemic has had, and we expect will continue to have, certain negative impacts on our business, and such impacts have had, and may continue to have, a material adverse effect on our results of operations, financial condition and cash flows.

The public health crisis caused by the COVID-19 pandemic and the measures that have been taken or that may be taken in the future by governments, businesses, including us and our bottling partners, and the public at large to limit COVID-19's spread have had, and we expect will continue to have, certain negative impacts on our business including, without limitation, the following:

* We have experienced a decrease in sales of certain of our products in markets around the world that have been affected by the COVID-19 pandemic. In particular, sales of our products in the away-from-home channels have been significantly negatively affected by shelter-in-place regulations or recommendations, closings of restaurants and

54

cancellations of major sporting and other events that were imposed as a result of the initial COVID-19 outbreak. While some of these restrictions have been lifted or eased in many jurisdictions as the rates of COVID-19 infections have decreased or stabilized, resurgence of the pandemic in some markets has slowed the reopening process. If COVID-19 infection trends continue to reverse and the pandemic intensifies and expands geographically, its negative impacts on our sales could be more prolonged and may become more severe. While we initially experienced increased sales in the at-home channels from pantry loading as consumers stocked up on certain of our products with the expectation of spending more time at home during the crisis, such increased sales levels have not, and we expect will not, fully offset the sales pressures we have experienced and we expect will continue to experience in the away-from-home channels while social distancing mandates or recommendations are in effect.

* In certain COVID-19 affected markets, consumer demand has shifted away from some of our more profitable beverages and away-from-home consumption to lower- margin products and at-home consumption, and this shift in consumer purchasing patterns is likely to continue while shelter-in-place and social distancing behaviors are mandated or encouraged.
* Deteriorating economic and political conditions in many of our major markets affected by the COVID-19 pandemic, such as increased unemployment, decreases in disposable income, declines in consumer confidence, or economic slowdowns or recessions, have caused a decrease in demand for our products. Continuing economic and political uncertainties in such markets may slow down or prevent the recovery of the demand for our products or may even further erode such demand.
* We are accelerating our business strategy and are taking certain actions to address challenges posed by the COVID-19 pandemic and deliver on our commitment to emerge stronger from this crisis. These actions include focusing investments on a defined growth portfolio by prioritizing brands best positioned for consumer reach; streamlining the innovation pipeline through initiatives that are scalable regionally or globally as well as maintaining a disciplined approach to local experimentation; refreshing our marketing approach, with a focus on improving our marketing investment effectiveness and efficiency; and investing in new capabilities to capitalize on emerging shifts in consumer behaviors that we anticipate may last beyond this crisis. These actions, which may require substantial additional investment of management time and financial resources, may not be sufficient to accomplish our goals.
* We have experienced temporary disruptions in certain of our concentrate production operations. We have taken measures to protect our employees and facilities around the world, which have included, but have not been limited to, checking the temperature of employees when they enter our facilities, requiring employees to wear masks and other protective clothing as appropriate, and implementing additional cleaning and sanitization routines. These measures may not be sufficient to prevent the spread of COVID-19 among our employees and, therefore, we may face additional concentrate production disruptions in the future, which may place constraints on our ability to supply concentrates to our bottling partners in a timely manner or may increase our concentrate supply costs.
* We have faced, and may continue to face, delays in the delivery of concentrates to our bottling partners as a result of shipping delays due to, among other things, additional safety requirements imposed by port authorities, closures of or congestion at ports, and capacity constraints experienced by our transportation contractors.
* Some of our bottling partners have experienced, and may experience in the future, temporary plant closures, production slowdowns and disruptions in distribution operations as a result of the impact of the COVID-19 pandemic on their respective businesses.
* Disruptions in supply chains have placed, and may continue to place, constraints on our and our bottling partners’ ability to source beverage containers, such as glass bottles and cans, which has increased, and in the future may increase, our and their packaging costs.
* We have experienced, and expect to continue to experience, adverse fluctuations in foreign currency exchange rates, particularly an increase in the value of the U.S. dollar against certain key foreign currencies, which negatively affected, and we expect will continue to negatively affect, our reported results of operations and financial condition.
* Governmental authorities in the United States and throughout the world may increase or impose new income taxes or indirect taxes, or revise interpretations of existing tax rules and regulations, as a means of financing the costs of stimulus and other measures enacted or taken, or that may be enacted or taken in the future, to protect populations and economies from the impact of the COVID-19 pandemic. Such actions could have an adverse effect on our results of operations and/or cash flows.
* We rely on third-party service providers and business partners, such as cloud data storage and other information technology service providers, suppliers, distributors, contractors, joint venture partners and other external business partners, for certain functions or for services in support of key portions of our operations. These third-party service providers and business partners are subject to risks and uncertainties related to the COVID-19 pandemic, which may

55

interfere with their ability to fulfill their respective commitments and responsibilities to us in a timely manner and in accordance with the agreed-upon terms.

* The financial impact of the COVID-19 pandemic may cause one or more of our counterparty financial institutions to fail or default on their obligations to us, which could cause us to incur significant losses.
* We may be required to record significant impairment charges with respect to noncurrent assets, including trademarks, bottler franchise rights, goodwill and other intangible assets, equity method investments, and other long-lived assets, whose fair values may be negatively affected by the effects of the COVID-19 pandemic on our operations. In addition, we are required to record impairment charges related to our proportionate share of impairment charges that may be recorded by equity method investees, and such charges may be significant.
* As a result of the COVID-19 pandemic, including related governmental guidance or directives, we have required most office-based employees, including most employees based at our global headquarters in Atlanta, to work remotely. We may experience reductions in productivity and disruptions to our business routines while our remote work policy remains in place.
* Actions we have taken or may take, or decisions we have made or may make, as a consequence of the COVID-19 pandemic may result in legal claims or litigation against us.

The resumption of normal business operations after the disruptions caused by the COVID-19 pandemic may be delayed or constrained by the pandemic's lingering effects on our bottling partners, consumers, suppliers and/or third-party service providers.

Any of the negative impacts of the COVID-19 pandemic, including those described above, alone or in combination with others, may have a material adverse effect on our results of operations, financial condition and cash flows. Any of these negative impacts, alone or in combination with others, could exacerbate many of the risk factors discussed in Part I, "Item 1A. Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2019. The full extent to which the COVID-19 pandemic will negatively affect our results of operations, financial condition and cash flows will depend on future developments that are highly uncertain and cannot be predicted, including the scope and duration of the pandemic, the duration of the various shelter-in-place orders and reopening plans across the globe, and actions taken, or that may be taken in the future, by governmental authorities and other third parties in response to the pandemic.

### If we do not realize the economic benefits we anticipate from our recently announced reorganization and related reduction in workforce, or are unable to successfully manage their possible negative consequences, our business operations could be adversely affected.

Over the last three years, we worked to develop the strategies and evolve our culture to equip us to grow and become a total beverage company – one that is empowered and energized, working toward our purpose and vision. Equipping our organization is not just about strategies or the culture, it is also about the structure of our organization.

Through the implementation of our strategies and the recent pandemic, we recognized we must operate differently to emerge stronger. As a result, in August 2020, we announced a series of strategic steps to transform our organizational structure and better enable the Coca-Cola system to pursue our beverages for life ambition. These changes will result in the reallocation of some people and resources, along with both voluntary and involuntary reductions in employees. We have incurred and expect we will incur in future periods significant expenses in connection with the reorganization and related reduction in employees. If we are unable to timely capture the efficiencies, cost savings and revenue growth opportunities we anticipate from these actions, our results of operations in future periods could be negatively affected. In addition, the reorganization and related reduction in employees may become a distraction for our managers and employees remaining with the Company and may disrupt our ongoing business operations; cause deterioration in employee morale which may make it more difficult for us to retain or attract qualified managers and employees in the future; disrupt or weaken our internal control and financial reporting structures; and/or give rise to negative publicity which could affect our corporate reputation. If we are unable to successfully manage the possible negative consequences of our reorganization and reduction in employees, our business operations could be adversely affected.

56

### Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

The following table presents information with respect to purchases of common stock of the Company made during the three months ended September 25, 2020 by the Company or any "affiliated purchaser" of the Company as defined in Rule 10b-18(a)(3) under the Exchange Act:

Period

Total Number

of Shares Purchased1

Average Price Paid Per Share

Total Number

of Shares Purchased as

Part of Publicly Announced

Plan2

Maximum Number of Shares That May

Yet Be Purchased Under

Publicly Announced

Plans3

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| June 27, 2020 through July 24, 2020 | 2,342 $ | 46.36 | — | 161,029,667 |
| July 25, 2020 through August 21, 2020 | 1,351 | 47.47 | — | 161,029,667 |
| August 22, 2020 through September 25, 2020 | 43 | 51.09 | — | 161,029,667 |
| Total | 3,736 $ | 46.82 | — |  |

1 The total number of shares purchased includes: (1) shares purchased pursuant to the 2012 Plan described in footnote 2 below, if any, and (2) shares surrendered to the Company to pay the exercise price and/or to satisfy tax withholding obligations in connection with so-called stock swap exercises of employee stock options and/or the vesting of restricted stock issued to employees.

2 On October 18, 2012, the Company publicly announced that our Board of Directors had authorized a plan ("2012 Plan") for the Company to purchase up to 500 million shares of our common stock. This column discloses the number of shares purchased pursuant to the 2012 Plan during the indicated time periods (including shares purchased pursuant to the terms of preset trading plans meeting the requirements of Rule 10b5-1 under the Exchange Act).

3 On February 21, 2019, the Company publicly announced that our Board of Directors had authorized a new plan ("2019 Plan") for the Company to purchase up to 150 million shares of our common stock following the completion of the 2012 Plan. This column discloses the number of shares available for purchase under the 2012 Plan and the number of shares authorized for purchase under the 2019 Plan.

### Item 6. Exhibits

In reviewing the agreements included as exhibits to this report, please remember they are included to provide you with information regarding their terms and are not intended to provide any other factual or disclosure information about the Company or the other parties to the agreements. The agreements contain representations, warranties, covenants and conditions by or of each of the parties to the applicable agreement. These representations, warranties, covenants and conditions have been made solely for the benefit of the other parties to the applicable agreement and:

* should not in all instances be treated as categorical statements of fact, but rather as a way of allocating the risk to one of the parties if those statements prove to be inaccurate;
* may have been qualified by disclosures that were made to the other party in connection with the negotiation of the applicable agreement, which disclosures are not necessarily reflected in the agreement;
* may apply standards of materiality in a way that is different from what may be viewed as material to you or other investors; and
* were made only as of the date of the applicable agreement or such other date or dates as may be specified in the agreement and are subject to more recent developments.

Accordingly, these representations, warranties, covenants and conditions may not describe the actual state of affairs as of the date they were made or at any other time. Additional information about the Company may be found elsewhere in this report and the Company's other public filings, which are available without charge through the Securities and Exchange Commission's website at [http://www.sec.gov.](http://www.sec.gov/)

57

***Exhibit No.***

## EXHIBIT INDEX

*(With regard to applicable cross-references in the list of exhibits below, the Company's Current, Quarterly and Annual Reports are filed with the Securities and Exchange Commission (the "SEC") under File No. 001-02217; and Coca-Cola Refreshments USA, Inc.'s (formerly known as Coca-Cola Enterprises Inc.) Current, Quarterly and Annual Reports are filed with the SEC under File No. 001-09300).*

* 1. [Certificate of Incorporation of the Company, including Amendment of Certificate of Incorporation, dated July 27, 2012 — incorporated herein by reference to Exhibit 3.1 to the Company's Quarterly Report on Form 10-Q for the quarter ended September 28, 2012.](http://www.sec.gov/Archives/edgar/data/21344/000002134412000051/a20120928ex-31.htm)
  2. By-Laws of the Company, as amended and restated through April 22, 2020 — incorporated herein by reference to Exhibit 3.2 to the Company's Quarterly Report on Form 10-Q for the quarter ended March 27, 2020.
  3. Intentionally omitted.
  4. As permitted by the rules of the SEC, the Company has not filed certain instruments defining the rights of holders of long-term debt of the Company or consolidated subsidiaries under which the total amount of securities authorized does not exceed 10 percent of the total assets of the Company and its consolidated subsidiaries. The Company agrees to furnish to the SEC, upon request, a copy of any omitted instrument.
  5. [Amended and Restated Indenture, dated as of April 26, 1988, between the Company and Deutsche Bank Trust Company Americas, as successor to Bankers Trust Company, as trustee — incorporated herein by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed on May 25, 2017.](http://www.sec.gov/Archives/edgar/data/21344/000110465917035229/a17-12823_3ex4d1.htm)
  6. [First Supplemental Indenture, dated as of February 24, 1992, to Amended and Restated Indenture, dated as of April 26, 1988, between the Company and Deutsche Bank Trust Company Americas, as successor to Bankers Trust Company, as trustee — incorporated herein by reference to Exhibit 4.2 to the Company's Current Report on Form 8-K filed on May 25, 2017.](http://www.sec.gov/Archives/edgar/data/21344/000110465917035229/a17-12823_3ex4d2.htm)
  7. [Second Supplemental Indenture, dated as of November 1, 2007, to Amended and Restated Indenture, dated as of April 26, 1988, as amended, between the Company and Deutsche Bank Trust Company Americas, as successor to Bankers Trust Company, as trustee — incorporated herein by reference to Exhibit 4.3 of the Company's Current Report on Form 8-K filed on May 25, 2017.](http://www.sec.gov/Archives/edgar/data/21344/000110465917035229/a17-12823_3ex4d3.htm)
  8. [Form of Note for 3.150% Notes due November 15, 2020 — incorporated herein by reference to Exhibit 4.7 to the Company's Current Report on Form 8-K file](http://www.sec.gov/Archives/edgar/data/21344/000110465910059174/a10-21233_1ex4d7.htm)d [on November 18, 2010.](http://www.sec.gov/Archives/edgar/data/21344/000110465910059174/a10-21233_1ex4d7.htm)
  9. [Form of Note for 3.30% Notes due September 1, 2021 — incorporated herein by reference to Exhibit 4.14 to the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2011.](http://www.sec.gov/Archives/edgar/data/21344/000134100411001698/form8k.htm)
  10. [Form of Note for 2.500% Notes due 2023 — incorporated herein by reference to Exhibit 4.6 to the Company's Current Report on Form 8-K filed on March 5, 2013.](http://www.sec.gov/Archives/edgar/data/21344/000110465913017549/a13-6735_1ex4d6.htm)
  11. [Form of Note for 2.450% Notes due 2020 — incorporated herein by reference to Exhibit 4.7 to the Company's Current Report on Form 8-K filed on November 1, 2013.](http://www.sec.gov/Archives/edgar/data/21344/000110465913080068/a13-23257_1ex4d7.htm)
  12. [Form of Note for 3.200% Notes due 2023 — incorporated herein by reference to Exhibit 4.8 to the Company's Current Report on Form 8-K filed on November 1, 2013.](http://www.sec.gov/Archives/edgar/data/21344/000110465913080068/a13-23257_1ex4d8.htm)
  13. [Form of Note for 1.875% Notes due 2026 — incorporated herein by reference to Exhibit 4.4 to the Company's Registration Statement on Form 8-A filed on September 19, 2014.](http://www.sec.gov/Archives/edgar/data/21344/000110465914067294/a14-20868_5ex4d4.htm)
  14. [Form of Note for 1.125% Notes due 2022 — incorporated herein by reference to Exhibit 4.5 to the Company's Registration Statement on Form 8-A filed on September 19, 2014.](http://www.sec.gov/Archives/edgar/data/21344/000110465914067294/a14-20868_5ex4d5.htm)
  15. [Form of Note for 0.75% Notes due 2023 — incorporated herein by reference to Exhibit 4.6 to the Company's Registration Statement on Form 8-A filed on March 6, 2015.](http://www.sec.gov/Archives/edgar/data/21344/000110465915017732/a15-5356_5ex4d6.htm)
  16. [Form of Note for 1.125% Notes due 2027 — incorporated herein by reference to Exhibit 4.7 to the Company's Registration Statement on Form 8-A filed on March 6, 2015.](http://www.sec.gov/Archives/edgar/data/21344/000110465915017732/a15-5356_5ex4d7.htm)
  17. [Form of Note for 1.625% Notes due 2035 — incorporated herein by reference to Exhibit 4.8 to the Company's Registration Statement on Form 8-A filed on March 6, 2015.](http://www.sec.gov/Archives/edgar/data/21344/000110465915017732/a15-5356_5ex4d8.htm)
  18. [Form of Note for 1.875% Notes due 2020 — incorporated herein by reference to Exhibit 4.5 to the Company's Current Report on Form 8-K filed on October 27, 2015.](http://www.sec.gov/Archives/edgar/data/21344/000110465915073126/a15-13610_6ex4d5.htm)
  19. [Form of Note for 2.875% Notes due 2025 — incorporated herein by reference to Exhibit 4.6 to the Company's Current Report on Form 8-K filed on October 27, 2015.](http://www.sec.gov/Archives/edgar/data/21344/000110465915073126/a15-13610_6ex4d6.htm)
  20. [Form of Note for 2.55% Notes due 2026 — incorporated herein by reference to Exhibit 4.6 to the Company's Current Report on Form 8-K filed on May 31, 2016.](http://www.sec.gov/Archives/edgar/data/21344/000110465916124532/a16-11929_6ex4d6.htm)
  21. [Form of Note for 1.550% Notes due 2021 — incorporated herein by reference to Exhibit 4.4 to the Company's Current Report on Form 8-K filed on September 1, 2016.](http://www.sec.gov/Archives/edgar/data/21344/000110465916142664/a16-17466_5ex4d4.htm)
  22. [Form of Note for 2.250% Notes due 2026 — incorporated herein by reference to Exhibit 4.5 to the Company's Current Report on Form 8-K filed on September 1, 2016.](http://www.sec.gov/Archives/edgar/data/21344/000110465916124532/a16-11929_6ex4d6.htm)

58

* 1. [Form of Note for 1.100% Notes due 2036 — incorporated herein by reference to Exhibit 4.4 to the Company’s Registration Statement on Form 8-A filed on September 2, 2016.](http://www.sec.gov/Archives/edgar/data/21344/000110465916142970/a16-17466_6ex4d4.htm)
  2. [Form of Note for 0.000% Notes due 2021 — incorporated herein by reference to Exhibit 4.5 to the Company’s Registration Statement on Form 8-A filed on March 9, 2017.](http://www.sec.gov/Archives/edgar/data/21344/000110465917015536/a17-7082_7ex4d5.htm)
  3. [Form of Note for 0.500% Notes due 2024 — incorporated herein by reference to Exhibit 4.6 to the Company’s Registration Statement on Form 8-A filed on March 9, 2017.](http://www.sec.gov/Archives/edgar/data/21344/000110465917015536/a17-7082_7ex4d6.htm)
  4. [Form of Note for 2.200% Notes due 2022 — incorporated herein by reference to Exhibit 4.4 to the Company’s Current Report on Form 8-K filed on May 25, 2017.](http://www.sec.gov/Archives/edgar/data/21344/000110465917035229/a17-12823_3ex4d4.htm)
  5. [Form of Note for 2.900% Notes due 2027 — incorporated herein by reference to Exhibit 4.5 to the Company’s Current Report on Form 8-K filed on May 25, 2017.](http://www.sec.gov/Archives/edgar/data/21344/000110465917035229/a17-12823_3ex4d5.htm)
  6. [Form of Note for Floating Rate Notes due 2021 — incorporated herein by reference to Exhibit 4.4 to the Company's Registration Statement on Form 8-A filed on March 8, 2019.](http://www.sec.gov/Archives/edgar/data/21344/000110465919013649/a19-5248_7ex4d4.htm#Exhibit4_4_015548)
  7. [Form of Note for 0.125% Notes due 2022 — incorporated herein by reference to Exhibit 4.5 to the Company's Registration Statement on Form 8-A filed on March 8, 2019.](http://www.sec.gov/Archives/edgar/data/21344/000110465919013649/a19-5248_7ex4d5.htm#Exhibit4_5_020711)
  8. [Form of Note for 0.750% Notes due 2026 — incorporated herein by reference to Exhibit 4.6 to the Company's Registration Statement on Form 8-A filed on March 8, 2019.](http://www.sec.gov/Archives/edgar/data/21344/000110465919013649/a19-5248_7ex4d6.htm#Exhibit4_6_031645)
  9. [Form of Note for 1.250% Notes due 2031 — incorporated herein by reference to Exhibit 4.7 to the Company's Registration Statement on Form 8-A filed on March 8, 2019.](http://www.sec.gov/Archives/edgar/data/21344/000110465919013649/a19-5248_7ex4d7.htm#Exhibit4_7_033619)
  10. [Form of Note for 1.750% Notes due 2024 — incorporated herein by reference to Exhibit 4.4 to the Company's Current Report on Form 8-K filed on September 9, 2019.](http://www.sec.gov/Archives/edgar/data/21344/000110465917041338/a17-15589_18k.htm)
  11. [Form of Note for 2.125% Notes due 2029 — incorporated herein by reference to Exhibit 4.5 to the Company's Current Report on Form 8-K filed on September 9, 2019.](http://www.sec.gov/Archives/edgar/data/21344/000110465917041338/a17-15589_18k.htm)
  12. [Form of Note for 2.950% Notes due 2025 — incorporated herein by reference to Exhibit 4.4 to the Company's Current Report on Form 8-K filed on March 25](http://www.sec.gov/Archives/edgar/data/21344/000110465920038321/tm2013248d2_ex4-4.htm), [2020.](http://www.sec.gov/Archives/edgar/data/21344/000110465920038321/tm2013248d2_ex4-4.htm)
  13. [Form of Note for 3.375% Notes due 2027 — incorporated herein by reference to Exhibit 4.5 to the Company's Current Report on Form 8-K filed on March 25](http://www.sec.gov/Archives/edgar/data/21344/000110465920038321/tm2013248d2_ex4-5.htm), [2020.](http://www.sec.gov/Archives/edgar/data/21344/000110465920038321/tm2013248d2_ex4-5.htm)
  14. [Form of Note for 3.450% Notes due 2030 — incorporated herein by reference to Exhibit 4.6 to the Company's Current Report on Form 8-K filed on March 25](http://www.sec.gov/Archives/edgar/data/21344/000110465920038321/tm2013248d2_ex4-6.htm), [2020.](http://www.sec.gov/Archives/edgar/data/21344/000110465920038321/tm2013248d2_ex4-6.htm)
  15. [Form of Note for 4.125% Notes due 2040 — incorporated herein by reference to Exhibit 4.7 to the Company's Current Report on Form 8-K filed on March 25](http://www.sec.gov/Archives/edgar/data/21344/000110465920038321/tm2013248d2_ex4-7.htm), [2020.](http://www.sec.gov/Archives/edgar/data/21344/000110465920038321/tm2013248d2_ex4-7.htm)
  16. [Form of Note for 4.200% Notes due 2050 — incorporated herein by reference to Exhibit 4.8 to the Company's Current Report on Form 8-K filed on March 25](http://www.sec.gov/Archives/edgar/data/21344/000110465920038321/tm2013248d2_ex4-8.htm), [2020.](http://www.sec.gov/Archives/edgar/data/21344/000110465920038321/tm2013248d2_ex4-8.htm)
  17. [Form of Note for 1.450% Notes due 2027 — incorporated herein by reference to Exhibit 4.4 to the Company's Current Report on Form 8-K filed on May 4, 2020.](http://www.sec.gov/Archives/edgar/data/21344/000110465920055758/tm2017862d4_ex4-4.htm)
  18. [Form of Note for 1.650% Notes due 2030 — incorporated herein by reference to Exhibit 4.5 to the Company's Current Report on Form 8-K filed on May 4, 2020.](http://www.sec.gov/Archives/edgar/data/21344/000110465920055758/tm2017862d4_ex4-5.htm)
  19. [Form of Note for 2.500% Notes due 2040 — incorporated herein by reference to Exhibit 4.6 to the Company's Current Report on Form 8-K filed on May 4, 2020.](http://www.sec.gov/Archives/edgar/data/21344/000110465920055758/tm2017862d4_ex4-6.htm)
  20. [Form of Note for 2.600% Notes due 2050 — incorporated herein by reference to Exhibit 4.7 to the Company's Current Report on Form 8-K filed on May 4, 2020.](http://www.sec.gov/Archives/edgar/data/21344/000110465920055758/tm2017862d4_ex4-7.htm)
  21. [Form of Note for 2.750% Notes due 2060 — incorporated herein by reference to Exhibit 4.8 to the Company's Current Report on Form 8-K filed on May 4, 2020.](http://www.sec.gov/Archives/edgar/data/21344/000110465920055758/tm2017862d4_ex4-8.htm)
  22. [Form of Note for 0.125% Notes due 2029 — incorporated herein by reference to Exhibit 4.4 to the Company's Current Report on Form 8-K filed on September 18, 2020.](http://www.sec.gov/Archives/edgar/data/21344/000155278120000488/i20511_ex4-4.htm)
  23. [Form of Note for 0.375% Notes due 2033 — incorporated herein by reference to Exhibit 4.5 to the Company's Current Report on Form 8-K filed on September 18, 2020.](http://www.sec.gov/Archives/edgar/data/21344/000155278120000488/i20511_ex4-5.htm)
  24. [Form of Note for 0.800% Notes due 2040 — incorporated herein by reference to Exhibit 4.6 to the Company's Current Report on Form 8-K filed on September 18, 2020.](http://www.sec.gov/Archives/edgar/data/21344/000155278120000488/i20511_ex4-6.htm)
  25. [Form of Note for 1.000% Notes due 2028 — incorporated herein by reference to Exhibit 4.7 to the Company's Current Report on Form 8-K filed on September 18, 2020.](http://www.sec.gov/Archives/edgar/data/21344/000155278120000488/i20511_ex4-7.htm)
  26. [Form of Note for 1.375% Notes due 2031 — incorporated herein by reference to Exhibit 4.8 to the Company's Current Report on Form 8-K filed on September 18, 2020.](http://www.sec.gov/Archives/edgar/data/21344/000155278120000488/i20511_ex4-8.htm)
  27. [Form of Note for 2.500% Notes due 2051 — incorporated herein by reference to Exhibit 4.9 to the Company's Current Report on Form 8-K filed on September 18, 2020.](http://www.sec.gov/Archives/edgar/data/21344/000155278120000488/i20511_ex4-9.htm)
  28. Indenture, dated as of July 30, 1991, between Coca-Cola Refreshments USA, Inc. and Deutsche Bank Trust Company Americas, as trustee — incorporated herein by reference to Exhibit 4.1 to Coca-Cola Refreshments USA, Inc.'s Current Report on Form 8-K dated July 30, 1991.

59

* 1. First Supplemental Indenture, dated as of January 29, 1992, to the Indenture, dated as of July 30, 1991, between Coca-Cola Refreshments USA, Inc. and Deutsche Bank Trust Company Americas, as trustee — incorporated herein by reference to Exhibit 4.01 to Coca-Cola Refreshments USA, Inc.'s Current Report on Form 8-K dated January 29, 1992.
  2. [Second Supplemental Indenture, dated as of June 22, 2017, to the Indenture, dated as of July 30, 1991, as amended, among Coca-Cola Refreshments USA, Inc.](http://www.sec.gov/Archives/edgar/data/21344/000110465917041338/a17-15589_18k.htm), [the Company and Deutsche Bank Trust Company Americas, as trustee — incorporated herein by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed on June 23, 2017.](http://www.sec.gov/Archives/edgar/data/21344/000110465917041338/a17-15589_18k.htm)
  3. [Third Supplemental Indenture, dated as of July 5, 2017, to the Indenture, dated as of July 30, 1991, as amended, among Coca-Cola Refreshments USA, Inc., the Company and Deutsche Bank Trust Company Americas, as trustee — incorporated herein by reference to Exhibit 4.3 to the Company's Current Report on Form 8-K filed on July 6, 2017.](http://www.sec.gov/Archives/edgar/data/21344/000110465917043873/a17-16896_1ex4d3.htm)
  4. Letter, dated July 15, 2020, from the Company to Bradley Gayton.
  5. Letter, dated September 14, 2020, from the Company to Henrique Braun.
  6. Rule 13a-14(a)/15d-14(a) Certification, executed by James Quincey, Chairman of the Board of Directors and Chief Executive Officer of The Coca-Cola Company.
  7. Rule 13a-14(a)/15d-14(a) Certification, executed by John Murphy, Executive Vice President and Chief Financial Officer of The Coca-Cola Company.

32.1 Certifications required by Rule 13a-14(b) or Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. Section 1350), executed by James Quincey, Chairman of the Board of Directors and Chief Executive Officer of The Coca-Cola Company, and by John Murphy, Executive Vice President and Chief Financial Officer of The Coca-Cola Company.

101 The following financial information from The Coca-Cola Company's Quarterly Report on Form 10-Q for the quarter ended September 25, 2020, formatted in iXBRL (Inline Extensible Business Reporting Language): (i) Condensed Consolidated Statements of Income for the three and nine months ended September 25, 2020 and September 27, 2019, (ii) Condensed Consolidated Statements of Comprehensive Income for the three and nine months ended September 25, 2020 and September 27, 2019, (iii) Condensed Consolidated Balance Sheets as of September 25, 2020 and December 31, 2019, (iv) Condensed Consolidated Statements of Cash Flows for the nine months ended September 25, 2020 and September 27, 2019, and (v) Notes to Condensed Consolidated Financial Statements.

104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the iXBRL document).

60

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

## THE COCA-COLA COMPANY

**(Registrant)**

/s/ KATHY LOVELESS

Date: October 22, 2020 Kathy Loveless

Vice President and Controller (On behalf of the Registrant)

/s/ MARK RANDAZZA

Date: October 22, 2020 Mark Randazza

Vice President, Assistant Controller and Chief Accounting Officer (Principal Accounting Officer)

61

# Exhibit 3.2

**BY-LAWS OF THE COCA-COLA COMPANY**

**AS AMENDED AND RESTATED THROUGH APRIL 22, 2020 ARTICLE I**

**SHAREHOLDERS:**

Section 1. Place, Date and Time of Holding Annual Meetings. Annual meetings of shareholders shall be held at such place, date and time as shall be designated from time to time by the Board of Directors. In the absence of a resolution adopted by the Board of Directors establishing such place, date and time, the annual meeting shall be held at 1209 Orange Street, Wilmington, Delaware, on the third Wednesday in April of each year at 9:00 A.M. (local time).

Section 2. Voting. Each outstanding share of common stock of the Company is entitled to one vote on each matter submitted to a vote. Except as provided below, all actions shall be authorized by a majority of the votes cast unless a greater vote is required by the laws of Delaware. A shareholder may vote in person or by proxy authorized by an instrument in writing or by a transmission permitted by law filed in accordance with the procedures established for the meeting. Any copy, facsimile telecommunication or other reliable reproduction of the writing or transmission created pursuant to this section may be substituted or used in lieu of the original writing or the transmission that could be used, provided that such copy, facsimile telecommunication or other reproduction shall be a complete reproduction of the entire original writing or transmission. A nominee for director election shall be elected by the affirmative vote of a majority of the votes cast with respect to such nominee at any meeting for the election of directors at which a quorum is present, provided that if the number of nominees exceeds the number of directors to be elected, the directors shall be elected by a plurality of the votes of the shares represented in person or by proxy at any such meeting and entitled to vote on the election of directors. In an election of directors, a majority of the votes cast means that the number of votes cast “for” a nominee must exceed 50% of the votes cast with respect to such nominee (excluding abstentions). If a director is not elected, the director shall promptly tender his or her resignation to the Board of Directors. The Committee on Directors and Corporate Governance will make a recommendation to the Board of Directors on whether to accept or reject the resignation, or whether other action should be taken. The Board of Directors will act on the resignation taking into account the recommendation of the Committee on Directors and Corporate Governance and publicly disclose its decision and the rationale behind it within 100 days from the date of the certification of the election results. The director who tenders his or her resignation will not participate in the decisions of the Committee on Directors and Corporate

Governance or the Board of Directors that concern such resignation. If a director’s resignation is accepted by the Board of Directors pursuant to this By-Law, or if a nominee for director is not elected and the nominee is not an incumbent director, then the Board of Directors, in its sole discretion, may fill any resulting vacancy pursuant to the provisions of Article VI, Section 2 or may decrease the size of the Board of Directors pursuant to the provisions of Article II, Section 1.

Section 3. Quorum. The holders of a majority of the issued and outstanding shares of capital stock of the Company, present in person or represented by proxy, shall constitute a quorum at all meetings of shareholders. Where a separate vote by a class or classes or series is required, a majority of the shares of such class or classes or series present in person or represented by proxy shall constitute a quorum entitled to take action with respect to that vote on that matter.

Section 4. Adjournment of Meetings. In the absence of a quorum or for any other reason, the chairman of the meeting may adjourn the meeting from time to time. If the adjournment is not for more than thirty days, the adjourned meeting may be held without notice other than an announcement at the meeting. If the adjournment is for more than thirty days, or if a new record date is fixed for the adjourned meeting, a notice of the adjourned meeting shall be given to each shareholder of record entitled to vote at such meeting. At any such adjourned meeting at which a quorum is present, any business may be transacted which might have been transacted at the meeting originally called.

Section 5. Special Meetings.

1. General. Special meetings of the shareholders for any purpose or purposes may be called by, and only by, (i) the Board of Directors, (ii) the Chairman of the Board of Directors, (iii) the Chief Executive Officer or (iv) solely to the extent required by Section 5(b), the Secretary of the Company. Each special meeting shall be held at such date, time and place either within or without the State of Delaware as may be stated in the notice of the meeting.
2. Shareholder Requested Special Meetings.
   1. Special meetings of the shareholders (each a “Shareholder Requested Special Meeting”) shall be called by the Secretary upon the written request of a shareholder (or a group of shareholders formed for the purpose of making such request) who or which has Net Long Beneficial Ownership (as defined below) of 25% or more of the outstanding common stock of the Company (the “Requisite Percent”) as of the date of submission of the request. Compliance by the requesting shareholder or group of shareholders with the requirements of this section and related provisions of these By-Laws shall be determined in good faith by the Board of Directors, which determination shall be conclusive and binding on the Company and the shareholders.

“Net Long Beneficial Ownership” (and its correlative terms), when used to describe the nature of a shareholder’s ownership of common stock of the Company, shall mean those shares of common stock of the Company as to which the shareholder in question possesses (x) the sole power to vote or direct the voting, (y) the sole economic incidents of ownership (including the sole right to profits and the sole risk of loss), and (z) the sole power to dispose of or direct the disposition. The number of shares calculated in accordance with clauses (x), (y) and (z) shall not include any shares (1) sold by such shareholder in any transaction that has not been settled or closed, (2) borrowed by such shareholder for any purposes or purchased by such shareholder pursuant to an agreement to resell or (3) subject to any option, warrant, derivative or other agreement or understanding, whether any such arrangement is to be settled with shares of common stock of the Company or with cash based on the notional amount of shares subject

2

thereto, in any such case which has, or is intended to have, the purpose or effect of (A) reducing in any manner, to any extent or at any time in the future, such shareholder’s rights to vote or direct the voting and full rights to dispose or direct the disposition of any of such shares or (B) offsetting to any degree gain or loss arising from the sole economic ownership of such shares by such shareholder.

* 1. A request for a Shareholder Requested Special Meeting must be signed by the Net Long Beneficial Owners of the Requisite Percent of the Company’s common stock (or their duly authorized agents) and be delivered to the Secretary at the principal executive offices of the Company by registered mail, return receipt requested.

Such request shall (A) set forth a statement of the specific purpose or purposes of the meeting and the matters proposed to be acted on at such special meeting, (B) bear the date of signature of each shareholder (or duly authorized agent) signing the request, (C) set forth (w) the name and address, as they appear in the Company’s books, of each shareholder signing such request (or on whose behalf the request is signed),

1. the number of shares of common stock of the Company as to which such shareholder has Net Long Beneficial Ownership, (y) include evidence of the fact and duration of such shareholder’s beneficial ownership of such stock consistent with that which is required under Regulation 14A under the Securities Exchange Act of 1934, as amended (the "1934 Act") and (z) a certification from each such shareholder that the shareholders signing the request in the aggregate satisfy the Net Long Beneficial Ownership requirement of these By-Laws, (D) set forth all information relating to each such shareholder that must be disclosed in solicitations of proxies for election of directors in an election contest (even if an election contest is not involved), or is otherwise required, in each case, pursuant to Regulation 14A under the 1934 Act, (E) describe any material interest of each such shareholder in the specific purpose or purposes of the meeting, and (F) include an acknowledgment by each shareholder and any duly authorized agent that any disposition of shares of common stock of the Company as to which such shareholder has Net Long Beneficial Ownership as of the date of delivery of the special meeting request and prior to the record date for the proposed meeting requested by such shareholder shall constitute a revocation of such request with respect to such shares. In addition, the shareholder and any duly authorized agent shall promptly provide any other information reasonably requested by the Company to allow it to satisfy its obligations under applicable law.

Any requesting shareholder may revoke a request for a special meeting at any time by written revocation delivered to the Secretary at the principal executive offices of the Company. If, following such revocation at any time before the date of the Shareholder Requested Special Meeting, the remaining requests are from shareholders holding in the aggregate less than the Requisite Percent, the Board of Directors, in its discretion, may cancel the Shareholder Requested Special Meeting.

* 1. Notwithstanding the foregoing, the Secretary shall not be required to call a special meeting of shareholders if (A) the request for such special meeting does not comply with this Section 5(b), (B) the Board of Directors, the Chairman of the Board of Directors or the Chief Executive Officer has called or calls an annual or special meeting of shareholders to be held not later than ninety (90) days after the date on which a valid

3

request has been delivered to the Secretary (the “Delivery Date”), (C) the request is received by the Secretary during the period commencing ninety (90) days prior to the first anniversary of the date of the immediately preceding annual meeting and ending on the date of the next annual meeting, (D) the request contains an identical or substantially similar item (a “Similar Item”) to an item that was presented at any meeting of shareholders held within one hundred and twenty (120) days prior to the Delivery Date (and, for purposes of this clause (D) the election of directors shall be deemed a “Similar Item” with respect to all items of business involving the election or removal of directors), (E) the request relates to an item of business that is not a proper subject for action by the shareholders of the Company under applicable law or (F) the request was made in a manner that involved a violation of Regulation 14A under the 1934 Act or other applicable law.

* 1. Any Shareholder Requested Special Meeting shall be held at such date, time and place within or without the state of Delaware as may be fixed by the Board of Directors; provided, however, that the date of any Shareholder Requested Special Meeting shall be not more than sixty (60) days after the record date for such meeting (the “Meeting Record Date”), which shall be fixed in accordance with Article I, Section 9 of these By-Laws. In fixing a date and time for any Shareholder Requested Special Meeting, the Board of Directors may consider such factors as it deems relevant within the good faith exercise of business judgment, including, without limitation, the nature of the matters to be considered, the facts and circumstances surrounding any request for the special meeting and any plan of the Board of Directors to call an annual meeting or a special meeting.
  2. Business transacted at any Shareholder Requested Special Meeting shall be limited to the purpose(s) stated in the request; provided, however, that nothing herein shall prohibit the Company from submitting matters to a vote of the shareholders at any Shareholder Requested Special Meeting.

Section 6. Notice of Shareholders Meeting. Notice, stating the place, date, hour and purpose of the annual or special meeting shall be given by the Secretary not less than ten nor more than sixty days before the date of the meeting to each shareholder entitled to vote at such meeting.

Section 7. Organization. The Chairman of the Board of Directors shall preside at all meetings of shareholders. In the absence of, or in case of a vacancy in the office of, the Chairman of the Board of Directors, the Chief Executive Officer, the President, or in the President’s absence or in the event that the Board of Directors has not selected a President, any Senior Executive Vice President, Executive Vice President, Senior Vice President or Vice President in order of seniority as specified in this sentence, and, within each classification of office in order of seniority in time in that office, shall preside. The Secretary of the Company shall act as secretary at all meetings of the shareholders and in the Secretary’s absence, the chairman of the meeting may appoint a secretary.

The Board of Directors of the Company shall be entitled to make such rules or regulations for the conduct of meetings of shareholders as it shall deem necessary, appropriate or convenient. Subject to such rules and regulations of the Board of Directors,

4

if any, the chairman of the meeting shall have the right and the authority to prescribe such rules, regulations and procedures and to do all such acts as, in the judgment of such chairman, are necessary, appropriate or convenient for the proper conduct of the meeting, including, without limitation, establishing (i) an agenda or order of business for the meeting, (ii) rules and procedures for maintaining order at the meeting and the safety of those present, (iii) limitations on participation in such meetings to shareholders of record of the Company and their duly authorized and constituted proxies, and such other persons as the chairman of the meeting shall permit, (iv) restrictions on entries to the meeting after the time affixed for the commencement thereof, (v) limitations on the time allotted to the questions or comments by participants and (vi) regulation of the opening and closing of the polls for balloting and matters which are to be voted on by ballot. Unless and to the extent determined by the Board of Directors or the chairman of the meeting, meetings of shareholders shall not be required to be held in accordance with rules of parliamentary procedure.

Section 8. Inspectors of Election. All votes by ballot at any meeting of shareholders shall be conducted by such number of inspectors of election as are appointed for that purpose by the Company. The Company may designate one or more alternate inspectors to replace any inspector who fails to act. If no inspector or alternate is able to act at a meeting of shareholders, the person presiding at the meeting may, and to the extent required by law, shall, appoint one or more inspectors to act at the meeting. Each inspector, before entering upon the discharge of his or her duties, shall take and sign an oath faithfully to execute the duties of inspector with strict impartiality and according to the best of his or her ability. Every vote taken by ballots shall be counted by a duly appointed inspector or inspectors.

Section 9. Record Date. The Board of Directors, in order to determine the shareholders entitled to notice of or to vote at any meeting of shareholders or any adjournment thereof, or entitled to take action by written consent, or entitled to receive payment of any dividend or other distribution or allotment of any rights or entitled to exercise any rights in respect of any change, conversion or exchange of stock or for the purpose of any other lawful action, shall fix in advance a record date which shall not be more than sixty nor less than ten days before the date of such meeting, nor more than sixty days prior to any other action and in such case only such shareholders as shall be shareholders of record on the date so fixed, shall be entitled to such notice of or to vote at such meeting or any adjournment thereof, or entitled to take action by written consent, or be entitled to receive payment of any such dividend or other distribution or allotment of any rights or be entitled to exercise any such rights in respect of stock or to take any such other lawful action, as the case may be, notwithstanding any transfer of any stock on the books of the Company after any such record date fixed as aforesaid.

Section 10. Nature of Business; Notice of Shareholder Business. At any annual or special meeting of shareholders, only such business shall be conducted as shall have been properly brought before the meeting. To be properly brought before an annual or special meeting, business must be: (A) specified in the notice of meeting (or any supplement thereto) given by or at the direction of the Board of Directors, (B) otherwise properly

5

brought before the meeting by or at the direction of the Board of Directors, or (C) otherwise properly brought before the meeting by a shareholder.

In order for business to be properly brought before an annual meeting by a shareholder, the shareholder must have given timely notice thereof in writing to the Secretary of the Company, and such business must be a proper matter for shareholder action under the General Corporation Law of the State of Delaware. With respect to nominations of persons for election to the Board of Directors of the Company, the shareholder (or group of shareholders) must comply with the notice and other requirements set forth in Article I, Section 11 and Section 12 of these By- Laws, as applicable. In order for business to be properly brought before a Shareholder Requested Special Meeting by a shareholder, such shareholder must comply with the notice and other requirements set forth in Article I, Section 5 of these By-Laws.

To be timely, a shareholder’s notice with respect to an annual meeting, other than with respect to nominations of persons for election to the Board of Directors of the Company pursuant to Article I, Section 12 of these By-Laws, must be delivered to or mailed and received at the principal executive offices of the Company not later than the close of business on the one hundred twentieth (120th) day prior to the first anniversary of the preceding year’s annual meeting; provided, however, that in the event no annual meeting was held in the previous year or the date of the annual meeting has been changed by more than thirty (30) days, notice by the shareholder to be timely must be so received not later than the close of business on the later of one hundred and twenty (120) days in advance of such annual meeting or ten (10) days following the date on which public announcement of the date of the meeting is first made. A shareholder’s notice to the Secretary shall set forth as to each matter the shareholder proposes to bring before the annual meeting: (i) a brief description of the business desired to be brought before the annual meeting (including the text of any resolutions proposed for consideration and in the event that such business includes a proposal to amend the Company’s By-Laws, the language of the proposed amendment) and the reasons for conducting such business at the annual meeting, (ii) the name and address, as they appear on the Company’s books, of the shareholder proposing such business, (iii) the class and number of shares of the Company which are beneficially owned and owned of record by the shareholder, (iv) any material interest of the shareholder or the shareholder’s affiliates or associates in such business, (v) a description of any agreement, arrangement or understanding (including any derivative or short positions, profit interests, options, warrants, convertible securities, stock appreciation or similar rights, hedging transactions, and borrowed or loaned shares) that has been entered into as of the date of the shareholder’s notice by, or on behalf of, such shareholder and, whether or not such instrument or right shall be subject to settlement in underlying shares of capital stock of the Company, the effect or intent of which is to mitigate loss to, manage risk or benefit of share price changes for, or increase or decrease the voting power of, such shareholder, with respect to securities of the Company and (vi) any other information that is required to be provided by the shareholder pursuant to Regulation 14A under the1934 Act, in his capacity as a proponent to a shareholder proposal and any other information reasonably requested by the Company to allow it to satisfy its obligations under applicable law. Notwithstanding

6

the foregoing, in order to include information with respect to a shareholder proposal in the proxy statement and form of proxy for a shareholders’ meeting, shareholders must provide notice as required by the regulations promulgated under the 1934 Act. Notwithstanding anything in these By-Laws to the contrary, no business (other than the nominations for the election of directors) shall be conducted at any annual meeting except in accordance with the procedures set forth in this Section 10. The chairman of the meeting shall, if the facts warrant, determine and declare at the meeting that business was not properly brought before the meeting and in accordance with the provisions of this Section 10, and, if he should so determine, he shall so declare at the meeting that any such business not properly brought before the meeting shall not be transacted.

Section 11. Election of Directors. Only persons who are nominated in accordance with the procedures set forth in this Section 11 or the procedures set forth in Section 12 of this Article I shall be eligible for election as directors. Nominations of persons for election to the Board of Directors of the Company may be made at an annual meeting of shareholders or at a special meeting of shareholders called for the purpose of electing directors. Nominations may be made (i) by or at the direction of the Board of Directors, (ii) at an annual meeting by any shareholder of the Company entitled to vote in the election of directors at the meeting who complies with the notice procedures set forth in this Section 11,

(iii) at an annual meeting by a shareholder or group of shareholders of the Company who complies with the notice and other requirements set forth in Article I, Section 12 of these By-Laws or (iv) at a Shareholder Requested Special Meeting by a shareholder or group of shareholders of the Company who complies with the notice and other requirements set forth in Article I, Section 5 of these By-Laws.

Nominations by a shareholder or a group of shareholders at an annual meeting pursuant to this Section 11, other than with respect to nominations of persons for election to the Board of Directors of the Company pursuant to Article I, Section 12 of these By-Laws, shall be made pursuant to timely notice in writing to the Secretary of the Company in accordance with the provisions of Section 10. Such shareholder’s notice shall set forth (i) as to each person, if any, whom the shareholder proposes to nominate for election or re-election as a director: (A) the name, age, business address and residence address of such person, (B) the principal occupation or employment of such person, (C) the class and number of shares of the Company which are beneficially owned by such person, (D) a description of all arrangements or understandings between the shareholder and each nominee or any other person or persons (naming such person or persons) pursuant to which the nominations are to be made by the shareholder, and (E) any other information relating to such person that is required to be disclosed in solicitations of proxies for elections of directors, or is otherwise required, in each case pursuant to Regulation 14A under the 1934 Act (including, without limitation, such person’s written consent to being named in the proxy statement, if any, as a nominee and to serving as a director if elected); and (ii) as to such shareholder giving notice, the information required to be provided pursuant to Section 10. At the request of the Board of Directors, any person nominated by a shareholder for election as a director shall furnish to the Secretary of the Company that information required to be set forth in the shareholder’s notice of nomination which pertains to the nominee. The chairman of the meeting shall, if the facts warrant,

7

determine and declare at the meeting that nomination was not made in accordance with the procedures prescribed by these By-Laws, and if he should so determine, he shall so declare at the meeting, and the defective nomination shall be disregarded.

Section 12. Proxy Access for Director Nominations.

1. The Company shall include in its proxy statement for an annual meeting of shareholders the name, together with the Required Information (as defined below), of any person nominated for election (a “Shareholder Nominee”) to the Board of Directors by a shareholder that satisfies, or by a group of no more than twenty (20) shareholders that satisfy, the requirements of this Section 12 (an “Eligible Shareholder”), and that expressly elects at the time of providing the notice required by this Section 12 (the “Nomination Notice”) to have its nominee included in the Company’s proxy materials pursuant to this Section 12.
2. To be timely, a shareholder’s Nomination Notice must be delivered to or mailed and received by the Secretary at the principal executive offices of the Company not less than one hundred and twenty (120) days nor more than one hundred and fifty (150) days prior to the anniversary of the date the Company commenced mailing of its proxy materials in connection with the most recent annual meeting of shareholders; provided, however, that in the event that the annual meeting is called for a date that is more than thirty (30) days before or seventy (70) days after the anniversary of the preceding year’s annual meeting, in order to be timely the Nomination Notice must be so received not later than the close of business on the later of one hundred and twenty (120) days in advance of such annual meeting or ten (10) days following the day on which public disclosure of the date of the annual meeting was made. In no event shall the public announcement of an adjournment or postponement of an annual meeting commence a new time period (or extend any time period) for the giving of a Nomination Notice as described above.
3. For purposes of this Section 12, the “Required Information” that the Company will include in its proxy statement is (i) the information concerning the Shareholder Nominee and the Eligible Shareholder that is required to be disclosed in the Company’s proxy statement by the regulations promulgated under the 1934 Act; and (ii) if the Eligible Shareholder so elects, a Statement (as defined below). To be timely, the Required Information must be delivered to or mailed and received by the Secretary within the time period specified in this Section 12 for providing the Nomination Notice,
4. The number of Shareholder Nominees (including Shareholder Nominees that were submitted by an Eligible Shareholder for inclusion in the Company’s proxy materials pursuant to this Section 12 but either are subsequently withdrawn or that the Board of Directors decides to nominate as Board of Director nominees) appearing in the Company’s proxy materials with respect to an annual meeting of shareholders shall not exceed the greater of (i) two or (ii) twenty percent (20%) of the number of directors in office as of the last day on which a Nomination Notice may be delivered pursuant to this Section 12, or if such amount is not a whole number, the closest whole number below twenty percent (20%). In the event that the number of Shareholder Nominees submitted by Eligible Shareholders pursuant to this Section 12 exceeds this maximum number, each Eligible Shareholder will select one Shareholder Nominee for inclusion in the Company’s

8

proxy materials until the maximum number is reached, going in order of the amount (largest to smallest) of shares of the capital stock of the Company each Eligible Shareholder disclosed as owned in its respective Nomination Notice submitted to the Company and confirmed by the Company. If the maximum number is not reached after each Eligible Shareholder has selected one Shareholder Nominee, this selection process will continue as many times as necessary, following the same order each time, until the maximum number is reached.

1. For purposes of this Section 12, an Eligible Shareholder shall be deemed to “own” only those outstanding shares of the capital stock of the Company as to which the shareholder possesses both (i) the full voting and investment rights pertaining to the shares and (ii) the full economic interest in (including the opportunity for profit and risk of loss on) such shares; provided that the number of shares calculated in accordance with clauses (i) and (ii) shall not include any shares (x) sold by such shareholder or any of its affiliates in any transaction that has not been settled or closed, (y) borrowed by such shareholder or any of its affiliates for any purposes or purchased by such shareholder or any of its affiliates pursuant to an agreement to resell or (z) subject to any option, warrant, forward contract, swap, contract of sale, or other derivative or similar agreement entered into by such shareholder or any of its affiliates, whether any such instrument or agreement is to be settled with shares or with cash based on the notional amount or value of shares of outstanding capital stock of the Company, in any such case which instrument or agreement has, or is intended to have, the purpose or effect of (1) reducing in any manner, to any extent or at any time in the future, such shareholder’s or its affiliates’ full right to vote or direct the voting of any such shares, and/or (2) hedging, offsetting or altering to any degree gain or loss arising from the full economic ownership of such shares by such shareholder or affiliate. A shareholder shall “own” shares held in the name of a nominee or other intermediary so long as the shareholder retains the right to instruct how the shares are voted with respect to the election of directors and possesses the full economic interest in the shares. A person’s ownership of shares shall be deemed to continue during any period in which (i) the person has loaned such shares, provided that the person has the power to recall such loaned shares on three (3) business days’ notice; or (ii) the person has delegated any voting power by means of a proxy, power of attorney or other instrument or arrangement that is revocable at any time by the person. The terms “owned,” “owning” and other variations of the word “own” shall have correlative meanings. Whether outstanding shares of the capital stock of the Company are “owned” for these purposes shall be determined by the Board of Directors, which determination shall be conclusive and binding on the Company and its shareholders.
2. An Eligible Shareholder must have owned (as defined above) continuously for at least three (3) years that number of shares of capital stock as shall constitute three percent (3%) or more of the outstanding capital stock of the Company (the “Required Shares”) as of both (i) a date within seven (7) days prior to the date of the Nomination Notice and (ii) the record date for determining shareholders entitled to vote at the annual meeting. For purposes of satisfying the foregoing ownership requirement under this Section 12, (i) the shares of the capital stock of the Company owned by one or more shareholders, or by the person or persons who own shares of the capital stock of the Company and on whose

9

behalf any shareholder is acting, may be aggregated, provided that the number of shareholders and other persons whose ownership of shares of capital stock of the Company is aggregated for such purpose shall not exceed twenty (20), and (ii) a group of funds under common management and investment control shall be treated as one shareholder or person for this purpose. No person may be a member of more than one group of persons constituting an Eligible Shareholder under this Section 12. For the avoidance of doubt, if a group of shareholders aggregates ownership of shares in order to meet the requirements under this Section 12, all shares held by each shareholder constituting their contribution to the foregoing 3% threshold must be held by that shareholder continuously for at least three (3) years, and evidence of such continuous ownership shall be provided as specified in this Section 12(f).

Within the time period specified in this Section 12 for providing the Nomination Notice, an Eligible Shareholder must provide the following information in writing to the Secretary of the Company:

* 1. one or more written statements from the record holder of the shares (and from each intermediary through which the shares are or have been held during the requisite three (3)-year holding period) verifying that, as of a date within seven (7) days prior to the date of the Nomination Notice, the Eligible Shareholder owns, and has owned continuously for the preceding three (3) years, the Required Shares, and the Eligible Shareholder’s agreement to provide, within five (5) business days after the record date for the annual meeting, written statements from the record holder and intermediaries verifying the Eligible Shareholder’s continuous ownership of the Required Shares through the record date;
  2. the written consent of each Shareholder Nominee to being named in the proxy statement as a nominee and to serving as a director if elected, together with the information and representations that would be required to be set forth in a shareholder’s notice of a nomination pursuant to Section 11 of this Article I;
  3. a copy of the Schedule 14N that has been filed with the Securities and Exchange Commission as required by Rule 14a-18 under the 1934 Act, as such rule may be amended;
  4. a representation that the Eligible Shareholder (including each member of any group of shareholders that together is an Eligible Shareholder under this Section 12) (A) acquired the Required Shares in the ordinary course of business and not with the intent to change or influence control at the Company, and does not presently have such intent, (B) has not nominated and will not nominate for election to the Board of Directors at the annual meeting any person other than the Shareholder Nominee(s) being nominated pursuant to this Section 12, (C) has not engaged and will not engage in, and has not and will not be a “participant” in another person’s, “solicitation” within the meaning of Rule 14a-1(l) under the 1934 Act in support of the election of any individual as a director at the annual meeting other than its Shareholder Nominee or a nominee of the Board of Directors, (D) will not distribute to any shareholder any form of proxy for the annual meeting other than the form distributed by the Company and (E) in the case of a nomination by a group of shareholders that together is an Eligible Shareholder, the

10

designation by all group members of one group member that is authorized to act on behalf of all such members with respect to the nomination and matters related thereto, including any withdrawal of the nomination; and

* 1. an undertaking that the Eligible Shareholder agrees to (A) own the Required Shares through the date of the annual meeting, (B) assume all liability stemming from any legal or regulatory violation arising out of the Eligible Shareholder’s communications with the shareholders of the Company or out of the information that the Eligible Shareholder provided to the Company, (C) indemnify and hold harmless the Company and each of its directors, officers and employees individually against any liability, loss or damages in connection with any threatened or pending action, suit or proceeding, whether legal, administrative or investigative, against the Company or any of its directors, officers or employees arising out of any nomination, solicitation or other activity by the Eligible Shareholder in connection with its efforts to elect the Shareholder Nominee pursuant to this Section 12, (D) comply with all other laws and regulations applicable to any solicitation in connection with the annual meeting and (E) provide to the Company prior to the annual meeting such additional information as necessary with respect thereto.

1. The Eligible Shareholder may provide to the Secretary of the Company, at the time the information required by this Section 12 is provided, a written statement for inclusion in the Company’s proxy statement for the annual meeting, not to exceed five hundred (500) words, in support of the Shareholder Nominee’s candidacy (the “Statement”). Notwithstanding anything to the contrary contained in this Section 12, the Company may omit from its proxy materials any information or Statement (or portion thereof) that it, in good faith, believes would violate any applicable law or regulation.
2. Within the time period specified in this Section 12 for delivering the Nomination Notice, a Shareholder Nominee must deliver to the Secretary of the Company a written representation and agreement that the Shareholder Nominee (i) is not and will not become a party to any agreement, arrangement or understanding with, and has not given any commitment or assurance to, any person or entity as to how such person, if elected as a director of the Company, will act or vote on any issue or question that has not been disclosed to the Company, (ii) is not and will not become a party to any agreement, arrangement or understanding with any person or entity other than the Company with respect to any direct or indirect compensation, reimbursement or indemnification in connection with service or action as a director that has not been disclosed to the Company, and (iii) will comply with all the Company’s corporate governance, conflict of interest, confidentiality and stock ownership and trading policies and guidelines, and any other Company policies and guidelines applicable to directors, as well as any applicable law, rule or regulation or listing requirement. At the request of the Company, the Shareholder Nominee must submit all completed and signed questionnaires required of the Company’s directors and officers. The Company may request such additional information as necessary to permit the Board of Directors to determine if each Shareholder Nominee is independent under the listing standards of the principal U.S. exchange upon which the Company’s capital stock is listed, any applicable rules of the Securities and Exchange Commission and any publicly disclosed standards used by the Board of Directors in determining and disclosing the independence of the Company’s

11

directors (the “Applicable Independence Standards”). If the Board of Directors determines that the Shareholder Nominee is not independent under the Applicable Independence Standards, the Shareholder Nominee will not be eligible for inclusion in the Company’s proxy materials.

1. Any Shareholder Nominee who is included in the Company’s proxy materials for a particular annual meeting of shareholders but either (i) withdraws from or becomes ineligible or unavailable for election at the annual meeting, or (ii) does not receive at least twenty-five percent (25%) of the votes cast “for” the Shareholder Nominee’s election, will be ineligible to be a Shareholder Nominee pursuant to this Section 12 for the next two (2) annual meetings.
2. The Company shall not be required to include, pursuant to this Section 12, any Shareholder Nominees in its proxy materials for any meeting of shareholders (i) for which the Secretary of Company receives a notice that a shareholder has nominated a person for election to the Board of Directors pursuant to the advance notice requirements for shareholder nominees for director set forth in Section 11 of this Article I and such shareholder does not expressly elect at the time of providing the notice to have its nominee included in the Company’s proxy materials pursuant to this Section 12, (ii) if the Eligible Shareholder who has nominated such Shareholder Nominee has engaged in or is currently engaged in, or has been or is a “participant” in another person’s, “solicitation” within the meaning of Rule 14a-1(l) under the 1934 Act in support of the election of any individual as a director at the meeting other than its Shareholder Nominee(s) or a nominee of the Board of Directors, (iii) who is not independent under the Applicable Independence Standards, as determined by the Board of Directors, (iv) whose election as a member of the Board of Directors would cause the Company to be in violation of these By-Laws, the Certificate of Incorporation, the listing standards of the principal exchange upon which the Company’s capital stock is traded, or any applicable law, rule or regulation, (v) who is or has been, within the past three years, an officer or director of a competitor, as defined in Section 8 of the Clayton Antitrust Act of 1914, (vi) who is a named subject of a pending criminal proceeding (excluding traffic violations and other minor offenses) or has been convicted in such a criminal proceeding within the past ten (10) years, (vii) who is subject to any order of the type specified in Rule 506(d) of Regulation D promulgated under the Securities Act of 1933, as amended, (viii) if such Shareholder Nominee or the applicable Eligible

Shareholder shall have provided information to the Company in respect to such nomination that was untrue in any material respect or omitted to state a material fact necessary in order to make the statement made, in light of the circumstances under which it was made, not misleading, as determined by the Board of Directors, or (ix) if the Eligible Shareholder or applicable Shareholder Nominee otherwise contravenes any of the agreements or representations made by such Eligible Shareholder or Shareholder Nominee or fails to comply with its obligations pursuant to this Section 12.

1. Notwithstanding anything to the contrary set forth herein, the Board of Directors or the person presiding at the meeting shall declare a nomination by an Eligible Shareholder to be invalid, and such nomination shall be disregarded notwithstanding that proxies in respect of such vote may have been received by the Company, if (i) the Shareholder

12

Nominee(s) and/or the applicable Eligible Shareholder shall have breached its or their obligations, agreements or representations under this Section 12, as determined by the Board of Directors or the person presiding at the annual meeting of shareholders, or (ii) the Eligible Shareholder (or a qualified representative thereof) does not appear at the annual meeting of shareholders to present any nomination pursuant to this Section 12.

1. The Eligible Shareholder (including any person who owns shares of capital stock of the Company that constitute part of the Eligible Shareholder’s ownership for purposes of satisfying Section 12(f) hereof) shall file with the Securities and Exchange Commission any solicitation or other communication with the Company’s shareholders relating to the meeting at which the Shareholder Nominee will be nominated, regardless of whether any such filing is required under Regulation 14A of the 1934 Act or whether any exemption from filing is available for such solicitation or other communication under Regulation 14A of the 1934 Act.

**ARTICLE II DIRECTORS:**

Section 1. Number and Term and Classes of Directors. The whole Board of Directors shall consist of not less than ten (10) nor more than twenty (20) members, the exact number to be set from time to time by the Board of Directors. No decrease in the number of directors shall shorten the term of any incumbent director. In absence of the Board of Directors setting the number of directors, the number shall be 20. The Board of Directors shall be elected each year, at the annual meeting of shareholders, to hold office until the next annual meeting and until their successors are elected and qualified.

Section 2. Regular Meetings. Regular meetings of the Board of Directors shall be held at such times as the Board of Directors may determine from time to time.

Section 3. Special Meetings. Special meetings of the Board of Directors may be called by the Chairman of the Board of Directors, the Secretary or by a majority of the directors by written request to the Secretary.

Section 4. Notice of Meetings. The Secretary shall give notice of all meetings of the Board of Directors by mailing the notice at least three days before each meeting or by telegraphing or telephoning the directors, or sending notice to the directors by facsimile or other electronic transmission, not later than one day before the meeting. The notice shall state the time, date and place of the meeting, which shall be determined by the Chairman of the Board of Directors, or, in absence of the Chairman, by the Secretary of the Company, unless otherwise determined by the Board of Directors by action taken prior to the meeting.

Section 5. Quorum and Voting. A majority of the directors holding office shall constitute a quorum for the transaction of business. Except as otherwise specifically required by Delaware law or by the Certificate of Incorporation of the Company or by these By-Laws, any action required to be taken shall be authorized by a majority of the directors present at any meeting at which a quorum is present.

Section 6. Participation in Meetings; Action by Unanimous Consent. Members of the Board of Directors, or any committee thereof, may participate in a meeting of the Board

13

of Directors or any committee thereof by means of conference telephone or other communications equipment by means of which all persons participating in the meeting can hear each other and such participation shall constitute presence in person at such meeting. Action may be taken by the Board of Directors without a meeting if all members thereof consent thereto in writing or by electronic transmission, and the writing or writings or electronic transmission or transmissions are filed with the minutes of the proceedings of the Board of Directors. Such filing shall be in paper form if the minutes are maintained in paper form and shall be in electronic form if the minutes are maintained in electronic form.

Section 7. General Powers of Directors. The business and affairs of the Company shall be managed under the direction of the Board of Directors.

Section 8. Chairman. At all meetings of the Board of Directors, the Chairman of the Board of Directors shall preside and in the absence of, or in the case of a vacancy in the office of, the Chairman of the Board of Directors, a chairman selected by the Chairman of the Board of Directors or, if he fails to do so, by the directors, shall preside.

Section 9. Compensation of Directors. Directors and members of any committee of the Board of Directors shall be entitled to such reasonable compensation and fees for their services as shall be fixed from time to time by resolution of the Board of Directors and shall also be entitled to reimbursement for any reasonable expenses incurred in attending meetings of the Board of Directors and any committee thereof, except that a director who is an officer or employee of the Company shall receive no compensation or fees for serving as a director or a committee member.

Section 10. Qualification of Directors. Any director who was elected or re-elected because he or she was an officer of the Company at the time of that election or the most recent re-election shall resign as a member of the Board of Directors simultaneously when he or she ceases to be an officer of the Company.

**ARTICLE III**

**COMMITTEES OF THE BOARD OF DIRECTORS:**

Section 1. Committees of the Board of Directors. The Board of Directors shall designate an Audit Committee, a Compensation Committee and a Committee on Directors and Corporate Governance, and whatever other committees the Board of Directors deems advisable, each of which shall have and may exercise the powers and authority of the Board of Directors to the extent provided in the charters of each committee adopted by the Board of Directors in one or more resolutions.

The Chairman of the Board shall have the power and authority of a committee of the Board of Directors for purposes of taking any action which the Chairman of the Board is authorized to take under the provisions of this Article.

Section 2. Election of Committee Members. The members of each committee shall be elected by the Board of Directors and shall serve until the first meeting of the Board of Directors after the annual meeting of shareholders and until their successors are elected and qualified or until the members’ earlier resignation or removal. The Board of

14

Directors may designate the Chairman and Vice Chairman of each committee. Vacancies may be filled by the Board of Directors at any meeting.

The Chairman of the Board may designate one or more directors to serve as an alternate member or members at any committee meeting to replace any absent or disqualified member, such alternate or alternates to serve for that committee meeting only, and the Chairman of the Board may designate a committee member as acting chairman of that committee, in the absence of the elected committee chairman, to serve for that committee meeting only.

Section 3. Procedure/Quorum/Notice. The Committee Chairman, Vice Chairman or a majority of any committee may call a meeting of that committee. A quorum of any committee shall consist of a majority of its members unless otherwise provided by resolution of the Board of Directors. The majority vote of a quorum shall be required for the transaction of business. The secretary of the committee or the chairman of the committee shall give notice of all meetings of the committee by mailing the notice to the members of the committee at least three days before each meeting or by telegraphing or telephoning the members or sending the notice to members by facsimile or other electronic transmission, not later than one day before the meeting. The notice shall state the time, date and place of the meeting. Each committee shall fix its other rules of procedure. Action may be taken by any committee without a meeting if all members thereof consent thereto in writing or by electronic transmission, and the writing or writings or electronic transmission or transmissions are filed with the minutes of the proceedings of such committee. Such filing shall be in paper form if the minutes are maintained in paper form and shall be in electronic form if the minutes are maintained in electronic form.

**ARTICLE IV**

**NOTICE AND WAIVER OF NOTICE:**

Section 1. Notice. Any notice required to be given to shareholders or directors under these By-Laws, the Certificate of Incorporation or by law may be given by mailing the same, addressed to the person entitled thereto, at such person’s last known post office address and such notice shall be deemed to be given at the time of such mailing. Without limiting the manner by which notice otherwise may be given effectively to shareholders, any notice to shareholders may be given by electronic transmission in the manner provided in Section 232 of the Delaware General Corporation Law.

Section 2. Waiver of Notice. Whenever any notice is required to be given under these By‑Laws, the Certificate of Incorporation or by law, a written waiver thereof, signed by the person entitled to notice, or a waiver given by such person by electronic transmission, whether before or after the time stated therein, shall be deemed equivalent to notice. Attendance of a person at a meeting shall constitute a waiver of notice of such meeting, except when the person attends a meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. Neither the business to be transacted at, nor the purpose of any regular or special meeting of the shareholders, directors or a committee of directors need be specified in any written waiver of notice.

15

**ARTICLE V OFFICERS:**

Section 1. Officers of the Company. The officers of the Company shall be selected by the Board of Directors and shall be a Chairman of the Board of Directors, a Chief Executive Officer, one or more Vice Presidents, a Secretary and a Treasurer. The Board of Directors may elect one or more Vice Chairmen, President and a Controller and one or more of the following: Senior Executive Vice President, Executive Vice President, Senior Vice President, Assistant Vice President, Assistant Secretary, Associate Treasurer, Assistant Treasurer, Associate Controller and Assistant Controller. Two or more offices may be held by the same person.

The Company may have a General Counsel who shall be appointed by the Board of Directors and shall have general supervision of all matters of a legal nature concerning the Company, unless the Board of Directors has also appointed a General Tax Counsel, in which event the General Tax Counsel shall have general supervision of all tax matters of a legal nature concerning the Company.

The Company may have a Chief Financial Officer who shall be appointed by the Board of Directors and shall have general supervision over the financial affairs of the Company. The Company may also have a Chief of Internal Audits who shall be appointed by the Board of Directors.

Section 2. Election of Officers. At the first meeting of the Board of Directors after each annual meeting of shareholders, the Board of Directors shall elect the officers. From time to time the Board of Directors may elect other officers.

Section 3. Tenure of Office; Removal. Each officer shall hold office until the first meeting of the Board of Directors after the annual meeting of shareholders following the officer’s election and until the officer’s successor is elected and qualified or until the officer’s earlier resignation or removal. Each officer shall be subject to removal at any time, with or without cause, by the affirmative vote of a majority of the entire Board of Directors.

Section 4. Chairman of the Board of Directors. The Chairman of the Board of Directors shall preside over meetings of the Board of Directors and shall consult and advise with the Board of Directors and committees thereof on the business and the affairs of the Company. The Chairman of the Board of Directors shall have such other duties as may be assigned by the Board of Directors.

Section 5. Chief Executive Officer. The Chief Executive Officer, subject to the overall direction and supervision of the Board of Directors and committees thereof, shall be in general charge of the affairs of the Company, and shall consult and advise with the Board of Directors and committees thereof on the business and the affairs of the Company. The Chief Executive Officer shall have the power to make and execute contracts and other instruments, including powers of attorney, on behalf of the Company and to delegate such power to others.

Section 6. President. The Board of Directors may select a President who shall have such powers and perform such duties, including those of Chief Operating Officer, as may be

16

assigned by the Board of Directors or by the Chief Executive Officer. In the absence or disability of the President, his or her duties shall be performed by the Chief Executive Officer or such persons as the Board of Directors or the Chief Executive Officer may designate. The President shall also have the power to make and execute contracts on the Company’s behalf and to delegate such power to others.

Section 7. Vice Presidents. Each Senior Executive Vice President, Executive Vice President, Senior Vice President and Vice President shall have such powers and perform such duties as may be assigned to the officer by the Board of Directors or by the Chief Executive Officer.

Section 8. Secretary. The Secretary shall keep minutes of all meetings of the shareholders and of the Board of Directors, and shall keep, or cause to be kept, minutes of all meetings of committees of the Board of Directors, except where such responsibility is otherwise fixed by the Board of Directors. The Secretary shall issue all notices for meetings of the shareholders and Board of Directors and shall have charge of and keep the seal of the Company and shall affix the seal attested by the Secretary’s signature to such instruments as may properly require same. The Secretary shall cause to be kept such books and records as the Board of Directors, the Chairman of the Board of Directors, the Chief Executive Officer or the President may require; and shall cause to be prepared, recorded, transferred, issued, sealed and cancelled certificates of stock as required by the transactions of the Company and its shareholders. The Secretary shall attend to such correspondence and such other duties as may be incident to the office of the Secretary or assigned by the Board of Directors, the Chairman of the Board of Directors, the Chief Executive Officer or the President.

In the absence of the Secretary, an Assistant Secretary is authorized to assume the duties herein imposed upon the Secretary.

Section 9. Treasurer. The Treasurer shall perform all duties and acts incident to the position of Treasurer, shall have custody of the Company funds and securities, and shall deposit all money and other valuable effects in the name and to the credit of the Company in such depositories as may be designated by the Board of Directors. The Treasurer shall disburse the funds of the Company as may be authorized, taking proper vouchers for such disbursements, and shall render to the Board of Directors, whenever required, an account of all the transactions of the Treasurer and of the financial condition of the Company. The Treasurer shall vote all of the stock owned by the Company in any corporation and may delegate this power to others. The Treasurer shall perform such other duties as may be assigned to the Treasurer and shall report to the Chief Financial Officer or, in the absence of the Chief Financial Officer, to the Chief Executive Officer.

In the absence of the Treasurer, an Assistant Treasurer is authorized to assume the duties herein imposed upon the Treasurer.

Section 10. Controller. The Board of Directors may select a Controller who shall keep or cause to be kept in the books of the Company provided for that purpose a true account of all transactions and of the assets and liabilities of the Company. The Controller shall prepare and submit to the Chief Financial Officer or, in the absence of the Chief Financial Officer, to the Chief Executive Officer, such financial statements and schedules as may

17

be required to keep the Chief Financial Officer and the Chief Executive Officer currently informed of the operations and financial condition of the Company, and perform such other duties as may be assigned by the Chief Financial Officer or the Chief Executive Officer.

In the absence of the Controller, an Assistant Controller is authorized to assume the duties herein imposed upon the Controller.

Section 11. Chief of Internal Audits. The Board of Directors may select a Chief of Internal Audits, who shall cause to be performed, and have general supervision over, auditing activities of the financial transactions of the Company, including the coordination of such auditing activities with the independent accountants of the Company and who shall perform such other duties as may be assigned to him from time to time. The Chief of Internal Audits shall report to the Chief Financial Officer or, in the absence of the Chief Financial Officer, to the Chief Executive Officer. From time to time at the request of the Audit Committee, the Chief of Internal Audits shall inform that committee of the auditing activities of the Company.

Section 12. Assistant Vice Presidents. The Company may have Assistant Vice Presidents who shall be appointed by a committee whose membership shall include one or more executive officers of the Company (the "Committee"). Each such Assistant Vice President shall have such powers and shall perform such duties as may be assigned from time to time by the Committee, the Chief Executive Officer, the President or any Vice President, and which are not inconsistent with the powers and duties granted and assigned by these By-Laws or the Board of Directors. Assistant Vice Presidents appointed by the Committee shall be subject to removal at any time, with or without cause, by the Committee. Annually the Committee shall report to the Board of Directors who it has appointed to serve as Assistant Vice Presidents and their respective responsibilities.

**ARTICLE VI RESIGNATIONS: FILLING OF VACANCIES:**

Section 1. Resignations. Any director, member of a committee, or officer may resign at any time. Such resignation shall be made by notice to the Chairman of the Board of Directors or the Secretary given in writing or by electronic transmission and shall take effect at the time specified therein, and, if no time be specified, at the time of its receipt by the Chairman of the Board of Directors or the Secretary. The acceptance of a resignation shall not be necessary to make it effective.

Section 2. Filling of Vacancies. If the office of any director becomes vacant, the directors in office, although less than a quorum, or, if the number of directors is increased, the directors in office, may elect any qualified person to fill such vacancy. In the case of a vacancy in the office of a director caused by an increase in the number of directors, the person so elected shall hold office until the next annual meeting of shareholders, or until his successor shall be elected and qualified. In the case of a vacancy in the office of a director resulting otherwise than from an increase in the number of directors, the person so elected to fill such vacancy shall hold office for the unexpired term of the director whose office became vacant. If the office of any officer becomes vacant, the Chairman of

18

the Board of Directors may appoint any qualified person to fill such vacancy temporarily until the Board of Directors elects any qualified person for the unexpired portion of the term. Such person shall hold office for the unexpired term and until the officer’s successor shall be duly elected and qualified or until the officer’s earlier resignation or removal.

**ARTICLE VII INDEMNIFICATION:**

Section 1. Indemnification of Directors, Officers, Employees and Agents. The Company shall indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the Company) by reason of the fact that he is or was a director, officer, employee or agent of the Company, or is or was serving at the request of the Company as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by him in connection with such action, suit or proceeding if he acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interest of the Company, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful. The termination of any action, suit or proceeding by judgment, order, settlement, conviction, or upon a plea of nolo contendere or its equivalent, shall not, of itself, create a presumption that the person did not act in good faith and in a manner which he reasonably believed to be in or not opposed to the best interest of the Company, and with respect to any criminal action or proceeding, had reasonable cause to believe that his conduct was unlawful.

The Company shall indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the Company to procure a judgment in its favor by reason of the fact that he is or was a director, officer, employee or agent of the Company, or is or was serving at the request of the Company, as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against expenses (including attorneys’ fees) actually and reasonably incurred by him in connection with the defense or settlement of such action or suit if he acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the Company and except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the Company unless and only to the extent that the Court of Chancery or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper.

Notwithstanding the foregoing, except with respect to a proceeding to enforce rights to indemnification or advancement of expenses under this Article VII, the Company shall be required to indemnify a person under this Article VII in connection with a proceeding (or

19

part thereof) initiated by such person only if such proceeding (or part thereof) was authorized by the Board of Directors.

Section 2. Expenses. To the extent that a director, officer, employee or agent of the Company has been successful on the merits or otherwise, in whole or in part, in defense of any action, suit or proceeding referred to in Section 1 or in defense of any claim, issue or matter therein, he shall be indemnified against expenses (including attorneys’ fees) actually and reasonably incurred by him in connection therewith. The entitlement to expenses under this Section 2 shall include any expenses incurred by a director, officer, employee or agent of the Company in connection with any action, suit or proceeding brought by such director, officer, employee or agent to enforce a right to indemnification or payment of expenses under this Article. If successful in whole or in part in any such action, suit or proceeding, or in any action, suit or proceeding brought by the Company to recover a payment of expenses pursuant to the terms of an undertaking provided in accordance with Section 4, the director, officer, employee or agent also shall be entitled to be paid the expense of prosecuting or defending such action, suit or proceeding.

Section 3. Procedure for Receiving Indemnification. To receive indemnification under this By-Law, a director, officer, employee or agent of the Company shall submit to the Company a written request, including therein or therewith such documentation and information as is reasonably available to him and reasonably necessary to determine his entitlement to indemnification. Upon receipt by the Company of a written request for indemnification, a determination, if required by applicable law, with respect to a claimant’s request shall be made: (1) by the Board of Directors by a majority vote of a quorum consisting of directors who were not parties to such action, suit or proceeding, even though less than a quorum; or (2) by a committee of such directors designated by majority vote of such directors, even though less than a quorum; or

(3) if there are no such directors, or if such directors so direct, by independent legal counsel in a written opinion; or (4) by the shareholders. The determination of a claimant’s entitlement to indemnification shall be made within a reasonable time, and in any event within no more than 60 days, after receipt by the Company of a written request for indemnification, together with the supporting documentation required by this Section. The burden of establishing that a claimant is not entitled to be indemnified under this Article or otherwise shall be on the Company.

Section 4. Payment of Expenses. Expenses incurred in defending a civil or criminal action, suit or proceeding shall be paid by the Company in advance of the final disposition of such action, suit or proceeding within 30 days after receipt by the Company of a statement requesting payment of such expenses. Such statement shall evidence the expenses incurred by the claimant and shall include an undertaking by or on behalf of the claimant to repay such expenses if it shall ultimately be determined, by final judicial decision from which there is no further right to appeal, that he is not entitled to be indemnified by the Company as authorized by this Article. The burden of establishing that a claimant is not entitled to payment of expenses under this Article or otherwise shall be on the Company. Any such payment shall not be deemed to be a loan or extension or arrangement of credit by or on behalf of the Company.

20

Section 5. Provisions Non-Exclusive; Survival of Rights. The indemnification and payment of expenses provided by or granted pursuant to this Article shall not be deemed exclusive of any other rights to which those indemnified or those who receive payment of expenses may be entitled under any By-Law, agreement, vote of shareholders or disinterested directors or otherwise, both as to action in an official capacity and as to action in another capacity while holding such office, and shall continue as to a person who has ceased to be a director, officer, employee or agent and shall inure to the benefit of the heirs, executors and administrators of such a person.

Section 6. Insurance. The Company shall have power to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the Company, or is or was serving at the request of the Company as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against him and incurred by him in any such capacity, or arising out of his status as such, whether or not the Company would have the power to indemnify him against such liability under the provisions of this Article.

Section 7. Authority to Enter into Indemnification Agreements. The Company shall have the power to enter into contracts with any director, officer, employee or agent of the Company in furtherance of the provisions of this Article to provide for the payment of such amounts as may be appropriate, in the discretion of the Board of Directors, to effect indemnification and payment of expenses as provided in this Article.

Section 8. Effect of Amendment. Any amendment, repeal or modification of this Article shall not adversely affect any right or protection existing at the time of such amendment, repeal or modification in respect of any act or omission occurring prior to such amendment, repeal or modification.

Section 9. No Duplication of Payments. The Company’s obligation, if any, to indemnify or pay expenses to any person under this Article shall be reduced to the extent such person has otherwise received payment (under any insurance policy, indemnity clause, bylaw, agreement, vote or otherwise).

**ARTICLE VIII CAPITAL STOCK:**

Section 1. Form and Execution of Certificates. The certificates of shares of the capital stock of the Company shall be in such form as shall be approved by the Board of Directors. The certificates shall be signed by the Chairman of the Board of Directors or the Chief Executive Officer or the President, or a Vice President, and by the Secretary or an Assistant Secretary or the Treasurer or an Assistant Treasurer. Each certificate of stock shall certify the number of shares owned by the shareholder in the Company.

A facsimile of the seal of the Company may be used in connection with the certificates of stock of the Company, and facsimile signatures of the officers named in this Section may be used in connection with said certificates. In the event any officer whose facsimile signature has been placed upon a certificate shall cease to be such officer before the certificate is issued, the certificate may be issued with the same effect as if such person was an officer at the date of issue.

21

Section 2. Record Ownerships. All certificates shall be numbered appropriately and the names of the owners, the number of shares and the date of issue shall be entered in the books of the Company. The Company shall be entitled to treat the holder of record of any share of stock as the holder in fact thereof and accordingly shall not be bound to recognize any equitable or other claim to or interest in any share on the part of any other person, whether or not it shall have express or other notice thereof, except as required by the laws of Delaware.

Section 3. Transfer of Shares. Upon surrender to the Company or to a transfer agent of the Company of a certificate for shares duly endorsed or accompanied by proper evidence of succession, assignment, or authority to transfer, it shall be the duty of the Company, if it is satisfied that all provisions of law regarding transfers of shares have been duly complied with, to issue a new certificate to the person entitled thereto, cancel the old certificate and record the transaction upon its books.

Section 4. Lost, Stolen or Destroyed Stock Certificates. Any person claiming a stock certificate in lieu of one lost, stolen or destroyed shall give the Company an affidavit as to such person’s ownership of the certificate and of the facts which go to prove that it was lost, stolen or destroyed. The person shall also, if required by the Board of Directors, give the Company a bond, sufficient to indemnify the Company against any claims that may be made against it on account of the alleged loss, theft or destruction of any such certificate or the issuance of such new certificate. Any Vice President or the Secretary or any Assistant Secretary of the Company is authorized to issue such duplicate certificates or to authorize any of the transfer agents and registrars to issue and register such duplicate certificates.

Section 5. Regulations. The Board of Directors from time to time may make such rules and regulations as it may deem expedient concerning the issue, transfer and registration of shares.

Section 6. Transfer Agent and Registrar. The Board of Directors may appoint such transfer agents and registrars of transfers as may be deemed necessary, and may require all stock certificates to bear the signature of either or both.

**ARTICLE IX SEAL:**

Section 1. Seal. The Board of Directors shall provide a suitable seal containing the name of the Company, the year of its creation, and the words, "CORPORATE SEAL, DELAWARE," or other appropriate words. The Secretary shall have custody of the seal.

**ARTICLE X FISCAL YEAR:**

Section 1. Fiscal Year. The fiscal year of the Company shall be the calendar year.

**ARTICLE XI**

**EXCLUSIVE FORUM FOR ADJUDICATION OF DISPUTES:**

22

Section 1. Exclusive Forum for Adjudication of Disputes. Unless the Company consents in writing to the selection of an alternative forum, the sole and exclusive forum for (i) any derivative action or proceeding brought on behalf of the Company; (ii) any action asserting a claim for or based on a breach of a fiduciary duty owed by any current or former director or officer or other employee of the Company to the Company or to the Company’s shareowners, including a claim alleging the aiding and abetting of such a breach of fiduciary duty; (iii) any action asserting a claim against the Company or any current or former director or officer or other employee of the Company arising pursuant to any provision of the General Corporation Law of the State of Delaware or the Certificate of Incorporation or these By-laws (as either may be amended from time to time); (iv) any action asserting a claim related to or involving the Company that is governed by the internal affairs doctrine; or (iv) any action asserting an “internal corporate claim” as that term is defined in Section 115 of the General Corporation Law of the State of Delaware, shall be a state court located within the State of Delaware (or, if no state court located within the State of Delaware has jurisdiction, the federal court for the District of Delaware).

**ARTICLE XII AMENDMENTS:**

Section 1. Directors May Amend By-Laws. The Board of Directors shall have the power to make, amend and repeal the By-laws of the Company.

Section 2. By-laws Subject to Amendment by Shareholders. All By-Laws shall be subject to amendment, alteration, or repeal by the shareholders entitled to vote at any annual meeting or at any special meeting.

**ARTICLE XIII EMERGENCY BY-LAWS:**

Section 1. Emergency By-laws. This Article XIII shall be operative during any emergency resulting from an attack on the United States or on a locality in which the Company conducts its business or customarily holds meetings of its Board of Directors or its shareholders, or during any nuclear or atomic disaster or during the existence of any catastrophe or other similar emergency condition, as a result of which a quorum of the Board of Directors or, if one has been constituted, the Executive Committee thereof cannot be readily convened (an "emergency"), notwithstanding any different or conflicting provision in the preceding Articles of these By-laws or in the Certificate of Incorporation of the Company. To the extent not inconsistent with the provisions of this Article, the By-laws provided in the preceding Articles and the provisions of the Certificate of Incorporation of the Company shall remain in effect during such emergency, and upon termination of such emergency, the provisions of this Article XIII shall cease to be operative.

Section 2. Meetings. During any emergency, a meeting of the Board of Directors, or any committee thereof, may be called by any officer or director of the Company. Notice of the time and place of the meeting shall be given by any available means of communication by the person calling the meeting to such of the directors and/or

23

Designated Officers, as defined in Section 3 hereof, as it may be feasible to reach. Such notice shall be given at such time in advance of the meeting as, in the judgment of the person calling the meeting, circumstances permit.

Section 3. Quorum. At any meeting of the Board of Directors, or any committee thereof, called in accordance with Section 2 of this Article XIII, the presence or participation of two directors, one director and a Designated Officer or two Designated Officers shall constitute a quorum for the transaction of business.

The Board of Directors or the committees thereof, as the case may be, shall, from time to time but in any event prior to such time or times as an emergency may have occurred, designate the officers of the Company in a numbered list (the "Designated Officers") who shall be deemed, in the order in which they appear on such list, directors of the Company for purposes of obtaining a quorum during an emergency, if a quorum of directors cannot otherwise be obtained.

Section 4. By-laws. At any meeting called in accordance with Section 2 of this Article XIII, the Board of Directors or the committees thereof, as the case may be, may modify, amend or add to the provisions of this Article XIII so as to make any provision that may be practical or necessary for the circumstances of the emergency.

Section 5. Liability. No officer, director or employee of the Company acting in accordance with the provisions of this Article XIII shall be liable except for willful misconduct.

Section 6. Repeal or Change. The provisions of this Article XIII shall be subject to repeal or change by further action of the Board of Directors or by action of the shareholders, but no such repeal or change shall modify the provisions of Section 5 of this Article XIII with regard to action taken prior to the time of such repeal or change.

24

## Exhibit 31.1

**CERTIFICATIONS**

I, James Quincey, Chairman of the Board of Directors and Chief Executive Officer of The Coca-Cola Company, certify that:

1. I have reviewed this quarterly report on Form 10-Q of The Coca-Cola Company;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
   1. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
   2. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
   3. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
   4. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
   1. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
   2. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: October 22, 2020

/s/ James Quincey James Quincey

*Chairman of the Board of Directors and Chief Executive Officer of The Coca-Cola Company*

## Exhibit 31.2

**CERTIFICATIONS**

I, John Murphy, Executive Vice President and Chief Financial Officer of The Coca-Cola Company, certify that:

1. I have reviewed this quarterly report on Form 10-Q of The Coca-Cola Company;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
   1. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
   2. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
   3. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
   4. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
   1. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
   2. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: October 22, 2020

/s/ John Murphy John Murphy

*Executive Vice President and Chief Financial Officer of The Coca-Cola Company*

## Exhibit 32.1

**CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,**

**AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the quarterly report of The Coca-Cola Company (the "Company") on Form 10-Q for the period ended September 25, 2020 (the "Report"), I, James Quincey, Chairman of the Board of Directors and Chief Executive Officer of the Company and I, John Murphy, Executive Vice President and Chief Financial Officer of the Company, each certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1. to my knowledge, the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ JAMES QUINCEY

James Quincey

*Chairman of the Board of Directors and Chief Executive Officer of The Coca-Cola Company*

October 22, 2020

/s/ JOHN MURPHY

John Murphy

*Executive Vice President and Chief Financial Officer of The Coca-Cola Company*

October 22, 2020

## Exhibit 10.1



COCA-COLA PLAZA ATLANTA, GEORGIA

**JAMES R. QUINCEY**

CHAIRMAN & CHIEF EXECUTIVE OFFICER THE COCA-COLA COMPANY

ADDRESS REPLY TO:

P.O. BOX 1734 Atlanta, GA 30301

+1-404 676-9980

FAX: +1-404 598-9980

July 15, 2020

Bradley Gayton

Ann Arbor, Michigan Dear Bradley,

We are delighted to offer you the position of Senior Vice President, General Counsel, job grade 21, with an effective date of September 1, 2020, pending election to the position by The

Coca-Cola Company Board of Directors. You will report to me. The information contained in this letter provides the terms and compensation details of this position. All payments set forth below are subject to tax and withholding.

* Your principal place of employment will be Atlanta, Georgia.
* Your annual base pay for your new position will be USD 760,000.
* At the next regularly scheduled meeting of the Talent and Compensation Committee following your employment with the Company (October 2020), The Coca-Cola Company management will request special long-term incentive award(s) with approximate value(s) as follows:
  + USD 3,820,000 in Restricted Stock Units (RSUs). The RSUs will vest 15% on December 10, 2021 and 85% on December 10, 2023, provided all required conditions are met. The number of RSUs will be determined using the 30-calendar day average stock price of The Coca-Cola Company common stock immediately preceding the first of the month in which the award is approved. Dividend equivalents will not be paid during the restriction period. This award is subject to Talent and Compensation Committee approval. All long-term incentive awards you will receive will be governed solely by the terms of the Company’s long-term incentive plans and agreements that will be provided to you at the time any awards are made.
* You will receive a one-time sign on bonus of USD 500,000 provided as a lump sum cash payment, paid by September 30, 2020. Should you voluntarily terminate employment with the Company for any reason, or if you are terminated as a result of a violation of the Company’s Code of Business Conduct, within 36 months of your initial employment date, you agree to repay these monies in full within 30 days of your separation. If for any reason you do not return such payments, the Company will offset the amount due from any form of compensation due, including but not limited to, salary, bonus, and non-qualified compensation. The terms of this payment will be governed solely by the terms of the enclosed hiring bonuses agreement.

Bradley Gayton July 15, 2020

Page 2 of 3

* Following Ford Motor Company’s disclosure of 2020 annual incentive results, you will receive a one-time cash payment in 2021 equal to the annual incentive amount you would have earned, but have forfeited, pro-rated for the time you were employed by Ford Motor Company in 2020. The terms of this payment will be governed solely by the terms of the enclosed deferred cash agreement.
* You are eligible for certain relocation benefits, plus an additional discretionary amount of up to $200,000, to cover potential loss on home sale (if any); this additional amount is only payable if loss on home sale exceeds what would otherwise be covered by the relocation policy and is subject to verification. You will be contacted within three business days of your acceptance by your Relocation Manager to review the details of these benefits. Should you voluntarily terminate employment with the Company for any reason, or if you are terminated as a result of a violation of the Company’s Code of Business Conduct, within 36 months of your initial employment date, you agree to repay these monies in full within 30 days. If for any reason you do not return such payments, the Company will offset the amount due from any form of compensation due, including but not limited to, salary, bonus, and non-qualified compensation. The terms of this payment will be governed solely by the terms of the enclosed hiring bonuses agreement.
* You will be eligible to participate in the annual Performance Incentive Plan. Your target annual incentive for your new position is 100% of your annual base pay. Any payment will depend on both the business performance and your personal contributions. Awards are made at the discretion of the Talent and Compensation Committee of the Board of Directors based upon recommendations by Senior Management. As a discretionary program, the performance factors, eligibility criteria, payment frequency, award opportunity levels and other provisions are variable. The plan may be modified from time to time.
* You will be eligible to participate in The Coca-Cola Company’s Long-Term Incentive (LTI) program. Awards are made at the discretion of the Talent and Compensation Committee of the Board of Directors based upon recommendations by Senior Management. You will be eligible to receive LTI awards within guidelines for the job grade assigned to your position and based upon your leadership potential to impact the Company’s future growth. As a discretionary program, eligibility criteria, award opportunity levels, the award timing, frequency, size and mix of award vehicles are variable.
* You will be expected to acquire and maintain share ownership at a level equal to two times your base pay. As part of the Company’s ownership expectations, you will have five years, or until December 31, 2025 to comply with this requirement. You will be asked to provide information in December each year on your progress toward your ownership goal, and that information will be reviewed with the Talent and Compensation Committee of the Board of Directors the following February.

Bradley Gayton July 15, 2020

Page 3 of 3

* You will be eligible for the Company’s Financial Planning Reimbursement Program which provides reimbursement of certain financial planning services, up to USD 10,000 annually.
* You will be eligible for the Emory Executive Health benefit which includes a comprehensive physical exam and one-on-one medical and lifestyle management consultation.
* You are required to enter into the Agreement on Confidentiality, Non-Competition, and Non-Solicitation, as well as the Agreement Covering Inventions, Discoveries, Copyrightable Material, Trade Secrets, and Confidential Information that will be provided to you soon.
* This letter is provided as information and does not constitute an employment contract.

Bradley, I feel certain that you will find challenge, satisfaction and opportunity in this role as we start our journey together during this time. Sincerely,

**/s/ James Quincey**

James Quincey Chairman and CEO

C: Carl Saunders

Executive Compensation Executive Services

I, Bradley Gayton, accept this offer

Signature: /s/ Bradley Gayton

Date: July 15, 2020

Exhibit 10.2



**BRIAN J. SMITH**

PRESIDENT & CHIEF OPERATING OFFICER

COCA-COLA PLAZA

ATLANTA, GEORGIA ADDRESS REPLY TO

P.O. Box 1734 Atlanta, GA 30301

404.676.9818

Fax: 404.598.0818

September 14, 2020

Henrique Braun

Rio de Janeiro, Brazil Dear Henrique,

We are delighted to confirm your promotion as Operating Unit President, Latin America, with an effective date of October 1, 2020. You will report to me. The information contained in this letter provides details of your new position.

* Your principal place of assignment will continue to be Rio de Janeiro, Brazil. You will continue to be employed by Recofarma Industria do Amazonas Ltda.
* Your annual base pay for your new position will be USD 580,000.
* You will continue to be eligible to participate in the annual Performance Incentive Plan. Any payment will depend on both the business performance and your personal contributions. Awards are made at the discretion of the Talent and Compensation Committee of the Board of Directors based upon recommendations by Senior Management. As a discretionary program, the performance factors, eligibility criteria, payment frequency, award opportunity levels and other provisions are variable. The plan may be modified from time to time.
* You will continue to be eligible to participate in The Coca-Cola Company’s Long-Term Incentive (LTI) program. Awards are made at the discretion of the Talent and Compensation Committee of the Board of Directors based upon recommendations by Senior Management. You will be eligible to receive LTI awards within guidelines for the job grade assigned to your position, and based upon your leadership potential to impact the Company’s future growth. As a discretionary program, eligibility criteria, award opportunity levels, the award timing, frequency, size and mix of award vehicles are variable
* You are expected to maintain share ownership pursuant to the Company’s share ownership guidelines at a level equal to four times your base pay. Because this represents an increase from your prior target level, you will have an additional 2 years, or until December 31, 2022, to meet your requirement. You will be asked to provide information in December each year on your progress toward your ownership goal, and that information will be reviewed with the Talent and Compensation Committee of the Board of Directors the following February.

Henrique Braun September 14, 2020

Page 2

* You will continue to be eligible for the Company’s Financial Planning Reimbursement Program which provides reimbursement of certain financial planning services, up to USD 10,000, subject to taxes and withholding.
* You will continue to be eligible for the Emory Executive Health benefit which includes a comprehensive physical exam and one-on-one medical and lifestyle management consultation.
* As a mobile assignee, you will continue to participate in the Global Mobility Tier 1 HQ Program and be provided the standard benefits of that program. The duration and type of assignment are contingent upon the business needs of the Company provided suitable performance standards are maintained. The Code of Business Conduct, Confidentiality Agreements, or any other document related to knowledge you acquire of Company business or conducting business remain in effect during international assignments.
* This letter is provided as information and does not constitute an employment contract.

Henrique, I feel certain that you will find challenge, satisfaction and opportunity in this role as we start our journey together during this important time.

Sincerely,

/s/ Brian J. Smith Brian J. Smith

President and Chief Operating Officer

C: Carl Saunders Executive Compensation Executive Services Global Mobility

I, Henrique Braun, accept this offer

Signature: /s/ Henrique Braun

Date: September 30, 2020